data_2lx6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lx6 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.587 -1.119 . . . . 73.14 115.382 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.66 -177.13 6.37 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.366 1.583 . . . . 52.0 108.282 175.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -64.3 -29.32 70.41 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.105 -1.426 . . . . 73.31 113.685 -173.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -156.43 151.6 9.02 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.709 1.595 . . . . 75.42 111.401 -173.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.68 -107.27 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.666 -1.63 . . . . 71.42 111.497 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.78 159.96 31.71 Favored Pre-proline 0 C--N 1.356 0.86 0 CA-C-O 115.45 -2.214 . . . . 72.5 108.248 -176.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -55.35 130.5 40.95 Favored 'Trans proline' 0 C--N 1.362 1.265 0 CA-C-N 124.839 2.764 . . . . 72.32 112.61 -173.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 81.3 mt-10 -68.98 -57.14 5.87 Favored 'General case' 0 C--N 1.354 0.77 0 N-CA-C 108.004 -1.11 . . . . 72.4 108.004 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.15 -61.27 1.85 Allowed 'General case' 0 C--N 1.354 0.782 0 CA-C-O 118.343 -0.837 . . . . 73.2 109.632 179.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.72 -51.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.773 0 CA-C-O 118.64 -0.695 . . . . 70.23 109.786 -176.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.42 145.38 67.87 Favored Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.538 -2.172 . . . . 71.51 105.18 172.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -70.42 75.06 1.52 Allowed 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.752 2.376 . . . . 71.41 112.211 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -88.91 -56.74 3.16 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 106.697 -1.594 . . . . 74.24 106.697 171.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.94 145.16 16.2 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.523 -1.831 . . . . 64.44 108.523 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.22 93.95 4.18 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.937 1.368 . . . . 72.35 111.139 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -120.11 157.19 29.5 Favored 'General case' 0 C--N 1.36 1.047 0 CA-C-O 117.248 -1.358 . . . . 73.42 107.868 170.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -92.3 141.04 15.17 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 105.344 -2.095 . . . . 74.24 105.344 164.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 . . . . . 0 C--N 1.355 0.821 0 CA-C-N 119.84 1.2 . . . . 75.54 109.747 -174.548 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.721 0 CA-C-O 118.708 -1.051 . . . . 73.3 115.306 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.14 -177.33 6.53 Favored 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.273 1.537 . . . . 75.23 108.388 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -63.92 -29.64 70.8 Favored 'General case' 0 C--N 1.351 0.665 0 CA-C-O 117.07 -1.443 . . . . 65.02 113.615 -173.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.9 p -156.37 151.71 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 120.811 1.642 . . . . 74.24 111.374 -173.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.66 -107.12 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.682 -1.621 . . . . 63.33 111.455 177.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.89 159.86 31.77 Favored Pre-proline 0 C--N 1.356 0.859 0 CA-C-O 115.418 -2.23 . . . . 73.52 108.296 -176.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -54.95 129.81 37.31 Favored 'Trans proline' 0 C--N 1.361 1.233 0 CA-C-N 124.818 2.756 . . . . 74.34 112.584 -173.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -68.37 -57.03 6.53 Favored 'General case' 0 C--N 1.355 0.839 0 N-CA-C 108.047 -1.094 . . . . 63.42 108.047 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.11 -61.32 1.84 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-O 118.396 -0.811 . . . . 74.2 109.66 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.73 -50.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-O 118.653 -0.689 . . . . 74.11 109.858 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.68 145.45 66.96 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.566 -2.159 . . . . 73.23 105.194 172.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -70.3 75.14 1.47 Allowed 'Trans proline' 0 C--N 1.358 1.044 0 CA-C-N 123.777 2.384 . . . . 71.02 112.252 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -89.42 -56.85 3.09 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 106.769 -1.567 . . . . 73.14 106.769 171.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.62 144.63 16.06 Favored Glycine 0 C--N 1.357 1.721 0 N-CA-C 108.45 -1.86 . . . . 52.23 108.45 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -120.8 94.16 4.26 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.963 1.381 . . . . 73.41 111.185 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -120.7 156.53 31.56 Favored 'General case' 0 C--N 1.359 1.012 0 CA-C-O 117.186 -1.388 . . . . 75.21 107.843 170.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.6 pt -91.24 141.07 14.98 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.283 -2.117 . . . . 74.31 105.283 164.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 . . . . . 0 C--N 1.355 0.816 0 CA-C-N 119.808 1.185 . . . . 74.33 109.626 -174.41 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 N-CA-C 117.347 1.699 . . . . 62.14 117.347 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.23 -169.52 2.97 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 120.619 2.21 . . . . 72.05 107.081 173.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -72.83 -25.95 61.31 Favored 'General case' 0 C--N 1.351 0.659 0 CA-C-N 120.389 1.45 . . . . 74.22 113.38 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -156.35 149.62 10.83 Favored 'Isoleucine or valine' 0 C--N 1.355 0.816 0 CA-C-N 120.555 1.525 . . . . 74.12 110.569 -175.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.98 -108.37 0.36 Allowed Glycine 0 C--N 1.357 1.74 0 CA-C-O 117.592 -1.671 . . . . 65.43 111.969 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.9 161.12 29.94 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.359 -2.258 . . . . 73.24 108.512 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -57.68 131.83 46.51 Favored 'Trans proline' 0 C--N 1.361 1.195 0 CA-C-N 124.969 2.81 . . . . 75.1 112.119 -172.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -70.26 -58.19 4.04 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.063 -1.088 . . . . 65.3 108.063 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -85.22 -61.78 1.69 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.038 0.835 . . . . 73.44 109.56 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.65 -51.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.767 0 CA-C-O 118.736 -0.65 . . . . 63.53 109.838 -176.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.85 145.51 81.51 Favored Pre-proline 0 C--N 1.355 0.839 0 N-CA-C 105.056 -2.201 . . . . 74.23 105.056 172.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.26 72.87 2.16 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.743 2.373 . . . . 74.43 112.223 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.9 mt -86.24 -55.79 3.75 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.826 -1.546 . . . . 60.42 106.826 171.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.48 155.94 15.94 Favored Glycine 0 C--N 1.357 1.73 0 N-CA-C 109.503 -1.439 . . . . 75.24 109.503 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -129.75 86.56 2.43 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.077 -0.963 . . . . 75.41 111.642 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -120.03 145.21 47.04 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-O 116.67 -1.633 . . . . 64.12 108.243 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.4 pt -84.22 141.35 14.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.924 0 N-CA-C 106.127 -1.805 . . . . 72.52 106.127 166.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 . . . . . 0 C--N 1.355 0.841 0 CA-C-N 119.442 1.019 . . . . 74.12 109.428 -175.894 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.71 0 N-CA-C 116.363 1.305 . . . . 73.43 116.363 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -150.3 -173.47 4.46 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.912 1.856 . . . . 65.23 107.76 174.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -67.86 -27.42 66.67 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.155 -1.402 . . . . 71.04 113.585 -172.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.62 151.03 9.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 120.703 1.592 . . . . 64.14 110.998 -174.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.71 -107.64 0.33 Allowed Glycine 0 C--N 1.358 1.787 0 CA-C-O 117.618 -1.657 . . . . 75.45 111.594 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.09 160.7 30.61 Favored Pre-proline 0 C--N 1.357 0.924 0 CA-C-O 115.314 -2.279 . . . . 73.41 108.428 -175.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -55.96 130.06 38.25 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 125.031 2.832 . . . . 71.52 112.287 -173.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -68.99 -57.27 5.69 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.024 -1.102 . . . . 72.13 108.024 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.69 -61.58 1.75 Allowed 'General case' 0 C--N 1.354 0.775 0 CA-C-O 118.403 -0.808 . . . . 73.25 109.563 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.29 -51.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 118.614 -0.707 . . . . 74.43 109.798 -176.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -77.09 145.42 73.38 Favored Pre-proline 0 C--N 1.354 0.789 0 N-CA-C 105.059 -2.2 . . . . 62.42 105.059 172.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -70.67 74.45 1.69 Allowed 'Trans proline' 0 C--N 1.358 1.053 0 CA-C-N 123.804 2.394 . . . . 73.4 112.168 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 65.5 mt -88.22 -56.52 3.29 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 106.722 -1.584 . . . . 71.43 106.722 171.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.75 150.27 16.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 108.909 -1.677 . . . . 55.31 108.909 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -125.44 91.34 3.39 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 118.452 1.126 . . . . 74.1 111.422 -178.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -120.77 151.82 39.09 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.907 -1.52 . . . . 72.31 107.937 171.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.4 pt -88.01 142.14 13.35 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 105.525 -2.028 . . . . 74.55 105.525 165.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 . . . . . 0 C--N 1.355 0.836 0 CA-C-N 119.718 1.145 . . . . 73.32 109.589 -175.351 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.666 0 N-CA-C 115.658 1.023 . . . . 63.35 115.658 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 -176.9 6.22 Favored 'General case' 0 C--N 1.353 0.747 0 CA-C-N 119.046 1.423 . . . . 70.05 108.438 175.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -64.56 -29.63 70.66 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-O 117.178 -1.391 . . . . 73.11 113.779 -173.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.14 151.56 9.34 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.703 1.592 . . . . 73.01 111.31 -173.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.65 -106.91 0.31 Allowed Glycine 0 C--N 1.358 1.762 0 CA-C-O 117.556 -1.691 . . . . 72.01 111.585 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.7 159.88 31.87 Favored Pre-proline 0 C--N 1.357 0.919 0 CA-C-O 115.247 -2.311 . . . . 75.54 108.333 -176.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -55.32 130.12 38.89 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.865 2.773 . . . . 74.12 112.42 -173.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.6 mt-10 -68.59 -57.17 6.14 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.035 -1.098 . . . . 73.22 108.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.24 1.86 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-O 118.389 -0.815 . . . . 72.01 109.563 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.77 -50.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.538 -0.744 . . . . 64.12 109.755 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.37 145.41 68.14 Favored Pre-proline 0 C--N 1.354 0.803 0 N-CA-C 105.193 -2.151 . . . . 74.11 105.193 172.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.44 75.34 1.51 Allowed 'Trans proline' 0 C--N 1.359 1.13 0 CA-C-N 123.762 2.379 . . . . 73.22 112.161 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 63.3 mt -89.42 -56.87 3.09 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.785 -1.561 . . . . 74.45 106.785 171.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.7 145.12 16.13 Favored Glycine 0 C--N 1.357 1.698 0 N-CA-C 108.517 -1.833 . . . . 71.14 108.517 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.15 93.18 3.94 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.958 1.379 . . . . 74.33 111.104 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -119.13 156.3 30.03 Favored 'General case' 0 C--N 1.359 0.996 0 CA-C-O 117.174 -1.394 . . . . 70.34 107.955 170.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.7 pt -90.58 140.61 15.67 Favored 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 105.245 -2.131 . . . . 73.1 105.245 165.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 . . . . . 0 C--N 1.355 0.83 0 CA-C-N 119.876 1.216 . . . . 74.43 109.642 -174.613 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 N-CA-C 117.019 1.568 . . . . 65.11 117.019 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.79 -171.47 3.7 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-N 120.341 2.07 . . . . 73.11 107.301 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -70.57 -26.42 63.52 Favored 'General case' 0 C--N 1.351 0.663 0 CA-C-O 117.21 -1.376 . . . . 72.55 113.502 -172.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.52 150.09 10.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.823 0 CA-C-N 120.641 1.564 . . . . 73.03 110.795 -174.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.99 -108.11 0.35 Allowed Glycine 0 C--N 1.358 1.796 0 CA-C-O 117.541 -1.699 . . . . 71.25 111.784 178.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.86 161.03 30.22 Favored Pre-proline 0 C--N 1.357 0.892 0 CA-C-O 115.298 -2.287 . . . . 74.21 108.421 -174.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 131.22 44.16 Favored 'Trans proline' 0 C--N 1.361 1.202 0 CA-C-N 125.119 2.864 . . . . 75.01 112.078 -172.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -69.92 -57.73 4.69 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.027 -1.101 . . . . 74.51 108.027 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.97 -61.65 1.72 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.347 -0.835 . . . . 73.03 109.58 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.6 p -174.98 -51.58 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.706 -0.664 . . . . 73.21 109.769 -176.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.74 145.39 78.27 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 105.076 -2.194 . . . . 73.42 105.076 172.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -71.02 73.8 1.92 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.724 2.366 . . . . 73.21 112.137 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.1 mt -87.29 -56.27 3.44 Favored 'General case' 0 C--N 1.355 0.841 0 N-CA-C 106.842 -1.54 . . . . 75.22 106.842 171.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.01 153.14 16.89 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 109.176 -1.569 . . . . 75.14 109.176 -178.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -127.69 88.34 2.76 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.218 1.009 . . . . 72.41 111.509 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -118.97 148.76 42.62 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-O 116.841 -1.552 . . . . 75.22 107.982 171.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 48.4 pt -85.61 141.83 14.0 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.796 -1.927 . . . . 73.05 105.796 165.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 . . . . . 0 C--N 1.355 0.816 0 CA-C-N 119.679 1.127 . . . . 65.31 109.547 -175.704 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.672 0 CA-C-O 118.757 -1.024 . . . . 75.53 114.846 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -159.59 -178.67 7.27 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.107 1.453 . . . . 74.14 108.534 176.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -63.05 -30.56 71.69 Favored 'General case' 0 C--N 1.351 0.671 0 CA-C-O 117.086 -1.435 . . . . 73.31 113.693 -173.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -156.19 151.8 9.03 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 120.741 1.61 . . . . 74.42 111.42 -172.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 151.99 -106.43 0.3 Allowed Glycine 0 C--N 1.358 1.77 0 CA-C-O 117.707 -1.607 . . . . 74.42 111.49 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.72 159.37 32.54 Favored Pre-proline 0 C--N 1.356 0.878 0 CA-C-O 115.395 -2.24 . . . . 74.51 108.347 -176.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -54.95 130.11 38.94 Favored 'Trans proline' 0 C--N 1.362 1.266 0 CA-C-N 124.761 2.736 . . . . 73.33 112.578 -173.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -68.44 -57.2 6.22 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.063 -1.088 . . . . 75.11 108.063 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.83 -61.14 1.9 Allowed 'General case' 0 C--N 1.354 0.788 0 CA-C-O 118.364 -0.827 . . . . 64.55 109.615 179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -175.77 -50.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.572 -0.727 . . . . 72.32 109.86 -176.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -79.04 145.53 65.65 Favored Pre-proline 0 C--N 1.355 0.823 0 CA-C-O 115.56 -2.162 . . . . 74.22 105.249 172.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -70.23 75.42 1.41 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.768 2.381 . . . . 72.11 112.255 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.8 mt -89.83 -56.86 3.07 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 106.725 -1.583 . . . . 74.34 106.725 171.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.64 142.77 15.89 Favored Glycine 0 C--N 1.357 1.719 0 N-CA-C 108.318 -1.913 . . . . 71.14 108.318 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -119.32 94.49 4.44 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-N 119.108 1.454 . . . . 74.15 110.959 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -119.37 155.83 31.21 Favored 'General case' 0 C--N 1.36 1.035 0 CA-C-O 117.165 -1.397 . . . . 71.34 107.903 170.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.5 pt -88.97 140.42 15.82 Favored 'Isoleucine or valine' 0 C--N 1.357 0.922 0 N-CA-C 105.157 -2.164 . . . . 74.15 105.157 164.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 . . . . . 0 C--N 1.355 0.822 0 CA-C-N 119.972 1.26 . . . . 74.42 109.794 -174.691 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.699 0 N-CA-C 117.434 1.734 . . . . 73.44 117.434 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -140.25 -162.39 1.34 Allowed 'General case' 0 C--N 1.356 0.871 0 CA-C-N 120.668 2.234 . . . . 63.23 106.716 172.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -79.39 -27.84 41.84 Favored 'General case' 0 C--N 1.352 0.716 0 CA-C-N 121.023 1.738 . . . . 73.13 113.263 -172.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.5 p -154.16 148.69 13.17 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.286 1.403 . . . . 74.51 110.265 -175.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.26 -106.47 0.3 Allowed Glycine 0 C--N 1.357 1.745 0 CA-C-O 117.603 -1.665 . . . . 61.42 112.278 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.93 160.99 30.32 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.447 -2.216 . . . . 73.32 108.915 -172.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -58.48 128.79 29.7 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.797 2.749 . . . . 75.13 112.048 -173.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -67.34 -57.68 6.18 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 108.228 -1.027 . . . . 73.44 108.228 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -86.16 -62.43 1.52 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.057 0.844 . . . . 74.31 109.646 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.09 -51.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.784 -0.627 . . . . 74.33 109.855 -176.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.23 146.17 84.03 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 104.946 -2.242 . . . . 75.34 104.946 172.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.24 72.01 2.25 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 123.855 2.412 . . . . 73.02 112.188 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.6 mt -86.36 -55.29 3.97 Favored 'General case' 0 C--N 1.354 0.78 0 N-CA-C 106.898 -1.519 . . . . 71.22 106.898 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.3 157.57 15.45 Favored Glycine 0 C--N 1.356 1.67 0 N-CA-C 110.022 -1.231 . . . . 74.22 110.022 -176.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.58 84.24 2.16 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-O 118.13 -0.938 . . . . 75.22 111.758 -177.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -122.81 134.64 54.41 Favored 'General case' 0 C--N 1.36 1.042 0 CA-C-O 116.665 -1.636 . . . . 60.41 108.817 173.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -74.83 140.35 17.64 Favored 'Isoleucine or valine' 0 C--N 1.357 0.926 0 N-CA-C 106.813 -1.551 . . . . 72.0 106.813 167.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.4 mt-30 . . . . . 0 C--N 1.355 0.846 0 CA-C-N 119.405 1.002 . . . . 73.21 109.398 -176.841 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.679 0 N-CA-C 117.288 1.675 . . . . 75.32 117.288 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.02 -174.04 4.16 Favored 'General case' 0 C--N 1.356 0.872 0 CA-C-N 120.384 2.092 . . . . 74.22 107.284 173.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -68.45 -25.76 65.17 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-O 117.147 -1.406 . . . . 74.15 113.343 -172.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.49 151.42 8.14 Favored 'Isoleucine or valine' 0 C--N 1.354 0.787 0 CA-C-N 120.85 1.659 . . . . 72.34 110.75 -175.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.47 -104.72 0.26 Allowed Glycine 0 C--N 1.358 1.758 0 CA-C-O 117.848 -1.529 . . . . 73.32 111.459 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.67 158.55 29.44 Favored Pre-proline 0 C--N 1.355 0.847 0 CA-C-O 115.364 -2.255 . . . . 73.32 107.903 -174.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -55.58 135.7 70.58 Favored 'Trans proline' 0 C--N 1.36 1.156 0 CA-C-N 124.842 2.765 . . . . 71.13 112.901 -170.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -73.39 -59.79 2.54 Favored 'General case' 0 C--N 1.355 0.818 0 N-CA-C 108.116 -1.068 . . . . 72.22 108.116 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.23 -61.17 1.87 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.012 0.824 . . . . 65.54 109.322 178.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.07 -51.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-O 118.727 -0.654 . . . . 73.02 109.697 -177.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.7 145.02 81.23 Favored Pre-proline 0 C--N 1.355 0.832 0 N-CA-C 105.031 -2.211 . . . . 75.25 105.031 172.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -71.51 73.04 2.29 Favored 'Trans proline' 0 C--N 1.357 1.024 0 CA-C-N 123.706 2.359 . . . . 55.43 112.045 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.8 mt -84.82 -55.38 4.12 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 106.585 -1.635 . . . . 74.52 106.585 171.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.47 159.39 13.78 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 109.273 -1.531 . . . . 74.3 109.273 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -130.59 90.15 2.88 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 117.998 -1.001 . . . . 73.42 111.773 -177.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -124.86 143.14 50.99 Favored 'General case' 0 C--N 1.36 1.065 0 CA-C-O 116.868 -1.539 . . . . 72.23 108.259 172.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 46.6 pt -79.09 139.01 19.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.898 0 N-CA-C 106.355 -1.72 . . . . 73.53 106.355 167.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 . . . . . 0 C--N 1.355 0.839 0 CA-C-N 119.507 1.049 . . . . 74.41 109.297 -176.289 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.684 0 N-CA-C 117.447 1.739 . . . . 73.13 117.447 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.53 -173.18 3.7 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-N 120.539 2.17 . . . . 74.53 107.127 172.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -69.95 -25.18 63.52 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-O 117.286 -1.34 . . . . 73.33 113.329 -172.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.34 151.02 8.62 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.733 1.606 . . . . 73.41 110.632 -175.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.39 -104.66 0.26 Allowed Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.865 -1.519 . . . . 64.21 111.703 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.16 29.18 Favored Pre-proline 0 C--N 1.356 0.869 0 CA-C-O 115.433 -2.222 . . . . 75.52 107.975 -173.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -55.88 136.18 73.34 Favored 'Trans proline' 0 C--N 1.361 1.187 0 CA-C-N 124.659 2.7 . . . . 74.4 113.0 -170.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -73.74 -60.12 2.4 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.177 -1.046 . . . . 73.42 108.177 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.58 -61.28 1.83 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-N 119.096 0.862 . . . . 74.15 109.271 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.7 -51.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.822 0 CA-C-O 118.735 -0.65 . . . . 74.4 109.693 -177.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.0 145.16 83.3 Favored Pre-proline 0 C--N 1.355 0.845 0 N-CA-C 104.954 -2.239 . . . . 74.22 104.954 172.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.66 72.73 2.43 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 123.833 2.405 . . . . 63.11 111.911 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.7 mt -84.45 -55.04 4.36 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 106.618 -1.623 . . . . 74.02 106.618 171.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.88 161.64 12.68 Favored Glycine 0 C--N 1.358 1.754 0 N-CA-C 109.467 -1.453 . . . . 73.25 109.467 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -132.25 88.6 2.56 Favored 'General case' 0 C--N 1.354 0.8 0 CA-C-O 117.937 -1.03 . . . . 72.42 111.733 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -124.84 140.16 53.18 Favored 'General case' 0 C--N 1.361 1.069 0 CA-C-O 116.827 -1.559 . . . . 65.14 108.423 172.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.9 pt -77.5 138.66 20.01 Favored 'Isoleucine or valine' 0 C--N 1.358 0.938 0 N-CA-C 106.661 -1.607 . . . . 71.34 106.661 167.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 . . . . . 0 C--N 1.356 0.85 0 CA-C-N 119.342 0.974 . . . . 75.24 109.227 -176.412 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 117.367 1.707 . . . . 72.4 117.367 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -143.44 -172.79 3.78 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 120.475 2.137 . . . . 64.54 107.222 172.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.21 -25.64 64.42 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.208 -1.377 . . . . 75.31 113.339 -173.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.47 151.5 8.09 Favored 'Isoleucine or valine' 0 C--N 1.354 0.782 0 CA-C-N 120.753 1.615 . . . . 74.01 110.695 -175.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.51 -103.8 0.24 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.948 -1.473 . . . . 54.54 111.681 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.04 158.1 28.59 Favored Pre-proline 0 C--N 1.356 0.867 0 CA-C-O 115.413 -2.232 . . . . 74.34 108.097 -173.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.68 134.31 63.27 Favored 'Trans proline' 0 C--N 1.361 1.192 0 CA-C-N 124.759 2.735 . . . . 74.44 112.918 -170.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -72.22 -60.05 2.43 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.181 -1.044 . . . . 75.24 108.181 -178.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.44 -61.35 1.82 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.119 0.872 . . . . 73.23 109.34 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -174.72 -51.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.783 0 CA-C-O 118.673 -0.68 . . . . 72.31 109.75 -177.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.55 145.18 81.85 Favored Pre-proline 0 C--N 1.355 0.809 0 N-CA-C 104.986 -2.227 . . . . 73.53 104.986 172.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.58 72.75 2.37 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.811 2.397 . . . . 64.45 111.973 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.36 -55.13 4.33 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 106.579 -1.637 . . . . 74.1 106.579 171.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.63 160.99 12.91 Favored Glycine 0 C--N 1.357 1.711 0 N-CA-C 109.337 -1.505 . . . . 72.52 109.337 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.64 90.68 2.88 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 117.923 -1.037 . . . . 73.44 111.868 -177.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -127.77 140.08 52.27 Favored 'General case' 0 C--N 1.362 1.112 0 CA-C-O 116.759 -1.591 . . . . 74.25 108.478 172.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.9 pt -77.9 139.17 19.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 N-CA-C 106.662 -1.607 . . . . 71.22 106.662 167.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 . . . . . 0 C--N 1.357 0.898 0 CA-C-N 119.303 0.956 . . . . 73.12 109.166 -176.116 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 N-CA-C 117.217 1.647 . . . . 72.53 117.217 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.34 -174.03 4.27 Favored 'General case' 0 C--N 1.355 0.835 0 CA-C-N 120.327 2.064 . . . . 74.11 107.377 173.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -67.68 -25.74 65.84 Favored 'General case' 0 C--N 1.351 0.658 0 CA-C-O 117.164 -1.398 . . . . 74.2 113.426 -173.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.74 152.05 7.4 Favored 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-N 120.83 1.65 . . . . 75.43 110.826 -175.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.43 -103.89 0.24 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.962 -1.466 . . . . 72.52 111.522 177.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.21 158.19 28.23 Favored Pre-proline 0 C--N 1.356 0.865 0 CA-C-O 115.31 -2.281 . . . . 61.21 107.981 -174.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -55.27 134.42 63.72 Favored 'Trans proline' 0 C--N 1.359 1.113 0 CA-C-N 124.875 2.777 . . . . 74.01 112.947 -170.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -72.45 -59.97 2.46 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.172 -1.048 . . . . 74.42 108.172 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.16 -61.14 1.89 Allowed 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.031 0.832 . . . . 74.42 109.372 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.04 -51.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.724 -0.655 . . . . 74.44 109.711 -177.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.14 144.93 79.75 Favored Pre-proline 0 C--N 1.356 0.866 0 N-CA-C 104.942 -2.244 . . . . 63.02 104.942 172.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -71.59 72.96 2.35 Favored 'Trans proline' 0 C--N 1.358 1.032 0 CA-C-N 123.694 2.355 . . . . 73.41 112.09 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.2 mt -84.6 -55.52 4.08 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.592 -1.633 . . . . 75.33 106.592 171.42 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.97 159.05 13.99 Favored Glycine 0 C--N 1.357 1.712 0 N-CA-C 109.225 -1.55 . . . . 73.25 109.225 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -130.29 92.55 3.3 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 117.951 -1.023 . . . . 74.12 111.844 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -128.71 142.76 50.91 Favored 'General case' 0 C--N 1.361 1.072 0 CA-C-O 116.82 -1.562 . . . . 74.33 108.411 172.021 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -80.55 140.62 16.4 Favored 'Isoleucine or valine' 0 C--N 1.357 0.904 0 N-CA-C 106.399 -1.704 . . . . 73.21 106.399 166.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 . . . . . 0 C--N 1.355 0.846 0 CA-C-N 119.33 0.968 . . . . 75.15 109.189 -175.552 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 N-CA-C 116.97 1.548 . . . . 73.1 116.97 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.43 -174.7 4.53 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-N 120.246 2.023 . . . . 72.33 107.528 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -67.0 -26.11 66.64 Favored 'General case' 0 C--N 1.35 0.607 0 CA-C-O 117.12 -1.419 . . . . 63.41 113.393 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.8 152.15 7.28 Favored 'Isoleucine or valine' 0 C--N 1.354 0.796 0 CA-C-N 120.891 1.678 . . . . 74.11 110.888 -174.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.31 -104.27 0.25 Allowed Glycine 0 C--N 1.358 1.759 0 CA-C-O 117.93 -1.483 . . . . 73.32 111.436 178.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.06 158.42 28.82 Favored Pre-proline 0 C--N 1.355 0.836 0 CA-C-O 115.342 -2.266 . . . . 73.44 107.909 -174.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.23 134.47 64.0 Favored 'Trans proline' 0 C--N 1.36 1.143 0 CA-C-N 124.878 2.778 . . . . 74.23 112.957 -170.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -72.39 -59.53 2.68 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 108.154 -1.054 . . . . 65.44 108.154 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.94 -61.09 1.91 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 119.029 0.831 . . . . 63.24 109.344 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.49 -51.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.819 0 CA-C-O 118.738 -0.648 . . . . 72.01 109.6 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.31 144.93 79.12 Favored Pre-proline 0 C--N 1.356 0.853 0 N-CA-C 104.939 -2.245 . . . . 73.24 104.939 172.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.48 73.52 2.22 Favored 'Trans proline' 0 C--N 1.358 1.048 0 CA-C-N 123.84 2.407 . . . . 75.52 111.987 -179.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 68.8 mt -85.42 -55.63 3.92 Favored 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.516 -1.661 . . . . 74.12 106.516 171.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.04 157.96 14.65 Favored Glycine 0 C--N 1.357 1.704 0 N-CA-C 109.08 -1.608 . . . . 45.15 109.08 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.56 92.56 3.36 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 117.999 -1.001 . . . . 74.11 111.779 -178.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -127.13 143.97 51.14 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-O 116.837 -1.554 . . . . 74.42 108.247 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 47.8 pt -79.68 138.98 18.97 Favored 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 106.371 -1.714 . . . . 73.03 106.371 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.3 mt-30 . . . . . 0 C--N 1.355 0.836 0 CA-C-N 119.455 1.025 . . . . 74.24 109.223 -176.08 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 117.434 1.734 . . . . 53.42 117.434 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.66 -173.13 3.7 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-N 120.669 2.235 . . . . 71.33 107.185 172.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -69.9 -25.39 63.67 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-O 117.234 -1.365 . . . . 72.12 113.378 -172.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.07 150.97 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 CA-C-N 120.652 1.569 . . . . 73.43 110.558 -175.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.37 -104.57 0.26 Allowed Glycine 0 C--N 1.358 1.781 0 CA-C-O 117.902 -1.499 . . . . 63.44 111.802 178.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.14 29.16 Favored Pre-proline 0 C--N 1.356 0.871 0 CA-C-O 115.36 -2.257 . . . . 72.45 108.13 -173.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -55.89 135.95 72.19 Favored 'Trans proline' 0 C--N 1.359 1.088 0 CA-C-N 124.767 2.738 . . . . 74.14 112.94 -170.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -73.69 -60.31 2.31 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 108.158 -1.052 . . . . 72.2 108.158 -178.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.43 -61.19 1.86 Allowed 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.081 0.855 . . . . 71.53 109.274 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.65 -51.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.356 0.854 0 CA-C-O 118.672 -0.68 . . . . 73.14 109.75 -177.224 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.12 145.13 82.93 Favored Pre-proline 0 C--N 1.355 0.818 0 N-CA-C 104.997 -2.223 . . . . 73.31 104.997 172.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.64 72.91 2.39 Favored 'Trans proline' 0 C--N 1.358 1.04 0 CA-C-N 123.798 2.392 . . . . 74.15 111.894 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.0 mt -84.55 -55.0 4.36 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.587 -1.635 . . . . 75.43 106.587 171.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.86 161.4 12.76 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 109.43 -1.468 . . . . 74.52 109.43 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.87 88.46 2.56 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.879 -1.058 . . . . 74.33 111.84 -177.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -124.97 139.98 53.33 Favored 'General case' 0 C--N 1.36 1.057 0 CA-C-O 116.777 -1.582 . . . . 73.12 108.498 172.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -78.41 139.39 18.57 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 106.647 -1.612 . . . . 75.42 106.647 167.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 . . . . . 0 C--N 1.356 0.863 0 CA-C-N 119.275 0.943 . . . . 74.33 109.2 -176.262 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 N-CA-C 117.015 1.566 . . . . 60.54 117.015 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.45 -175.17 4.81 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 120.216 2.008 . . . . 73.3 107.847 173.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 51.3 m-85 -65.76 -27.2 68.12 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-O 117.101 -1.428 . . . . 70.05 113.463 -173.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.44 152.35 7.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 CA-C-N 120.879 1.672 . . . . 75.54 111.044 -174.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.67 -104.92 0.26 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.957 -1.468 . . . . 74.15 111.147 178.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.03 158.79 29.21 Favored Pre-proline 0 C--N 1.357 0.909 0 CA-C-O 115.525 -2.178 . . . . 73.35 107.791 -174.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -54.76 134.42 62.67 Favored 'Trans proline' 0 C--N 1.36 1.141 0 CA-C-N 124.834 2.762 . . . . 73.0 113.016 -170.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -72.41 -59.26 2.82 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.085 -1.08 . . . . 71.21 108.085 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.72 -60.97 1.95 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 118.968 0.804 . . . . 65.21 109.351 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.72 -51.48 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.805 0 CA-C-O 118.832 -0.604 . . . . 73.4 109.615 -177.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.95 144.97 76.86 Favored Pre-proline 0 C--N 1.355 0.811 0 N-CA-C 104.959 -2.237 . . . . 72.5 104.959 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -71.32 73.83 2.09 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.755 2.377 . . . . 71.35 112.007 -179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.4 mt -86.14 -56.0 3.66 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 106.495 -1.669 . . . . 74.23 106.495 171.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.08 156.33 15.64 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.993 -1.643 . . . . 73.03 108.993 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -128.28 93.48 3.66 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.99 -1.005 . . . . 75.34 111.668 -178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -127.69 146.55 50.53 Favored 'General case' 0 C--N 1.36 1.052 0 CA-C-O 116.908 -1.52 . . . . 74.42 108.198 171.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -82.1 139.65 17.6 Favored 'Isoleucine or valine' 0 C--N 1.357 0.934 0 N-CA-C 106.091 -1.818 . . . . 73.5 106.091 166.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 . . . . . 0 C--N 1.356 0.853 0 CA-C-N 119.58 1.082 . . . . 72.35 109.392 -175.598 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.587 -1.119 . . . . 73.14 115.382 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.66 -177.13 6.37 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.366 1.583 . . . . 52.0 108.282 175.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -64.3 -29.32 70.41 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.105 -1.426 . . . . 73.31 113.685 -173.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -156.43 151.6 9.02 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.709 1.595 . . . . 75.42 111.401 -173.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.68 -107.27 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.666 -1.63 . . . . 71.42 111.497 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.78 159.96 31.71 Favored Pre-proline 0 C--N 1.356 0.86 0 CA-C-O 115.45 -2.214 . . . . 72.5 108.248 -176.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -55.35 130.5 40.95 Favored 'Trans proline' 0 C--N 1.362 1.265 0 CA-C-N 124.839 2.764 . . . . 72.32 112.61 -173.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 81.3 mt-10 -68.98 -57.14 5.87 Favored 'General case' 0 C--N 1.354 0.77 0 N-CA-C 108.004 -1.11 . . . . 72.4 108.004 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.15 -61.27 1.85 Allowed 'General case' 0 C--N 1.354 0.782 0 CA-C-O 118.343 -0.837 . . . . 73.2 109.632 179.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.72 -51.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.773 0 CA-C-O 118.64 -0.695 . . . . 70.23 109.786 -176.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.42 145.38 67.87 Favored Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.538 -2.172 . . . . 71.51 105.18 172.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -70.42 75.06 1.52 Allowed 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.752 2.376 . . . . 71.41 112.211 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -88.91 -56.74 3.16 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 106.697 -1.594 . . . . 74.24 106.697 171.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.94 145.16 16.2 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.523 -1.831 . . . . 64.44 108.523 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.22 93.95 4.18 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.937 1.368 . . . . 72.35 111.139 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -120.11 157.19 29.5 Favored 'General case' 0 C--N 1.36 1.047 0 CA-C-O 117.248 -1.358 . . . . 73.42 107.868 170.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -92.3 141.04 15.17 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 105.344 -2.095 . . . . 74.24 105.344 164.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -147.73 164.11 34.6 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.84 1.2 . . . . 75.54 109.747 -174.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.545 0 N-CA-C 109.458 -1.457 . . . . 73.31 109.458 179.359 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.721 0 CA-C-O 118.708 -1.051 . . . . 73.3 115.306 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.14 -177.33 6.53 Favored 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.273 1.537 . . . . 75.23 108.388 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -63.92 -29.64 70.8 Favored 'General case' 0 C--N 1.351 0.665 0 CA-C-O 117.07 -1.443 . . . . 65.02 113.615 -173.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.9 p -156.37 151.71 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 120.811 1.642 . . . . 74.24 111.374 -173.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.66 -107.12 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.682 -1.621 . . . . 63.33 111.455 177.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.89 159.86 31.77 Favored Pre-proline 0 C--N 1.356 0.859 0 CA-C-O 115.418 -2.23 . . . . 73.52 108.296 -176.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -54.95 129.81 37.31 Favored 'Trans proline' 0 C--N 1.361 1.233 0 CA-C-N 124.818 2.756 . . . . 74.34 112.584 -173.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -68.37 -57.03 6.53 Favored 'General case' 0 C--N 1.355 0.839 0 N-CA-C 108.047 -1.094 . . . . 63.42 108.047 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.11 -61.32 1.84 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-O 118.396 -0.811 . . . . 74.2 109.66 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.73 -50.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-O 118.653 -0.689 . . . . 74.11 109.858 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.68 145.45 66.96 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.566 -2.159 . . . . 73.23 105.194 172.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -70.3 75.14 1.47 Allowed 'Trans proline' 0 C--N 1.358 1.044 0 CA-C-N 123.777 2.384 . . . . 71.02 112.252 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -89.42 -56.85 3.09 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 106.769 -1.567 . . . . 73.14 106.769 171.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.62 144.63 16.06 Favored Glycine 0 C--N 1.357 1.721 0 N-CA-C 108.45 -1.86 . . . . 52.23 108.45 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -120.8 94.16 4.26 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.963 1.381 . . . . 73.41 111.185 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -120.7 156.53 31.56 Favored 'General case' 0 C--N 1.359 1.012 0 CA-C-O 117.186 -1.388 . . . . 75.21 107.843 170.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.6 pt -91.24 141.07 14.98 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.283 -2.117 . . . . 74.31 105.283 164.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -147.43 164.59 32.87 Favored 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.808 1.185 . . . . 74.33 109.626 -174.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.563 0 N-CA-C 109.169 -1.572 . . . . 74.33 109.169 179.826 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 N-CA-C 117.347 1.699 . . . . 62.14 117.347 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.23 -169.52 2.97 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 120.619 2.21 . . . . 72.05 107.081 173.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -72.83 -25.95 61.31 Favored 'General case' 0 C--N 1.351 0.659 0 CA-C-N 120.389 1.45 . . . . 74.22 113.38 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -156.35 149.62 10.83 Favored 'Isoleucine or valine' 0 C--N 1.355 0.816 0 CA-C-N 120.555 1.525 . . . . 74.12 110.569 -175.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.98 -108.37 0.36 Allowed Glycine 0 C--N 1.357 1.74 0 CA-C-O 117.592 -1.671 . . . . 65.43 111.969 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.9 161.12 29.94 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.359 -2.258 . . . . 73.24 108.512 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -57.68 131.83 46.51 Favored 'Trans proline' 0 C--N 1.361 1.195 0 CA-C-N 124.969 2.81 . . . . 75.1 112.119 -172.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -70.26 -58.19 4.04 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.063 -1.088 . . . . 65.3 108.063 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -85.22 -61.78 1.69 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.038 0.835 . . . . 73.44 109.56 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.65 -51.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.767 0 CA-C-O 118.736 -0.65 . . . . 63.53 109.838 -176.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.85 145.51 81.51 Favored Pre-proline 0 C--N 1.355 0.839 0 N-CA-C 105.056 -2.201 . . . . 74.23 105.056 172.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.26 72.87 2.16 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.743 2.373 . . . . 74.43 112.223 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.9 mt -86.24 -55.79 3.75 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.826 -1.546 . . . . 60.42 106.826 171.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.48 155.94 15.94 Favored Glycine 0 C--N 1.357 1.73 0 N-CA-C 109.503 -1.439 . . . . 75.24 109.503 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -129.75 86.56 2.43 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.077 -0.963 . . . . 75.41 111.642 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -120.03 145.21 47.04 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-O 116.67 -1.633 . . . . 64.12 108.243 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.4 pt -84.22 141.35 14.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.924 0 N-CA-C 106.127 -1.805 . . . . 72.52 106.127 166.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -149.69 164.39 35.34 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 119.442 1.019 . . . . 74.12 109.428 -175.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.536 0 N-CA-C 109.512 -1.435 . . . . 62.54 109.512 178.973 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.71 0 N-CA-C 116.363 1.305 . . . . 73.43 116.363 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -150.3 -173.47 4.46 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.912 1.856 . . . . 65.23 107.76 174.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -67.86 -27.42 66.67 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.155 -1.402 . . . . 71.04 113.585 -172.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.62 151.03 9.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 120.703 1.592 . . . . 64.14 110.998 -174.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.71 -107.64 0.33 Allowed Glycine 0 C--N 1.358 1.787 0 CA-C-O 117.618 -1.657 . . . . 75.45 111.594 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.09 160.7 30.61 Favored Pre-proline 0 C--N 1.357 0.924 0 CA-C-O 115.314 -2.279 . . . . 73.41 108.428 -175.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -55.96 130.06 38.25 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 125.031 2.832 . . . . 71.52 112.287 -173.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -68.99 -57.27 5.69 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.024 -1.102 . . . . 72.13 108.024 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.69 -61.58 1.75 Allowed 'General case' 0 C--N 1.354 0.775 0 CA-C-O 118.403 -0.808 . . . . 73.25 109.563 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.29 -51.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 118.614 -0.707 . . . . 74.43 109.798 -176.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -77.09 145.42 73.38 Favored Pre-proline 0 C--N 1.354 0.789 0 N-CA-C 105.059 -2.2 . . . . 62.42 105.059 172.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -70.67 74.45 1.69 Allowed 'Trans proline' 0 C--N 1.358 1.053 0 CA-C-N 123.804 2.394 . . . . 73.4 112.168 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 65.5 mt -88.22 -56.52 3.29 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 106.722 -1.584 . . . . 71.43 106.722 171.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.75 150.27 16.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 108.909 -1.677 . . . . 55.31 108.909 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -125.44 91.34 3.39 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 118.452 1.126 . . . . 74.1 111.422 -178.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -120.77 151.82 39.09 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.907 -1.52 . . . . 72.31 107.937 171.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.4 pt -88.01 142.14 13.35 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 105.525 -2.028 . . . . 74.55 105.525 165.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 -148.52 163.88 35.87 Favored 'General case' 0 C--N 1.355 0.836 0 CA-C-N 119.718 1.145 . . . . 73.32 109.589 -175.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.563 0 N-CA-C 109.538 -1.425 . . . . 70.04 109.538 179.252 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.666 0 N-CA-C 115.658 1.023 . . . . 63.35 115.658 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 -176.9 6.22 Favored 'General case' 0 C--N 1.353 0.747 0 CA-C-N 119.046 1.423 . . . . 70.05 108.438 175.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -64.56 -29.63 70.66 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-O 117.178 -1.391 . . . . 73.11 113.779 -173.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.14 151.56 9.34 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.703 1.592 . . . . 73.01 111.31 -173.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.65 -106.91 0.31 Allowed Glycine 0 C--N 1.358 1.762 0 CA-C-O 117.556 -1.691 . . . . 72.01 111.585 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.7 159.88 31.87 Favored Pre-proline 0 C--N 1.357 0.919 0 CA-C-O 115.247 -2.311 . . . . 75.54 108.333 -176.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -55.32 130.12 38.89 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.865 2.773 . . . . 74.12 112.42 -173.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.6 mt-10 -68.59 -57.17 6.14 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.035 -1.098 . . . . 73.22 108.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.24 1.86 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-O 118.389 -0.815 . . . . 72.01 109.563 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.77 -50.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.538 -0.744 . . . . 64.12 109.755 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.37 145.41 68.14 Favored Pre-proline 0 C--N 1.354 0.803 0 N-CA-C 105.193 -2.151 . . . . 74.11 105.193 172.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.44 75.34 1.51 Allowed 'Trans proline' 0 C--N 1.359 1.13 0 CA-C-N 123.762 2.379 . . . . 73.22 112.161 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 63.3 mt -89.42 -56.87 3.09 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.785 -1.561 . . . . 74.45 106.785 171.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.7 145.12 16.13 Favored Glycine 0 C--N 1.357 1.698 0 N-CA-C 108.517 -1.833 . . . . 71.14 108.517 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.15 93.18 3.94 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.958 1.379 . . . . 74.33 111.104 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -119.13 156.3 30.03 Favored 'General case' 0 C--N 1.359 0.996 0 CA-C-O 117.174 -1.394 . . . . 70.34 107.955 170.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.7 pt -90.58 140.61 15.67 Favored 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 105.245 -2.131 . . . . 73.1 105.245 165.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -147.62 164.45 33.45 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 119.876 1.216 . . . . 74.43 109.642 -174.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.579 0 N-CA-C 109.172 -1.571 . . . . 74.31 109.172 179.68 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 N-CA-C 117.019 1.568 . . . . 65.11 117.019 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.79 -171.47 3.7 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-N 120.341 2.07 . . . . 73.11 107.301 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -70.57 -26.42 63.52 Favored 'General case' 0 C--N 1.351 0.663 0 CA-C-O 117.21 -1.376 . . . . 72.55 113.502 -172.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.52 150.09 10.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.823 0 CA-C-N 120.641 1.564 . . . . 73.03 110.795 -174.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.99 -108.11 0.35 Allowed Glycine 0 C--N 1.358 1.796 0 CA-C-O 117.541 -1.699 . . . . 71.25 111.784 178.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.86 161.03 30.22 Favored Pre-proline 0 C--N 1.357 0.892 0 CA-C-O 115.298 -2.287 . . . . 74.21 108.421 -174.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 131.22 44.16 Favored 'Trans proline' 0 C--N 1.361 1.202 0 CA-C-N 125.119 2.864 . . . . 75.01 112.078 -172.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -69.92 -57.73 4.69 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.027 -1.101 . . . . 74.51 108.027 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.97 -61.65 1.72 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.347 -0.835 . . . . 73.03 109.58 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.6 p -174.98 -51.58 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.706 -0.664 . . . . 73.21 109.769 -176.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.74 145.39 78.27 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 105.076 -2.194 . . . . 73.42 105.076 172.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -71.02 73.8 1.92 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.724 2.366 . . . . 73.21 112.137 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.1 mt -87.29 -56.27 3.44 Favored 'General case' 0 C--N 1.355 0.841 0 N-CA-C 106.842 -1.54 . . . . 75.22 106.842 171.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.01 153.14 16.89 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 109.176 -1.569 . . . . 75.14 109.176 -178.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -127.69 88.34 2.76 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.218 1.009 . . . . 72.41 111.509 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -118.97 148.76 42.62 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-O 116.841 -1.552 . . . . 75.22 107.982 171.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 48.4 pt -85.61 141.83 14.0 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.796 -1.927 . . . . 73.05 105.796 165.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -149.26 163.77 36.71 Favored 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.679 1.127 . . . . 65.31 109.547 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.593 0 N-CA-C 109.443 -1.463 . . . . 74.35 109.443 178.532 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.672 0 CA-C-O 118.757 -1.024 . . . . 75.53 114.846 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -159.59 -178.67 7.27 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.107 1.453 . . . . 74.14 108.534 176.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -63.05 -30.56 71.69 Favored 'General case' 0 C--N 1.351 0.671 0 CA-C-O 117.086 -1.435 . . . . 73.31 113.693 -173.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -156.19 151.8 9.03 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 120.741 1.61 . . . . 74.42 111.42 -172.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 151.99 -106.43 0.3 Allowed Glycine 0 C--N 1.358 1.77 0 CA-C-O 117.707 -1.607 . . . . 74.42 111.49 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.72 159.37 32.54 Favored Pre-proline 0 C--N 1.356 0.878 0 CA-C-O 115.395 -2.24 . . . . 74.51 108.347 -176.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -54.95 130.11 38.94 Favored 'Trans proline' 0 C--N 1.362 1.266 0 CA-C-N 124.761 2.736 . . . . 73.33 112.578 -173.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -68.44 -57.2 6.22 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.063 -1.088 . . . . 75.11 108.063 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.83 -61.14 1.9 Allowed 'General case' 0 C--N 1.354 0.788 0 CA-C-O 118.364 -0.827 . . . . 64.55 109.615 179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -175.77 -50.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.572 -0.727 . . . . 72.32 109.86 -176.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -79.04 145.53 65.65 Favored Pre-proline 0 C--N 1.355 0.823 0 CA-C-O 115.56 -2.162 . . . . 74.22 105.249 172.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -70.23 75.42 1.41 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.768 2.381 . . . . 72.11 112.255 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.8 mt -89.83 -56.86 3.07 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 106.725 -1.583 . . . . 74.34 106.725 171.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.64 142.77 15.89 Favored Glycine 0 C--N 1.357 1.719 0 N-CA-C 108.318 -1.913 . . . . 71.14 108.318 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -119.32 94.49 4.44 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-N 119.108 1.454 . . . . 74.15 110.959 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -119.37 155.83 31.21 Favored 'General case' 0 C--N 1.36 1.035 0 CA-C-O 117.165 -1.397 . . . . 71.34 107.903 170.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.5 pt -88.97 140.42 15.82 Favored 'Isoleucine or valine' 0 C--N 1.357 0.922 0 N-CA-C 105.157 -2.164 . . . . 74.15 105.157 164.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -147.46 164.42 33.42 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 119.972 1.26 . . . . 74.42 109.794 -174.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.559 0 N-CA-C 109.551 -1.42 . . . . 72.31 109.551 179.417 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.699 0 N-CA-C 117.434 1.734 . . . . 73.44 117.434 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -140.25 -162.39 1.34 Allowed 'General case' 0 C--N 1.356 0.871 0 CA-C-N 120.668 2.234 . . . . 63.23 106.716 172.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -79.39 -27.84 41.84 Favored 'General case' 0 C--N 1.352 0.716 0 CA-C-N 121.023 1.738 . . . . 73.13 113.263 -172.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.5 p -154.16 148.69 13.17 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.286 1.403 . . . . 74.51 110.265 -175.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.26 -106.47 0.3 Allowed Glycine 0 C--N 1.357 1.745 0 CA-C-O 117.603 -1.665 . . . . 61.42 112.278 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.93 160.99 30.32 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.447 -2.216 . . . . 73.32 108.915 -172.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -58.48 128.79 29.7 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.797 2.749 . . . . 75.13 112.048 -173.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -67.34 -57.68 6.18 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 108.228 -1.027 . . . . 73.44 108.228 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -86.16 -62.43 1.52 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.057 0.844 . . . . 74.31 109.646 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.09 -51.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.784 -0.627 . . . . 74.33 109.855 -176.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.23 146.17 84.03 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 104.946 -2.242 . . . . 75.34 104.946 172.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.24 72.01 2.25 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 123.855 2.412 . . . . 73.02 112.188 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.6 mt -86.36 -55.29 3.97 Favored 'General case' 0 C--N 1.354 0.78 0 N-CA-C 106.898 -1.519 . . . . 71.22 106.898 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.3 157.57 15.45 Favored Glycine 0 C--N 1.356 1.67 0 N-CA-C 110.022 -1.231 . . . . 74.22 110.022 -176.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.58 84.24 2.16 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-O 118.13 -0.938 . . . . 75.22 111.758 -177.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -122.81 134.64 54.41 Favored 'General case' 0 C--N 1.36 1.042 0 CA-C-O 116.665 -1.636 . . . . 60.41 108.817 173.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -74.83 140.35 17.64 Favored 'Isoleucine or valine' 0 C--N 1.357 0.926 0 N-CA-C 106.813 -1.551 . . . . 72.0 106.813 167.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.4 mt-30 -150.06 163.44 38.15 Favored 'General case' 0 C--N 1.355 0.846 0 CA-C-N 119.405 1.002 . . . . 73.21 109.398 -176.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.575 0 N-CA-C 109.305 -1.518 . . . . 71.21 109.305 177.93 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.679 0 N-CA-C 117.288 1.675 . . . . 75.32 117.288 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.02 -174.04 4.16 Favored 'General case' 0 C--N 1.356 0.872 0 CA-C-N 120.384 2.092 . . . . 74.22 107.284 173.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -68.45 -25.76 65.17 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-O 117.147 -1.406 . . . . 74.15 113.343 -172.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.49 151.42 8.14 Favored 'Isoleucine or valine' 0 C--N 1.354 0.787 0 CA-C-N 120.85 1.659 . . . . 72.34 110.75 -175.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.47 -104.72 0.26 Allowed Glycine 0 C--N 1.358 1.758 0 CA-C-O 117.848 -1.529 . . . . 73.32 111.459 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.67 158.55 29.44 Favored Pre-proline 0 C--N 1.355 0.847 0 CA-C-O 115.364 -2.255 . . . . 73.32 107.903 -174.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -55.58 135.7 70.58 Favored 'Trans proline' 0 C--N 1.36 1.156 0 CA-C-N 124.842 2.765 . . . . 71.13 112.901 -170.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -73.39 -59.79 2.54 Favored 'General case' 0 C--N 1.355 0.818 0 N-CA-C 108.116 -1.068 . . . . 72.22 108.116 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.23 -61.17 1.87 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.012 0.824 . . . . 65.54 109.322 178.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.07 -51.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-O 118.727 -0.654 . . . . 73.02 109.697 -177.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.7 145.02 81.23 Favored Pre-proline 0 C--N 1.355 0.832 0 N-CA-C 105.031 -2.211 . . . . 75.25 105.031 172.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -71.51 73.04 2.29 Favored 'Trans proline' 0 C--N 1.357 1.024 0 CA-C-N 123.706 2.359 . . . . 55.43 112.045 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.8 mt -84.82 -55.38 4.12 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 106.585 -1.635 . . . . 74.52 106.585 171.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.47 159.39 13.78 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 109.273 -1.531 . . . . 74.3 109.273 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -130.59 90.15 2.88 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 117.998 -1.001 . . . . 73.42 111.773 -177.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -124.86 143.14 50.99 Favored 'General case' 0 C--N 1.36 1.065 0 CA-C-O 116.868 -1.539 . . . . 72.23 108.259 172.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 46.6 pt -79.09 139.01 19.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.898 0 N-CA-C 106.355 -1.72 . . . . 73.53 106.355 167.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -149.5 163.6 37.36 Favored 'General case' 0 C--N 1.355 0.839 0 CA-C-N 119.507 1.049 . . . . 74.41 109.297 -176.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.577 0 N-CA-C 109.326 -1.51 . . . . 53.42 109.326 178.545 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.684 0 N-CA-C 117.447 1.739 . . . . 73.13 117.447 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.53 -173.18 3.7 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-N 120.539 2.17 . . . . 74.53 107.127 172.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -69.95 -25.18 63.52 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-O 117.286 -1.34 . . . . 73.33 113.329 -172.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.34 151.02 8.62 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.733 1.606 . . . . 73.41 110.632 -175.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.39 -104.66 0.26 Allowed Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.865 -1.519 . . . . 64.21 111.703 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.16 29.18 Favored Pre-proline 0 C--N 1.356 0.869 0 CA-C-O 115.433 -2.222 . . . . 75.52 107.975 -173.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -55.88 136.18 73.34 Favored 'Trans proline' 0 C--N 1.361 1.187 0 CA-C-N 124.659 2.7 . . . . 74.4 113.0 -170.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -73.74 -60.12 2.4 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.177 -1.046 . . . . 73.42 108.177 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.58 -61.28 1.83 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-N 119.096 0.862 . . . . 74.15 109.271 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.7 -51.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.822 0 CA-C-O 118.735 -0.65 . . . . 74.4 109.693 -177.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.0 145.16 83.3 Favored Pre-proline 0 C--N 1.355 0.845 0 N-CA-C 104.954 -2.239 . . . . 74.22 104.954 172.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.66 72.73 2.43 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 123.833 2.405 . . . . 63.11 111.911 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.7 mt -84.45 -55.04 4.36 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 106.618 -1.623 . . . . 74.02 106.618 171.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.88 161.64 12.68 Favored Glycine 0 C--N 1.358 1.754 0 N-CA-C 109.467 -1.453 . . . . 73.25 109.467 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -132.25 88.6 2.56 Favored 'General case' 0 C--N 1.354 0.8 0 CA-C-O 117.937 -1.03 . . . . 72.42 111.733 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -124.84 140.16 53.18 Favored 'General case' 0 C--N 1.361 1.069 0 CA-C-O 116.827 -1.559 . . . . 65.14 108.423 172.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.9 pt -77.5 138.66 20.01 Favored 'Isoleucine or valine' 0 C--N 1.358 0.938 0 N-CA-C 106.661 -1.607 . . . . 71.34 106.661 167.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -149.65 163.67 37.27 Favored 'General case' 0 C--N 1.356 0.85 0 CA-C-N 119.342 0.974 . . . . 75.24 109.227 -176.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 N-CA-C 109.329 -1.508 . . . . 75.21 109.329 178.423 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 117.367 1.707 . . . . 72.4 117.367 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -143.44 -172.79 3.78 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 120.475 2.137 . . . . 64.54 107.222 172.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.21 -25.64 64.42 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.208 -1.377 . . . . 75.31 113.339 -173.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.47 151.5 8.09 Favored 'Isoleucine or valine' 0 C--N 1.354 0.782 0 CA-C-N 120.753 1.615 . . . . 74.01 110.695 -175.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.51 -103.8 0.24 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.948 -1.473 . . . . 54.54 111.681 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.04 158.1 28.59 Favored Pre-proline 0 C--N 1.356 0.867 0 CA-C-O 115.413 -2.232 . . . . 74.34 108.097 -173.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.68 134.31 63.27 Favored 'Trans proline' 0 C--N 1.361 1.192 0 CA-C-N 124.759 2.735 . . . . 74.44 112.918 -170.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -72.22 -60.05 2.43 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.181 -1.044 . . . . 75.24 108.181 -178.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.44 -61.35 1.82 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.119 0.872 . . . . 73.23 109.34 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -174.72 -51.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.783 0 CA-C-O 118.673 -0.68 . . . . 72.31 109.75 -177.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.55 145.18 81.85 Favored Pre-proline 0 C--N 1.355 0.809 0 N-CA-C 104.986 -2.227 . . . . 73.53 104.986 172.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.58 72.75 2.37 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.811 2.397 . . . . 64.45 111.973 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.36 -55.13 4.33 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 106.579 -1.637 . . . . 74.1 106.579 171.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.63 160.99 12.91 Favored Glycine 0 C--N 1.357 1.711 0 N-CA-C 109.337 -1.505 . . . . 72.52 109.337 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.64 90.68 2.88 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 117.923 -1.037 . . . . 73.44 111.868 -177.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -127.77 140.08 52.27 Favored 'General case' 0 C--N 1.362 1.112 0 CA-C-O 116.759 -1.591 . . . . 74.25 108.478 172.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.9 pt -77.9 139.17 19.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 N-CA-C 106.662 -1.607 . . . . 71.22 106.662 167.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -149.62 163.65 37.3 Favored 'General case' 0 C--N 1.357 0.898 0 CA-C-N 119.303 0.956 . . . . 73.12 109.166 -176.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.528 0 N-CA-C 109.298 -1.521 . . . . 75.31 109.298 178.4 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 N-CA-C 117.217 1.647 . . . . 72.53 117.217 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.34 -174.03 4.27 Favored 'General case' 0 C--N 1.355 0.835 0 CA-C-N 120.327 2.064 . . . . 74.11 107.377 173.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -67.68 -25.74 65.84 Favored 'General case' 0 C--N 1.351 0.658 0 CA-C-O 117.164 -1.398 . . . . 74.2 113.426 -173.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.74 152.05 7.4 Favored 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-N 120.83 1.65 . . . . 75.43 110.826 -175.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.43 -103.89 0.24 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.962 -1.466 . . . . 72.52 111.522 177.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.21 158.19 28.23 Favored Pre-proline 0 C--N 1.356 0.865 0 CA-C-O 115.31 -2.281 . . . . 61.21 107.981 -174.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -55.27 134.42 63.72 Favored 'Trans proline' 0 C--N 1.359 1.113 0 CA-C-N 124.875 2.777 . . . . 74.01 112.947 -170.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -72.45 -59.97 2.46 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.172 -1.048 . . . . 74.42 108.172 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.16 -61.14 1.89 Allowed 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.031 0.832 . . . . 74.42 109.372 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.04 -51.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.724 -0.655 . . . . 74.44 109.711 -177.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.14 144.93 79.75 Favored Pre-proline 0 C--N 1.356 0.866 0 N-CA-C 104.942 -2.244 . . . . 63.02 104.942 172.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -71.59 72.96 2.35 Favored 'Trans proline' 0 C--N 1.358 1.032 0 CA-C-N 123.694 2.355 . . . . 73.41 112.09 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.2 mt -84.6 -55.52 4.08 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.592 -1.633 . . . . 75.33 106.592 171.42 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.97 159.05 13.99 Favored Glycine 0 C--N 1.357 1.712 0 N-CA-C 109.225 -1.55 . . . . 73.25 109.225 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -130.29 92.55 3.3 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 117.951 -1.023 . . . . 74.12 111.844 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -128.71 142.76 50.91 Favored 'General case' 0 C--N 1.361 1.072 0 CA-C-O 116.82 -1.562 . . . . 74.33 108.411 172.021 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -80.55 140.62 16.4 Favored 'Isoleucine or valine' 0 C--N 1.357 0.904 0 N-CA-C 106.399 -1.704 . . . . 73.21 106.399 166.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -149.22 164.01 36.01 Favored 'General case' 0 C--N 1.355 0.846 0 CA-C-N 119.33 0.968 . . . . 75.15 109.189 -175.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.08 -1.608 . . . . 62.4 109.08 179.387 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 N-CA-C 116.97 1.548 . . . . 73.1 116.97 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.43 -174.7 4.53 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-N 120.246 2.023 . . . . 72.33 107.528 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -67.0 -26.11 66.64 Favored 'General case' 0 C--N 1.35 0.607 0 CA-C-O 117.12 -1.419 . . . . 63.41 113.393 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.8 152.15 7.28 Favored 'Isoleucine or valine' 0 C--N 1.354 0.796 0 CA-C-N 120.891 1.678 . . . . 74.11 110.888 -174.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.31 -104.27 0.25 Allowed Glycine 0 C--N 1.358 1.759 0 CA-C-O 117.93 -1.483 . . . . 73.32 111.436 178.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.06 158.42 28.82 Favored Pre-proline 0 C--N 1.355 0.836 0 CA-C-O 115.342 -2.266 . . . . 73.44 107.909 -174.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.23 134.47 64.0 Favored 'Trans proline' 0 C--N 1.36 1.143 0 CA-C-N 124.878 2.778 . . . . 74.23 112.957 -170.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -72.39 -59.53 2.68 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 108.154 -1.054 . . . . 65.44 108.154 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.94 -61.09 1.91 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 119.029 0.831 . . . . 63.24 109.344 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.49 -51.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.819 0 CA-C-O 118.738 -0.648 . . . . 72.01 109.6 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.31 144.93 79.12 Favored Pre-proline 0 C--N 1.356 0.853 0 N-CA-C 104.939 -2.245 . . . . 73.24 104.939 172.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.48 73.52 2.22 Favored 'Trans proline' 0 C--N 1.358 1.048 0 CA-C-N 123.84 2.407 . . . . 75.52 111.987 -179.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 68.8 mt -85.42 -55.63 3.92 Favored 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.516 -1.661 . . . . 74.12 106.516 171.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.04 157.96 14.65 Favored Glycine 0 C--N 1.357 1.704 0 N-CA-C 109.08 -1.608 . . . . 45.15 109.08 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.56 92.56 3.36 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 117.999 -1.001 . . . . 74.11 111.779 -178.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -127.13 143.97 51.14 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-O 116.837 -1.554 . . . . 74.42 108.247 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 47.8 pt -79.68 138.98 18.97 Favored 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 106.371 -1.714 . . . . 73.03 106.371 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.3 mt-30 -149.29 164.24 35.42 Favored 'General case' 0 C--N 1.355 0.836 0 CA-C-N 119.455 1.025 . . . . 74.24 109.223 -176.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.522 0 N-CA-C 109.146 -1.582 . . . . 72.1 109.146 179.531 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 117.434 1.734 . . . . 53.42 117.434 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.66 -173.13 3.7 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-N 120.669 2.235 . . . . 71.33 107.185 172.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -69.9 -25.39 63.67 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-O 117.234 -1.365 . . . . 72.12 113.378 -172.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.07 150.97 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 CA-C-N 120.652 1.569 . . . . 73.43 110.558 -175.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.37 -104.57 0.26 Allowed Glycine 0 C--N 1.358 1.781 0 CA-C-O 117.902 -1.499 . . . . 63.44 111.802 178.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.14 29.16 Favored Pre-proline 0 C--N 1.356 0.871 0 CA-C-O 115.36 -2.257 . . . . 72.45 108.13 -173.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -55.89 135.95 72.19 Favored 'Trans proline' 0 C--N 1.359 1.088 0 CA-C-N 124.767 2.738 . . . . 74.14 112.94 -170.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -73.69 -60.31 2.31 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 108.158 -1.052 . . . . 72.2 108.158 -178.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.43 -61.19 1.86 Allowed 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.081 0.855 . . . . 71.53 109.274 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.65 -51.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.356 0.854 0 CA-C-O 118.672 -0.68 . . . . 73.14 109.75 -177.224 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.12 145.13 82.93 Favored Pre-proline 0 C--N 1.355 0.818 0 N-CA-C 104.997 -2.223 . . . . 73.31 104.997 172.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.64 72.91 2.39 Favored 'Trans proline' 0 C--N 1.358 1.04 0 CA-C-N 123.798 2.392 . . . . 74.15 111.894 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.0 mt -84.55 -55.0 4.36 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.587 -1.635 . . . . 75.43 106.587 171.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.86 161.4 12.76 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 109.43 -1.468 . . . . 74.52 109.43 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.87 88.46 2.56 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.879 -1.058 . . . . 74.33 111.84 -177.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -124.97 139.98 53.33 Favored 'General case' 0 C--N 1.36 1.057 0 CA-C-O 116.777 -1.582 . . . . 73.12 108.498 172.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -78.41 139.39 18.57 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 106.647 -1.612 . . . . 75.42 106.647 167.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -149.68 163.21 38.56 Favored 'General case' 0 C--N 1.356 0.863 0 CA-C-N 119.275 0.943 . . . . 74.33 109.2 -176.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.548 0 N-CA-C 109.26 -1.536 . . . . 61.43 109.26 178.425 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 N-CA-C 117.015 1.566 . . . . 60.54 117.015 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.45 -175.17 4.81 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 120.216 2.008 . . . . 73.3 107.847 173.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 51.3 m-85 -65.76 -27.2 68.12 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-O 117.101 -1.428 . . . . 70.05 113.463 -173.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.44 152.35 7.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 CA-C-N 120.879 1.672 . . . . 75.54 111.044 -174.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.67 -104.92 0.26 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.957 -1.468 . . . . 74.15 111.147 178.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.03 158.79 29.21 Favored Pre-proline 0 C--N 1.357 0.909 0 CA-C-O 115.525 -2.178 . . . . 73.35 107.791 -174.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -54.76 134.42 62.67 Favored 'Trans proline' 0 C--N 1.36 1.141 0 CA-C-N 124.834 2.762 . . . . 73.0 113.016 -170.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -72.41 -59.26 2.82 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.085 -1.08 . . . . 71.21 108.085 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.72 -60.97 1.95 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 118.968 0.804 . . . . 65.21 109.351 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.72 -51.48 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.805 0 CA-C-O 118.832 -0.604 . . . . 73.4 109.615 -177.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.95 144.97 76.86 Favored Pre-proline 0 C--N 1.355 0.811 0 N-CA-C 104.959 -2.237 . . . . 72.5 104.959 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -71.32 73.83 2.09 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.755 2.377 . . . . 71.35 112.007 -179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.4 mt -86.14 -56.0 3.66 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 106.495 -1.669 . . . . 74.23 106.495 171.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.08 156.33 15.64 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.993 -1.643 . . . . 73.03 108.993 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -128.28 93.48 3.66 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.99 -1.005 . . . . 75.34 111.668 -178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -127.69 146.55 50.53 Favored 'General case' 0 C--N 1.36 1.052 0 CA-C-O 116.908 -1.52 . . . . 74.42 108.198 171.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -82.1 139.65 17.6 Favored 'Isoleucine or valine' 0 C--N 1.357 0.934 0 N-CA-C 106.091 -1.818 . . . . 73.5 106.091 166.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -148.74 164.08 35.45 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.58 1.082 . . . . 72.35 109.392 -175.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.572 0 N-CA-C 109.362 -1.495 . . . . 72.44 109.362 178.667 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.587 -1.119 . . . . 65.42 115.382 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.66 -177.13 6.37 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.366 1.583 . . . . 52.0 108.282 175.276 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -64.3 -29.32 70.41 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.105 -1.426 . . . . 73.31 113.685 -173.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -156.43 151.6 9.02 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.709 1.595 . . . . 61.22 111.401 -173.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.68 -107.27 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.666 -1.63 . . . . 41.13 111.497 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.78 159.96 31.71 Favored Pre-proline 0 C--N 1.356 0.86 0 CA-C-O 115.45 -2.214 . . . . 63.11 108.248 -176.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -55.35 130.5 40.95 Favored 'Trans proline' 0 C--N 1.362 1.265 0 CA-C-N 124.839 2.764 . . . . 71.34 112.61 -173.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 81.3 mt-10 -68.98 -57.14 5.87 Favored 'General case' 0 C--N 1.354 0.77 0 N-CA-C 108.004 -1.11 . . . . 72.4 108.004 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.15 -61.27 1.85 Allowed 'General case' 0 C--N 1.354 0.782 0 CA-C-O 118.343 -0.837 . . . . 73.2 109.632 179.447 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.72 -51.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.773 0 CA-C-O 118.64 -0.695 . . . . 63.31 109.786 -176.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.42 145.38 67.87 Favored Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.538 -2.172 . . . . 71.51 105.18 172.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -70.42 75.06 1.52 Allowed 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.752 2.376 . . . . 71.41 112.211 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -88.91 -56.74 3.16 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 106.697 -1.594 . . . . 74.24 106.697 171.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.94 145.16 16.2 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.523 -1.831 . . . . 64.44 108.523 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.22 93.95 4.18 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.937 1.368 . . . . 72.35 111.139 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -120.11 157.19 29.5 Favored 'General case' 0 C--N 1.36 1.047 0 CA-C-O 117.248 -1.358 . . . . 65.33 107.868 170.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -92.3 141.04 15.17 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 105.344 -2.095 . . . . 72.22 105.344 164.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 . . . . . 0 C--N 1.355 0.821 0 CA-C-N 119.84 1.2 . . . . 75.41 109.747 -174.548 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.721 0 CA-C-O 118.708 -1.051 . . . . 73.3 115.306 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.14 -177.33 6.53 Favored 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.273 1.537 . . . . 70.22 108.388 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -63.92 -29.64 70.8 Favored 'General case' 0 C--N 1.351 0.665 0 CA-C-O 117.07 -1.443 . . . . 65.02 113.615 -173.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.9 p -156.37 151.71 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 120.811 1.642 . . . . 74.23 111.374 -173.24 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.66 -107.12 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.682 -1.621 . . . . 51.12 111.455 177.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.89 159.86 31.77 Favored Pre-proline 0 C--N 1.356 0.859 0 CA-C-O 115.418 -2.23 . . . . 73.52 108.296 -176.438 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -54.95 129.81 37.31 Favored 'Trans proline' 0 C--N 1.361 1.233 0 CA-C-N 124.818 2.756 . . . . 74.34 112.584 -173.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -68.37 -57.03 6.53 Favored 'General case' 0 C--N 1.355 0.839 0 N-CA-C 108.047 -1.094 . . . . 60.34 108.047 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.11 -61.32 1.84 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-O 118.396 -0.811 . . . . 74.2 109.66 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.73 -50.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-O 118.653 -0.689 . . . . 53.33 109.858 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.68 145.45 66.96 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.566 -2.159 . . . . 73.23 105.194 172.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -70.3 75.14 1.47 Allowed 'Trans proline' 0 C--N 1.358 1.044 0 CA-C-N 123.777 2.384 . . . . 71.02 112.252 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -89.42 -56.85 3.09 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 106.769 -1.567 . . . . 73.14 106.769 171.295 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.62 144.63 16.06 Favored Glycine 0 C--N 1.357 1.721 0 N-CA-C 108.45 -1.86 . . . . 52.23 108.45 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -120.8 94.16 4.26 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.963 1.381 . . . . 73.41 111.185 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -120.7 156.53 31.56 Favored 'General case' 0 C--N 1.359 1.012 0 CA-C-O 117.186 -1.388 . . . . 75.21 107.843 170.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.6 pt -91.24 141.07 14.98 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.283 -2.117 . . . . 74.31 105.283 164.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 . . . . . 0 C--N 1.355 0.816 0 CA-C-N 119.808 1.185 . . . . 74.33 109.626 -174.41 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 N-CA-C 117.347 1.699 . . . . 62.14 117.347 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.23 -169.52 2.97 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 120.619 2.21 . . . . 72.05 107.081 173.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -72.83 -25.95 61.31 Favored 'General case' 0 C--N 1.351 0.659 0 CA-C-N 120.389 1.45 . . . . 73.13 113.38 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -156.35 149.62 10.83 Favored 'Isoleucine or valine' 0 C--N 1.355 0.816 0 CA-C-N 120.555 1.525 . . . . 70.23 110.569 -175.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.98 -108.37 0.36 Allowed Glycine 0 C--N 1.357 1.74 0 CA-C-O 117.592 -1.671 . . . . 65.43 111.969 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -152.9 161.12 29.94 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.359 -2.258 . . . . 70.44 108.512 -174.111 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -57.68 131.83 46.51 Favored 'Trans proline' 0 C--N 1.361 1.195 0 CA-C-N 124.969 2.81 . . . . 75.1 112.119 -172.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -70.26 -58.19 4.04 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.063 -1.088 . . . . 64.11 108.063 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -85.22 -61.78 1.69 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.038 0.835 . . . . 73.44 109.56 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.65 -51.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.767 0 CA-C-O 118.736 -0.65 . . . . 63.53 109.838 -176.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.85 145.51 81.51 Favored Pre-proline 0 C--N 1.355 0.839 0 N-CA-C 105.056 -2.201 . . . . 25.32 105.056 172.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.26 72.87 2.16 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.743 2.373 . . . . 74.43 112.223 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.9 mt -86.24 -55.79 3.75 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.826 -1.546 . . . . 60.42 106.826 171.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.48 155.94 15.94 Favored Glycine 0 C--N 1.357 1.73 0 N-CA-C 109.503 -1.439 . . . . 52.34 109.503 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -129.75 86.56 2.43 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.077 -0.963 . . . . 70.32 111.642 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -120.03 145.21 47.04 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-O 116.67 -1.633 . . . . 62.34 108.243 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.4 pt -84.22 141.35 14.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.924 0 N-CA-C 106.127 -1.805 . . . . 72.52 106.127 166.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 . . . . . 0 C--N 1.355 0.841 0 CA-C-N 119.442 1.019 . . . . 74.12 109.428 -175.894 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.71 0 N-CA-C 116.363 1.305 . . . . 13.41 116.363 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -150.3 -173.47 4.46 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.912 1.856 . . . . 65.23 107.76 174.073 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -67.86 -27.42 66.67 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.155 -1.402 . . . . 64.32 113.585 -172.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.62 151.03 9.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 120.703 1.592 . . . . 55.32 110.998 -174.358 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.71 -107.64 0.33 Allowed Glycine 0 C--N 1.358 1.787 0 CA-C-O 117.618 -1.657 . . . . 54.43 111.594 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -153.09 160.7 30.61 Favored Pre-proline 0 C--N 1.357 0.924 0 CA-C-O 115.314 -2.279 . . . . 70.32 108.428 -175.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -55.96 130.06 38.25 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 125.031 2.832 . . . . 71.52 112.287 -173.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -68.99 -57.27 5.69 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.024 -1.102 . . . . 62.31 108.024 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.69 -61.58 1.75 Allowed 'General case' 0 C--N 1.354 0.775 0 CA-C-O 118.403 -0.808 . . . . 64.12 109.563 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.29 -51.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 118.614 -0.707 . . . . 71.12 109.798 -176.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -77.09 145.42 73.38 Favored Pre-proline 0 C--N 1.354 0.789 0 N-CA-C 105.059 -2.2 . . . . 62.42 105.059 172.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -70.67 74.45 1.69 Allowed 'Trans proline' 0 C--N 1.358 1.053 0 CA-C-N 123.804 2.394 . . . . 73.4 112.168 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 65.5 mt -88.22 -56.52 3.29 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 106.722 -1.584 . . . . 63.11 106.722 171.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.75 150.27 16.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 108.909 -1.677 . . . . 55.31 108.909 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -125.44 91.34 3.39 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 118.452 1.126 . . . . 73.24 111.422 -178.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -120.77 151.82 39.09 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.907 -1.52 . . . . 61.2 107.937 171.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.4 pt -88.01 142.14 13.35 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 105.525 -2.028 . . . . 73.45 105.525 165.119 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 . . . . . 0 C--N 1.355 0.836 0 CA-C-N 119.718 1.145 . . . . 70.13 109.589 -175.351 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.666 0 N-CA-C 115.658 1.023 . . . . 52.32 115.658 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 -176.9 6.22 Favored 'General case' 0 C--N 1.353 0.747 0 CA-C-N 119.046 1.423 . . . . 63.21 108.438 175.231 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -64.56 -29.63 70.66 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-O 117.178 -1.391 . . . . 73.11 113.779 -173.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.14 151.56 9.34 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.703 1.592 . . . . 73.01 111.31 -173.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.65 -106.91 0.31 Allowed Glycine 0 C--N 1.358 1.762 0 CA-C-O 117.556 -1.691 . . . . 72.01 111.585 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.7 159.88 31.87 Favored Pre-proline 0 C--N 1.357 0.919 0 CA-C-O 115.247 -2.311 . . . . 75.54 108.333 -176.248 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -55.32 130.12 38.89 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.865 2.773 . . . . 74.12 112.42 -173.339 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.6 mt-10 -68.59 -57.17 6.14 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.035 -1.098 . . . . 53.04 108.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.24 1.86 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-O 118.389 -0.815 . . . . 72.01 109.563 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.77 -50.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.538 -0.744 . . . . 51.13 109.755 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.37 145.41 68.14 Favored Pre-proline 0 C--N 1.354 0.803 0 N-CA-C 105.193 -2.151 . . . . 74.11 105.193 172.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.44 75.34 1.51 Allowed 'Trans proline' 0 C--N 1.359 1.13 0 CA-C-N 123.762 2.379 . . . . 61.2 112.161 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 63.3 mt -89.42 -56.87 3.09 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.785 -1.561 . . . . 64.41 106.785 171.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.7 145.12 16.13 Favored Glycine 0 C--N 1.357 1.698 0 N-CA-C 108.517 -1.833 . . . . 71.14 108.517 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.15 93.18 3.94 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.958 1.379 . . . . 74.33 111.104 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -119.13 156.3 30.03 Favored 'General case' 0 C--N 1.359 0.996 0 CA-C-O 117.174 -1.394 . . . . 70.34 107.955 170.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.7 pt -90.58 140.61 15.67 Favored 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 105.245 -2.131 . . . . 71.02 105.245 165.038 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 . . . . . 0 C--N 1.355 0.83 0 CA-C-N 119.876 1.216 . . . . 74.43 109.642 -174.613 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 N-CA-C 117.019 1.568 . . . . 54.32 117.019 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.79 -171.47 3.7 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-N 120.341 2.07 . . . . 73.11 107.301 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -70.57 -26.42 63.52 Favored 'General case' 0 C--N 1.351 0.663 0 CA-C-O 117.21 -1.376 . . . . 71.31 113.502 -172.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.52 150.09 10.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.823 0 CA-C-N 120.641 1.564 . . . . 73.03 110.795 -174.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.99 -108.11 0.35 Allowed Glycine 0 C--N 1.358 1.796 0 CA-C-O 117.541 -1.699 . . . . 71.25 111.784 178.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -152.86 161.03 30.22 Favored Pre-proline 0 C--N 1.357 0.892 0 CA-C-O 115.298 -2.287 . . . . 73.12 108.421 -174.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 131.22 44.16 Favored 'Trans proline' 0 C--N 1.361 1.202 0 CA-C-N 125.119 2.864 . . . . 75.01 112.078 -172.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -69.92 -57.73 4.69 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.027 -1.101 . . . . 71.32 108.027 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.97 -61.65 1.72 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.347 -0.835 . . . . 73.03 109.58 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.6 p -174.98 -51.58 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.706 -0.664 . . . . 62.1 109.769 -176.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.74 145.39 78.27 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 105.076 -2.194 . . . . 73.03 105.076 172.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -71.02 73.8 1.92 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.724 2.366 . . . . 73.21 112.137 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.1 mt -87.29 -56.27 3.44 Favored 'General case' 0 C--N 1.355 0.841 0 N-CA-C 106.842 -1.54 . . . . 70.11 106.842 171.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.01 153.14 16.89 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 109.176 -1.569 . . . . 62.22 109.176 -178.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -127.69 88.34 2.76 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.218 1.009 . . . . 72.41 111.509 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -118.97 148.76 42.62 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-O 116.841 -1.552 . . . . 75.22 107.982 171.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 48.4 pt -85.61 141.83 14.0 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.796 -1.927 . . . . 73.05 105.796 165.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 . . . . . 0 C--N 1.355 0.816 0 CA-C-N 119.679 1.127 . . . . 65.31 109.547 -175.704 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.672 0 CA-C-O 118.757 -1.024 . . . . 53.31 114.846 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -159.59 -178.67 7.27 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.107 1.453 . . . . 61.32 108.534 176.099 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -63.05 -30.56 71.69 Favored 'General case' 0 C--N 1.351 0.671 0 CA-C-O 117.086 -1.435 . . . . 73.31 113.693 -173.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -156.19 151.8 9.03 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 120.741 1.61 . . . . 72.44 111.42 -172.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 151.99 -106.43 0.3 Allowed Glycine 0 C--N 1.358 1.77 0 CA-C-O 117.707 -1.607 . . . . 53.12 111.49 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.72 159.37 32.54 Favored Pre-proline 0 C--N 1.356 0.878 0 CA-C-O 115.395 -2.24 . . . . 72.34 108.347 -176.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -54.95 130.11 38.94 Favored 'Trans proline' 0 C--N 1.362 1.266 0 CA-C-N 124.761 2.736 . . . . 73.33 112.578 -173.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -68.44 -57.2 6.22 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.063 -1.088 . . . . 72.44 108.063 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.83 -61.14 1.9 Allowed 'General case' 0 C--N 1.354 0.788 0 CA-C-O 118.364 -0.827 . . . . 64.55 109.615 179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -175.77 -50.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.572 -0.727 . . . . 72.32 109.86 -176.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -79.04 145.53 65.65 Favored Pre-proline 0 C--N 1.355 0.823 0 CA-C-O 115.56 -2.162 . . . . 74.22 105.249 172.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -70.23 75.42 1.41 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.768 2.381 . . . . 65.43 112.255 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.8 mt -89.83 -56.86 3.07 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 106.725 -1.583 . . . . 73.51 106.725 171.288 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.64 142.77 15.89 Favored Glycine 0 C--N 1.357 1.719 0 N-CA-C 108.318 -1.913 . . . . 71.14 108.318 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -119.32 94.49 4.44 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-N 119.108 1.454 . . . . 74.15 110.959 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -119.37 155.83 31.21 Favored 'General case' 0 C--N 1.36 1.035 0 CA-C-O 117.165 -1.397 . . . . 64.54 107.903 170.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.5 pt -88.97 140.42 15.82 Favored 'Isoleucine or valine' 0 C--N 1.357 0.922 0 N-CA-C 105.157 -2.164 . . . . 73.05 105.157 164.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 . . . . . 0 C--N 1.355 0.822 0 CA-C-N 119.972 1.26 . . . . 74.42 109.794 -174.691 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.699 0 N-CA-C 117.434 1.734 . . . . 73.44 117.434 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -140.25 -162.39 1.34 Allowed 'General case' 0 C--N 1.356 0.871 0 CA-C-N 120.668 2.234 . . . . 63.23 106.716 172.465 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -79.39 -27.84 41.84 Favored 'General case' 0 C--N 1.352 0.716 0 CA-C-N 121.023 1.738 . . . . 73.13 113.263 -172.099 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.5 p -154.16 148.69 13.17 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.286 1.403 . . . . 72.41 110.265 -175.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.26 -106.47 0.3 Allowed Glycine 0 C--N 1.357 1.745 0 CA-C-O 117.603 -1.665 . . . . 61.42 112.278 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 2.1 pp0? -153.93 160.99 30.32 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.447 -2.216 . . . . 73.12 108.915 -172.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -58.48 128.79 29.7 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.797 2.749 . . . . 73.31 112.048 -173.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -67.34 -57.68 6.18 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 108.228 -1.027 . . . . 73.44 108.228 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -86.16 -62.43 1.52 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.057 0.844 . . . . 52.14 109.646 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.09 -51.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.784 -0.627 . . . . 63.15 109.855 -176.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.23 146.17 84.03 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 104.946 -2.242 . . . . 60.25 104.946 172.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.24 72.01 2.25 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 123.855 2.412 . . . . 73.02 112.188 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.6 mt -86.36 -55.29 3.97 Favored 'General case' 0 C--N 1.354 0.78 0 N-CA-C 106.898 -1.519 . . . . 51.53 106.898 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.3 157.57 15.45 Favored Glycine 0 C--N 1.356 1.67 0 N-CA-C 110.022 -1.231 . . . . 74.22 110.022 -176.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.58 84.24 2.16 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-O 118.13 -0.938 . . . . 72.23 111.758 -177.188 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -122.81 134.64 54.41 Favored 'General case' 0 C--N 1.36 1.042 0 CA-C-O 116.665 -1.636 . . . . 60.41 108.817 173.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -74.83 140.35 17.64 Favored 'Isoleucine or valine' 0 C--N 1.357 0.926 0 N-CA-C 106.813 -1.551 . . . . 63.32 106.813 167.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.4 mt-30 . . . . . 0 C--N 1.355 0.846 0 CA-C-N 119.405 1.002 . . . . 73.21 109.398 -176.841 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.679 0 N-CA-C 117.288 1.675 . . . . 75.32 117.288 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.02 -174.04 4.16 Favored 'General case' 0 C--N 1.356 0.872 0 CA-C-N 120.384 2.092 . . . . 73.05 107.284 173.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -68.45 -25.76 65.17 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-O 117.147 -1.406 . . . . 74.15 113.343 -172.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.49 151.42 8.14 Favored 'Isoleucine or valine' 0 C--N 1.354 0.787 0 CA-C-N 120.85 1.659 . . . . 60.11 110.75 -175.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.47 -104.72 0.26 Allowed Glycine 0 C--N 1.358 1.758 0 CA-C-O 117.848 -1.529 . . . . 73.32 111.459 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.67 158.55 29.44 Favored Pre-proline 0 C--N 1.355 0.847 0 CA-C-O 115.364 -2.255 . . . . 73.32 107.903 -174.303 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -55.58 135.7 70.58 Favored 'Trans proline' 0 C--N 1.36 1.156 0 CA-C-N 124.842 2.765 . . . . 65.33 112.901 -170.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -73.39 -59.79 2.54 Favored 'General case' 0 C--N 1.355 0.818 0 N-CA-C 108.116 -1.068 . . . . 64.31 108.116 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.23 -61.17 1.87 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.012 0.824 . . . . 65.54 109.322 178.638 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.07 -51.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-O 118.727 -0.654 . . . . 73.02 109.697 -177.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.7 145.02 81.23 Favored Pre-proline 0 C--N 1.355 0.832 0 N-CA-C 105.031 -2.211 . . . . 75.25 105.031 172.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -71.51 73.04 2.29 Favored 'Trans proline' 0 C--N 1.357 1.024 0 CA-C-N 123.706 2.359 . . . . 52.11 112.045 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.8 mt -84.82 -55.38 4.12 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 106.585 -1.635 . . . . 74.14 106.585 171.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.47 159.39 13.78 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 109.273 -1.531 . . . . 61.12 109.273 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -130.59 90.15 2.88 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 117.998 -1.001 . . . . 70.11 111.773 -177.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -124.86 143.14 50.99 Favored 'General case' 0 C--N 1.36 1.065 0 CA-C-O 116.868 -1.539 . . . . 72.23 108.259 172.177 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 46.6 pt -79.09 139.01 19.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.898 0 N-CA-C 106.355 -1.72 . . . . 73.53 106.355 167.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 . . . . . 0 C--N 1.355 0.839 0 CA-C-N 119.507 1.049 . . . . 74.41 109.297 -176.289 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.684 0 N-CA-C 117.447 1.739 . . . . 73.13 117.447 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.53 -173.18 3.7 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-N 120.539 2.17 . . . . 62.1 107.127 172.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -69.95 -25.18 63.52 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-O 117.286 -1.34 . . . . 73.33 113.329 -172.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.34 151.02 8.62 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.733 1.606 . . . . 72.14 110.632 -175.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.39 -104.66 0.26 Allowed Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.865 -1.519 . . . . 63.23 111.703 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.16 29.18 Favored Pre-proline 0 C--N 1.356 0.869 0 CA-C-O 115.433 -2.222 . . . . 75.52 107.975 -173.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -55.88 136.18 73.34 Favored 'Trans proline' 0 C--N 1.361 1.187 0 CA-C-N 124.659 2.7 . . . . 74.4 113.0 -170.309 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -73.74 -60.12 2.4 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.177 -1.046 . . . . 73.42 108.177 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.58 -61.28 1.83 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-N 119.096 0.862 . . . . 62.01 109.271 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.7 -51.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.822 0 CA-C-O 118.735 -0.65 . . . . 72.11 109.693 -177.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.0 145.16 83.3 Favored Pre-proline 0 C--N 1.355 0.845 0 N-CA-C 104.954 -2.239 . . . . 74.22 104.954 172.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.66 72.73 2.43 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 123.833 2.405 . . . . 63.11 111.911 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.7 mt -84.45 -55.04 4.36 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 106.618 -1.623 . . . . 74.02 106.618 171.466 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.88 161.64 12.68 Favored Glycine 0 C--N 1.358 1.754 0 N-CA-C 109.467 -1.453 . . . . 40.02 109.467 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -132.25 88.6 2.56 Favored 'General case' 0 C--N 1.354 0.8 0 CA-C-O 117.937 -1.03 . . . . 72.42 111.733 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -124.84 140.16 53.18 Favored 'General case' 0 C--N 1.361 1.069 0 CA-C-O 116.827 -1.559 . . . . 65.14 108.423 172.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.9 pt -77.5 138.66 20.01 Favored 'Isoleucine or valine' 0 C--N 1.358 0.938 0 N-CA-C 106.661 -1.607 . . . . 62.13 106.661 167.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 . . . . . 0 C--N 1.356 0.85 0 CA-C-N 119.342 0.974 . . . . 75.24 109.227 -176.412 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 117.367 1.707 . . . . 60.32 117.367 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -143.44 -172.79 3.78 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 120.475 2.137 . . . . 64.54 107.222 172.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.21 -25.64 64.42 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.208 -1.377 . . . . 73.02 113.339 -173.056 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.47 151.5 8.09 Favored 'Isoleucine or valine' 0 C--N 1.354 0.782 0 CA-C-N 120.753 1.615 . . . . 74.01 110.695 -175.276 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.51 -103.8 0.24 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.948 -1.473 . . . . 54.54 111.681 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.04 158.1 28.59 Favored Pre-proline 0 C--N 1.356 0.867 0 CA-C-O 115.413 -2.232 . . . . 73.51 108.097 -173.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.68 134.31 63.27 Favored 'Trans proline' 0 C--N 1.361 1.192 0 CA-C-N 124.759 2.735 . . . . 62.41 112.918 -170.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -72.22 -60.05 2.43 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.181 -1.044 . . . . 71.34 108.181 -178.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.44 -61.35 1.82 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.119 0.872 . . . . 73.23 109.34 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -174.72 -51.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.783 0 CA-C-O 118.673 -0.68 . . . . 64.31 109.75 -177.191 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.55 145.18 81.85 Favored Pre-proline 0 C--N 1.355 0.809 0 N-CA-C 104.986 -2.227 . . . . 73.53 104.986 172.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.58 72.75 2.37 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.811 2.397 . . . . 64.45 111.973 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.36 -55.13 4.33 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 106.579 -1.637 . . . . 74.1 106.579 171.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.63 160.99 12.91 Favored Glycine 0 C--N 1.357 1.711 0 N-CA-C 109.337 -1.505 . . . . 23.44 109.337 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.64 90.68 2.88 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 117.923 -1.037 . . . . 71.35 111.868 -177.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -127.77 140.08 52.27 Favored 'General case' 0 C--N 1.362 1.112 0 CA-C-O 116.759 -1.591 . . . . 74.25 108.478 172.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.9 pt -77.9 139.17 19.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 N-CA-C 106.662 -1.607 . . . . 54.04 106.662 167.449 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 . . . . . 0 C--N 1.357 0.898 0 CA-C-N 119.303 0.956 . . . . 73.12 109.166 -176.116 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 N-CA-C 117.217 1.647 . . . . 63.41 117.217 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.34 -174.03 4.27 Favored 'General case' 0 C--N 1.355 0.835 0 CA-C-N 120.327 2.064 . . . . 74.11 107.377 173.237 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -67.68 -25.74 65.84 Favored 'General case' 0 C--N 1.351 0.658 0 CA-C-O 117.164 -1.398 . . . . 72.43 113.426 -173.231 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.74 152.05 7.4 Favored 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-N 120.83 1.65 . . . . 64.52 110.826 -175.174 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.43 -103.89 0.24 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.962 -1.466 . . . . 72.52 111.522 177.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.21 158.19 28.23 Favored Pre-proline 0 C--N 1.356 0.865 0 CA-C-O 115.31 -2.281 . . . . 61.21 107.981 -174.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -55.27 134.42 63.72 Favored 'Trans proline' 0 C--N 1.359 1.113 0 CA-C-N 124.875 2.777 . . . . 72.4 112.947 -170.449 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -72.45 -59.97 2.46 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.172 -1.048 . . . . 70.44 108.172 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.16 -61.14 1.89 Allowed 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.031 0.832 . . . . 73.55 109.372 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.04 -51.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.724 -0.655 . . . . 44.04 109.711 -177.189 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.14 144.93 79.75 Favored Pre-proline 0 C--N 1.356 0.866 0 N-CA-C 104.942 -2.244 . . . . 53.51 104.942 172.403 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -71.59 72.96 2.35 Favored 'Trans proline' 0 C--N 1.358 1.032 0 CA-C-N 123.694 2.355 . . . . 62.41 112.09 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.2 mt -84.6 -55.52 4.08 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.592 -1.633 . . . . 73.14 106.592 171.42 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.97 159.05 13.99 Favored Glycine 0 C--N 1.357 1.712 0 N-CA-C 109.225 -1.55 . . . . 73.25 109.225 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -130.29 92.55 3.3 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 117.951 -1.023 . . . . 65.32 111.844 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -128.71 142.76 50.91 Favored 'General case' 0 C--N 1.361 1.072 0 CA-C-O 116.82 -1.562 . . . . 74.33 108.411 172.021 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -80.55 140.62 16.4 Favored 'Isoleucine or valine' 0 C--N 1.357 0.904 0 N-CA-C 106.399 -1.704 . . . . 72.43 106.399 166.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 . . . . . 0 C--N 1.355 0.846 0 CA-C-N 119.33 0.968 . . . . 72.41 109.189 -175.552 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 N-CA-C 116.97 1.548 . . . . 54.44 116.97 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.43 -174.7 4.53 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-N 120.246 2.023 . . . . 72.33 107.528 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -67.0 -26.11 66.64 Favored 'General case' 0 C--N 1.35 0.607 0 CA-C-O 117.12 -1.419 . . . . 63.23 113.393 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.8 152.15 7.28 Favored 'Isoleucine or valine' 0 C--N 1.354 0.796 0 CA-C-N 120.891 1.678 . . . . 74.11 110.888 -174.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.31 -104.27 0.25 Allowed Glycine 0 C--N 1.358 1.759 0 CA-C-O 117.93 -1.483 . . . . 63.43 111.436 178.117 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.06 158.42 28.82 Favored Pre-proline 0 C--N 1.355 0.836 0 CA-C-O 115.342 -2.266 . . . . 73.44 107.909 -174.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.23 134.47 64.0 Favored 'Trans proline' 0 C--N 1.36 1.143 0 CA-C-N 124.878 2.778 . . . . 62.34 112.957 -170.447 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -72.39 -59.53 2.68 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 108.154 -1.054 . . . . 65.44 108.154 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.94 -61.09 1.91 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 119.029 0.831 . . . . 63.24 109.344 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.49 -51.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.819 0 CA-C-O 118.738 -0.648 . . . . 72.01 109.6 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.31 144.93 79.12 Favored Pre-proline 0 C--N 1.356 0.853 0 N-CA-C 104.939 -2.245 . . . . 71.01 104.939 172.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.48 73.52 2.22 Favored 'Trans proline' 0 C--N 1.358 1.048 0 CA-C-N 123.84 2.407 . . . . 71.24 111.987 -179.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 68.8 mt -85.42 -55.63 3.92 Favored 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.516 -1.661 . . . . 61.44 106.516 171.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.04 157.96 14.65 Favored Glycine 0 C--N 1.357 1.704 0 N-CA-C 109.08 -1.608 . . . . 43.04 109.08 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.56 92.56 3.36 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 117.999 -1.001 . . . . 72.44 111.779 -178.127 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -127.13 143.97 51.14 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-O 116.837 -1.554 . . . . 74.42 108.247 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 47.8 pt -79.68 138.98 18.97 Favored 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 106.371 -1.714 . . . . 72.34 106.371 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.3 mt-30 . . . . . 0 C--N 1.355 0.836 0 CA-C-N 119.455 1.025 . . . . 74.24 109.223 -176.08 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 117.434 1.734 . . . . 50.34 117.434 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.66 -173.13 3.7 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-N 120.669 2.235 . . . . 54.41 107.185 172.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -69.9 -25.39 63.67 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-O 117.234 -1.365 . . . . 72.12 113.378 -172.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.07 150.97 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 CA-C-N 120.652 1.569 . . . . 73.43 110.558 -175.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.37 -104.57 0.26 Allowed Glycine 0 C--N 1.358 1.781 0 CA-C-O 117.902 -1.499 . . . . 63.44 111.802 178.452 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.14 29.16 Favored Pre-proline 0 C--N 1.356 0.871 0 CA-C-O 115.36 -2.257 . . . . 72.45 108.13 -173.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -55.89 135.95 72.19 Favored 'Trans proline' 0 C--N 1.359 1.088 0 CA-C-N 124.767 2.738 . . . . 54.31 112.94 -170.344 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -73.69 -60.31 2.31 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 108.158 -1.052 . . . . 72.2 108.158 -178.684 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.43 -61.19 1.86 Allowed 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.081 0.855 . . . . 71.53 109.274 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.65 -51.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.356 0.854 0 CA-C-O 118.672 -0.68 . . . . 64.14 109.75 -177.224 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.12 145.13 82.93 Favored Pre-proline 0 C--N 1.355 0.818 0 N-CA-C 104.997 -2.223 . . . . 73.31 104.997 172.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.64 72.91 2.39 Favored 'Trans proline' 0 C--N 1.358 1.04 0 CA-C-N 123.798 2.392 . . . . 43.22 111.894 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.0 mt -84.55 -55.0 4.36 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.587 -1.635 . . . . 73.52 106.587 171.448 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.86 161.4 12.76 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 109.43 -1.468 . . . . 74.52 109.43 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.87 88.46 2.56 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.879 -1.058 . . . . 74.23 111.84 -177.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -124.97 139.98 53.33 Favored 'General case' 0 C--N 1.36 1.057 0 CA-C-O 116.777 -1.582 . . . . 73.12 108.498 172.721 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -78.41 139.39 18.57 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 106.647 -1.612 . . . . 75.42 106.647 167.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 . . . . . 0 C--N 1.356 0.863 0 CA-C-N 119.275 0.943 . . . . 73.51 109.2 -176.262 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 N-CA-C 117.015 1.566 . . . . 60.54 117.015 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.45 -175.17 4.81 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 120.216 2.008 . . . . 73.3 107.847 173.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 51.3 m-85 -65.76 -27.2 68.12 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-O 117.101 -1.428 . . . . 70.05 113.463 -173.341 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.44 152.35 7.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 CA-C-N 120.879 1.672 . . . . 75.54 111.044 -174.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.67 -104.92 0.26 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.957 -1.468 . . . . 70.52 111.147 178.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.03 158.79 29.21 Favored Pre-proline 0 C--N 1.357 0.909 0 CA-C-O 115.525 -2.178 . . . . 73.35 107.791 -174.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -54.76 134.42 62.67 Favored 'Trans proline' 0 C--N 1.36 1.141 0 CA-C-N 124.834 2.762 . . . . 73.0 113.016 -170.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -72.41 -59.26 2.82 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.085 -1.08 . . . . 71.21 108.085 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.72 -60.97 1.95 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 118.968 0.804 . . . . 65.21 109.351 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.72 -51.48 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.805 0 CA-C-O 118.832 -0.604 . . . . 73.4 109.615 -177.108 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.95 144.97 76.86 Favored Pre-proline 0 C--N 1.355 0.811 0 N-CA-C 104.959 -2.237 . . . . 70.24 104.959 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -71.32 73.83 2.09 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.755 2.377 . . . . 71.35 112.007 -179.418 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.4 mt -86.14 -56.0 3.66 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 106.495 -1.669 . . . . 74.23 106.495 171.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.08 156.33 15.64 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.993 -1.643 . . . . 70.32 108.993 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -128.28 93.48 3.66 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.99 -1.005 . . . . 75.34 111.668 -178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -127.69 146.55 50.53 Favored 'General case' 0 C--N 1.36 1.052 0 CA-C-O 116.908 -1.52 . . . . 54.44 108.198 171.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -82.1 139.65 17.6 Favored 'Isoleucine or valine' 0 C--N 1.357 0.934 0 N-CA-C 106.091 -1.818 . . . . 73.14 106.091 166.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 . . . . . 0 C--N 1.356 0.853 0 CA-C-N 119.58 1.082 . . . . 72.35 109.392 -175.598 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.587 -1.119 . . . . 65.42 115.382 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.66 -177.13 6.37 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.366 1.583 . . . . 52.0 108.282 175.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -64.3 -29.32 70.41 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.105 -1.426 . . . . 73.31 113.685 -173.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -156.43 151.6 9.02 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.709 1.595 . . . . 61.22 111.401 -173.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.68 -107.27 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.666 -1.63 . . . . 41.13 111.497 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.78 159.96 31.71 Favored Pre-proline 0 C--N 1.356 0.86 0 CA-C-O 115.45 -2.214 . . . . 63.11 108.248 -176.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -55.35 130.5 40.95 Favored 'Trans proline' 0 C--N 1.362 1.265 0 CA-C-N 124.839 2.764 . . . . 71.34 112.61 -173.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 81.3 mt-10 -68.98 -57.14 5.87 Favored 'General case' 0 C--N 1.354 0.77 0 N-CA-C 108.004 -1.11 . . . . 72.4 108.004 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.15 -61.27 1.85 Allowed 'General case' 0 C--N 1.354 0.782 0 CA-C-O 118.343 -0.837 . . . . 73.2 109.632 179.447 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.72 -51.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.773 0 CA-C-O 118.64 -0.695 . . . . 63.31 109.786 -176.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.42 145.38 67.87 Favored Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.538 -2.172 . . . . 71.51 105.18 172.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -70.42 75.06 1.52 Allowed 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.752 2.376 . . . . 71.41 112.211 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -88.91 -56.74 3.16 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 106.697 -1.594 . . . . 74.24 106.697 171.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.94 145.16 16.2 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.523 -1.831 . . . . 64.44 108.523 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.22 93.95 4.18 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.937 1.368 . . . . 72.35 111.139 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -120.11 157.19 29.5 Favored 'General case' 0 C--N 1.36 1.047 0 CA-C-O 117.248 -1.358 . . . . 65.33 107.868 170.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -92.3 141.04 15.17 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 105.344 -2.095 . . . . 72.22 105.344 164.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -147.73 164.11 34.6 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.84 1.2 . . . . 75.41 109.747 -174.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.545 0 N-CA-C 109.458 -1.457 . . . . 73.31 109.458 179.359 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.721 0 CA-C-O 118.708 -1.051 . . . . 73.3 115.306 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.14 -177.33 6.53 Favored 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.273 1.537 . . . . 70.22 108.388 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -63.92 -29.64 70.8 Favored 'General case' 0 C--N 1.351 0.665 0 CA-C-O 117.07 -1.443 . . . . 65.02 113.615 -173.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.9 p -156.37 151.71 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 120.811 1.642 . . . . 74.23 111.374 -173.24 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.66 -107.12 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.682 -1.621 . . . . 51.12 111.455 177.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.89 159.86 31.77 Favored Pre-proline 0 C--N 1.356 0.859 0 CA-C-O 115.418 -2.23 . . . . 73.52 108.296 -176.438 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -54.95 129.81 37.31 Favored 'Trans proline' 0 C--N 1.361 1.233 0 CA-C-N 124.818 2.756 . . . . 74.34 112.584 -173.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -68.37 -57.03 6.53 Favored 'General case' 0 C--N 1.355 0.839 0 N-CA-C 108.047 -1.094 . . . . 60.34 108.047 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.11 -61.32 1.84 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-O 118.396 -0.811 . . . . 74.2 109.66 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.73 -50.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-O 118.653 -0.689 . . . . 53.33 109.858 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.68 145.45 66.96 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.566 -2.159 . . . . 73.23 105.194 172.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -70.3 75.14 1.47 Allowed 'Trans proline' 0 C--N 1.358 1.044 0 CA-C-N 123.777 2.384 . . . . 71.02 112.252 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -89.42 -56.85 3.09 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 106.769 -1.567 . . . . 73.14 106.769 171.295 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.62 144.63 16.06 Favored Glycine 0 C--N 1.357 1.721 0 N-CA-C 108.45 -1.86 . . . . 52.23 108.45 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -120.8 94.16 4.26 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.963 1.381 . . . . 73.41 111.185 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -120.7 156.53 31.56 Favored 'General case' 0 C--N 1.359 1.012 0 CA-C-O 117.186 -1.388 . . . . 75.21 107.843 170.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.6 pt -91.24 141.07 14.98 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.283 -2.117 . . . . 74.31 105.283 164.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -147.43 164.59 32.87 Favored 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.808 1.185 . . . . 74.33 109.626 -174.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.563 0 N-CA-C 109.169 -1.572 . . . . 74.33 109.169 179.826 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 N-CA-C 117.347 1.699 . . . . 62.14 117.347 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.23 -169.52 2.97 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 120.619 2.21 . . . . 72.05 107.081 173.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -72.83 -25.95 61.31 Favored 'General case' 0 C--N 1.351 0.659 0 CA-C-N 120.389 1.45 . . . . 73.13 113.38 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -156.35 149.62 10.83 Favored 'Isoleucine or valine' 0 C--N 1.355 0.816 0 CA-C-N 120.555 1.525 . . . . 70.23 110.569 -175.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.98 -108.37 0.36 Allowed Glycine 0 C--N 1.357 1.74 0 CA-C-O 117.592 -1.671 . . . . 65.43 111.969 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -152.9 161.12 29.94 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.359 -2.258 . . . . 70.44 108.512 -174.111 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -57.68 131.83 46.51 Favored 'Trans proline' 0 C--N 1.361 1.195 0 CA-C-N 124.969 2.81 . . . . 75.1 112.119 -172.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -70.26 -58.19 4.04 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.063 -1.088 . . . . 64.11 108.063 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -85.22 -61.78 1.69 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.038 0.835 . . . . 73.44 109.56 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.65 -51.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.767 0 CA-C-O 118.736 -0.65 . . . . 63.53 109.838 -176.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.85 145.51 81.51 Favored Pre-proline 0 C--N 1.355 0.839 0 N-CA-C 105.056 -2.201 . . . . 25.32 105.056 172.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.26 72.87 2.16 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.743 2.373 . . . . 74.43 112.223 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.9 mt -86.24 -55.79 3.75 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.826 -1.546 . . . . 60.42 106.826 171.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.48 155.94 15.94 Favored Glycine 0 C--N 1.357 1.73 0 N-CA-C 109.503 -1.439 . . . . 52.34 109.503 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -129.75 86.56 2.43 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.077 -0.963 . . . . 70.32 111.642 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -120.03 145.21 47.04 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-O 116.67 -1.633 . . . . 62.34 108.243 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.4 pt -84.22 141.35 14.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.924 0 N-CA-C 106.127 -1.805 . . . . 72.52 106.127 166.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -149.69 164.39 35.34 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 119.442 1.019 . . . . 74.12 109.428 -175.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.536 0 N-CA-C 109.512 -1.435 . . . . 62.54 109.512 178.973 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.71 0 N-CA-C 116.363 1.305 . . . . 13.41 116.363 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -150.3 -173.47 4.46 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.912 1.856 . . . . 65.23 107.76 174.073 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -67.86 -27.42 66.67 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.155 -1.402 . . . . 64.32 113.585 -172.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.62 151.03 9.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 120.703 1.592 . . . . 55.32 110.998 -174.358 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.71 -107.64 0.33 Allowed Glycine 0 C--N 1.358 1.787 0 CA-C-O 117.618 -1.657 . . . . 54.43 111.594 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -153.09 160.7 30.61 Favored Pre-proline 0 C--N 1.357 0.924 0 CA-C-O 115.314 -2.279 . . . . 70.32 108.428 -175.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -55.96 130.06 38.25 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 125.031 2.832 . . . . 71.52 112.287 -173.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -68.99 -57.27 5.69 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.024 -1.102 . . . . 62.31 108.024 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.69 -61.58 1.75 Allowed 'General case' 0 C--N 1.354 0.775 0 CA-C-O 118.403 -0.808 . . . . 64.12 109.563 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.29 -51.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 118.614 -0.707 . . . . 71.12 109.798 -176.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -77.09 145.42 73.38 Favored Pre-proline 0 C--N 1.354 0.789 0 N-CA-C 105.059 -2.2 . . . . 62.42 105.059 172.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -70.67 74.45 1.69 Allowed 'Trans proline' 0 C--N 1.358 1.053 0 CA-C-N 123.804 2.394 . . . . 73.4 112.168 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 65.5 mt -88.22 -56.52 3.29 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 106.722 -1.584 . . . . 63.11 106.722 171.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.75 150.27 16.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 108.909 -1.677 . . . . 55.31 108.909 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -125.44 91.34 3.39 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 118.452 1.126 . . . . 73.24 111.422 -178.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -120.77 151.82 39.09 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.907 -1.52 . . . . 61.2 107.937 171.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.4 pt -88.01 142.14 13.35 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 105.525 -2.028 . . . . 73.45 105.525 165.119 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 -148.52 163.88 35.87 Favored 'General case' 0 C--N 1.355 0.836 0 CA-C-N 119.718 1.145 . . . . 70.13 109.589 -175.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.563 0 N-CA-C 109.538 -1.425 . . . . 70.04 109.538 179.252 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.666 0 N-CA-C 115.658 1.023 . . . . 52.32 115.658 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 -176.9 6.22 Favored 'General case' 0 C--N 1.353 0.747 0 CA-C-N 119.046 1.423 . . . . 63.21 108.438 175.231 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -64.56 -29.63 70.66 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-O 117.178 -1.391 . . . . 73.11 113.779 -173.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.14 151.56 9.34 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.703 1.592 . . . . 73.01 111.31 -173.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.65 -106.91 0.31 Allowed Glycine 0 C--N 1.358 1.762 0 CA-C-O 117.556 -1.691 . . . . 72.01 111.585 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.7 159.88 31.87 Favored Pre-proline 0 C--N 1.357 0.919 0 CA-C-O 115.247 -2.311 . . . . 75.54 108.333 -176.248 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -55.32 130.12 38.89 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.865 2.773 . . . . 74.12 112.42 -173.339 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.6 mt-10 -68.59 -57.17 6.14 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.035 -1.098 . . . . 53.04 108.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.24 1.86 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-O 118.389 -0.815 . . . . 72.01 109.563 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.77 -50.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.538 -0.744 . . . . 51.13 109.755 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.37 145.41 68.14 Favored Pre-proline 0 C--N 1.354 0.803 0 N-CA-C 105.193 -2.151 . . . . 74.11 105.193 172.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.44 75.34 1.51 Allowed 'Trans proline' 0 C--N 1.359 1.13 0 CA-C-N 123.762 2.379 . . . . 61.2 112.161 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 63.3 mt -89.42 -56.87 3.09 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.785 -1.561 . . . . 64.41 106.785 171.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.7 145.12 16.13 Favored Glycine 0 C--N 1.357 1.698 0 N-CA-C 108.517 -1.833 . . . . 71.14 108.517 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.15 93.18 3.94 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.958 1.379 . . . . 74.33 111.104 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -119.13 156.3 30.03 Favored 'General case' 0 C--N 1.359 0.996 0 CA-C-O 117.174 -1.394 . . . . 70.34 107.955 170.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.7 pt -90.58 140.61 15.67 Favored 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 105.245 -2.131 . . . . 71.02 105.245 165.038 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -147.62 164.45 33.45 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 119.876 1.216 . . . . 74.43 109.642 -174.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.579 0 N-CA-C 109.172 -1.571 . . . . 74.31 109.172 179.68 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 N-CA-C 117.019 1.568 . . . . 54.32 117.019 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.79 -171.47 3.7 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-N 120.341 2.07 . . . . 73.11 107.301 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -70.57 -26.42 63.52 Favored 'General case' 0 C--N 1.351 0.663 0 CA-C-O 117.21 -1.376 . . . . 71.31 113.502 -172.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.52 150.09 10.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.823 0 CA-C-N 120.641 1.564 . . . . 73.03 110.795 -174.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.99 -108.11 0.35 Allowed Glycine 0 C--N 1.358 1.796 0 CA-C-O 117.541 -1.699 . . . . 71.25 111.784 178.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -152.86 161.03 30.22 Favored Pre-proline 0 C--N 1.357 0.892 0 CA-C-O 115.298 -2.287 . . . . 73.12 108.421 -174.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 131.22 44.16 Favored 'Trans proline' 0 C--N 1.361 1.202 0 CA-C-N 125.119 2.864 . . . . 75.01 112.078 -172.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -69.92 -57.73 4.69 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.027 -1.101 . . . . 71.32 108.027 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.97 -61.65 1.72 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.347 -0.835 . . . . 73.03 109.58 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.6 p -174.98 -51.58 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.706 -0.664 . . . . 62.1 109.769 -176.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.74 145.39 78.27 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 105.076 -2.194 . . . . 73.03 105.076 172.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -71.02 73.8 1.92 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.724 2.366 . . . . 73.21 112.137 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.1 mt -87.29 -56.27 3.44 Favored 'General case' 0 C--N 1.355 0.841 0 N-CA-C 106.842 -1.54 . . . . 70.11 106.842 171.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.01 153.14 16.89 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 109.176 -1.569 . . . . 62.22 109.176 -178.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -127.69 88.34 2.76 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.218 1.009 . . . . 72.41 111.509 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -118.97 148.76 42.62 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-O 116.841 -1.552 . . . . 75.22 107.982 171.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 48.4 pt -85.61 141.83 14.0 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.796 -1.927 . . . . 73.05 105.796 165.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -149.26 163.77 36.71 Favored 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.679 1.127 . . . . 65.31 109.547 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.593 0 N-CA-C 109.443 -1.463 . . . . 74.35 109.443 178.532 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.672 0 CA-C-O 118.757 -1.024 . . . . 53.31 114.846 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -159.59 -178.67 7.27 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.107 1.453 . . . . 61.32 108.534 176.099 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -63.05 -30.56 71.69 Favored 'General case' 0 C--N 1.351 0.671 0 CA-C-O 117.086 -1.435 . . . . 73.31 113.693 -173.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -156.19 151.8 9.03 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 120.741 1.61 . . . . 72.44 111.42 -172.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 151.99 -106.43 0.3 Allowed Glycine 0 C--N 1.358 1.77 0 CA-C-O 117.707 -1.607 . . . . 53.12 111.49 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.72 159.37 32.54 Favored Pre-proline 0 C--N 1.356 0.878 0 CA-C-O 115.395 -2.24 . . . . 72.34 108.347 -176.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -54.95 130.11 38.94 Favored 'Trans proline' 0 C--N 1.362 1.266 0 CA-C-N 124.761 2.736 . . . . 73.33 112.578 -173.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -68.44 -57.2 6.22 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.063 -1.088 . . . . 72.44 108.063 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.83 -61.14 1.9 Allowed 'General case' 0 C--N 1.354 0.788 0 CA-C-O 118.364 -0.827 . . . . 64.55 109.615 179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -175.77 -50.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.572 -0.727 . . . . 72.32 109.86 -176.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -79.04 145.53 65.65 Favored Pre-proline 0 C--N 1.355 0.823 0 CA-C-O 115.56 -2.162 . . . . 74.22 105.249 172.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -70.23 75.42 1.41 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.768 2.381 . . . . 65.43 112.255 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.8 mt -89.83 -56.86 3.07 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 106.725 -1.583 . . . . 73.51 106.725 171.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.64 142.77 15.89 Favored Glycine 0 C--N 1.357 1.719 0 N-CA-C 108.318 -1.913 . . . . 71.14 108.318 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -119.32 94.49 4.44 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-N 119.108 1.454 . . . . 74.15 110.959 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -119.37 155.83 31.21 Favored 'General case' 0 C--N 1.36 1.035 0 CA-C-O 117.165 -1.397 . . . . 64.54 107.903 170.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.5 pt -88.97 140.42 15.82 Favored 'Isoleucine or valine' 0 C--N 1.357 0.922 0 N-CA-C 105.157 -2.164 . . . . 73.05 105.157 164.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -147.46 164.42 33.42 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 119.972 1.26 . . . . 74.42 109.794 -174.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.559 0 N-CA-C 109.551 -1.42 . . . . 70.11 109.551 179.417 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.699 0 N-CA-C 117.434 1.734 . . . . 73.44 117.434 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -140.25 -162.39 1.34 Allowed 'General case' 0 C--N 1.356 0.871 0 CA-C-N 120.668 2.234 . . . . 63.23 106.716 172.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -79.39 -27.84 41.84 Favored 'General case' 0 C--N 1.352 0.716 0 CA-C-N 121.023 1.738 . . . . 73.13 113.263 -172.099 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.5 p -154.16 148.69 13.17 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.286 1.403 . . . . 72.41 110.265 -175.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.26 -106.47 0.3 Allowed Glycine 0 C--N 1.357 1.745 0 CA-C-O 117.603 -1.665 . . . . 61.42 112.278 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 2.1 pp0? -153.93 160.99 30.32 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.447 -2.216 . . . . 73.12 108.915 -172.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -58.48 128.79 29.7 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.797 2.749 . . . . 73.31 112.048 -173.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -67.34 -57.68 6.18 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 108.228 -1.027 . . . . 73.44 108.228 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -86.16 -62.43 1.52 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.057 0.844 . . . . 52.14 109.646 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.09 -51.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.784 -0.627 . . . . 63.15 109.855 -176.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.23 146.17 84.03 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 104.946 -2.242 . . . . 60.25 104.946 172.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.24 72.01 2.25 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 123.855 2.412 . . . . 73.02 112.188 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.6 mt -86.36 -55.29 3.97 Favored 'General case' 0 C--N 1.354 0.78 0 N-CA-C 106.898 -1.519 . . . . 51.53 106.898 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.3 157.57 15.45 Favored Glycine 0 C--N 1.356 1.67 0 N-CA-C 110.022 -1.231 . . . . 74.22 110.022 -176.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.58 84.24 2.16 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-O 118.13 -0.938 . . . . 72.23 111.758 -177.188 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -122.81 134.64 54.41 Favored 'General case' 0 C--N 1.36 1.042 0 CA-C-O 116.665 -1.636 . . . . 60.41 108.817 173.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -74.83 140.35 17.64 Favored 'Isoleucine or valine' 0 C--N 1.357 0.926 0 N-CA-C 106.813 -1.551 . . . . 63.32 106.813 167.27 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.4 mt-30 -150.06 163.44 38.15 Favored 'General case' 0 C--N 1.355 0.846 0 CA-C-N 119.405 1.002 . . . . 73.21 109.398 -176.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.575 0 N-CA-C 109.305 -1.518 . . . . 41.13 109.305 177.93 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.679 0 N-CA-C 117.288 1.675 . . . . 75.32 117.288 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.02 -174.04 4.16 Favored 'General case' 0 C--N 1.356 0.872 0 CA-C-N 120.384 2.092 . . . . 73.05 107.284 173.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -68.45 -25.76 65.17 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-O 117.147 -1.406 . . . . 74.15 113.343 -172.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.49 151.42 8.14 Favored 'Isoleucine or valine' 0 C--N 1.354 0.787 0 CA-C-N 120.85 1.659 . . . . 60.11 110.75 -175.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.47 -104.72 0.26 Allowed Glycine 0 C--N 1.358 1.758 0 CA-C-O 117.848 -1.529 . . . . 73.32 111.459 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.67 158.55 29.44 Favored Pre-proline 0 C--N 1.355 0.847 0 CA-C-O 115.364 -2.255 . . . . 73.32 107.903 -174.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -55.58 135.7 70.58 Favored 'Trans proline' 0 C--N 1.36 1.156 0 CA-C-N 124.842 2.765 . . . . 65.33 112.901 -170.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -73.39 -59.79 2.54 Favored 'General case' 0 C--N 1.355 0.818 0 N-CA-C 108.116 -1.068 . . . . 64.31 108.116 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.23 -61.17 1.87 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.012 0.824 . . . . 65.54 109.322 178.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.07 -51.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-O 118.727 -0.654 . . . . 73.02 109.697 -177.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.7 145.02 81.23 Favored Pre-proline 0 C--N 1.355 0.832 0 N-CA-C 105.031 -2.211 . . . . 75.25 105.031 172.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -71.51 73.04 2.29 Favored 'Trans proline' 0 C--N 1.357 1.024 0 CA-C-N 123.706 2.359 . . . . 52.11 112.045 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.8 mt -84.82 -55.38 4.12 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 106.585 -1.635 . . . . 74.14 106.585 171.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.47 159.39 13.78 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 109.273 -1.531 . . . . 61.12 109.273 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -130.59 90.15 2.88 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 117.998 -1.001 . . . . 70.11 111.773 -177.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -124.86 143.14 50.99 Favored 'General case' 0 C--N 1.36 1.065 0 CA-C-O 116.868 -1.539 . . . . 72.23 108.259 172.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 46.6 pt -79.09 139.01 19.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.898 0 N-CA-C 106.355 -1.72 . . . . 73.53 106.355 167.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -149.5 163.6 37.36 Favored 'General case' 0 C--N 1.355 0.839 0 CA-C-N 119.507 1.049 . . . . 74.41 109.297 -176.289 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.577 0 N-CA-C 109.326 -1.51 . . . . 53.42 109.326 178.545 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.684 0 N-CA-C 117.447 1.739 . . . . 73.13 117.447 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.53 -173.18 3.7 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-N 120.539 2.17 . . . . 62.1 107.127 172.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -69.95 -25.18 63.52 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-O 117.286 -1.34 . . . . 73.33 113.329 -172.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.34 151.02 8.62 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.733 1.606 . . . . 72.14 110.632 -175.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.39 -104.66 0.26 Allowed Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.865 -1.519 . . . . 63.23 111.703 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.16 29.18 Favored Pre-proline 0 C--N 1.356 0.869 0 CA-C-O 115.433 -2.222 . . . . 75.52 107.975 -173.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -55.88 136.18 73.34 Favored 'Trans proline' 0 C--N 1.361 1.187 0 CA-C-N 124.659 2.7 . . . . 74.4 113.0 -170.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -73.74 -60.12 2.4 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.177 -1.046 . . . . 73.42 108.177 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.58 -61.28 1.83 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-N 119.096 0.862 . . . . 62.01 109.271 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.7 -51.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.822 0 CA-C-O 118.735 -0.65 . . . . 72.11 109.693 -177.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.0 145.16 83.3 Favored Pre-proline 0 C--N 1.355 0.845 0 N-CA-C 104.954 -2.239 . . . . 74.22 104.954 172.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.66 72.73 2.43 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 123.833 2.405 . . . . 63.11 111.911 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.7 mt -84.45 -55.04 4.36 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 106.618 -1.623 . . . . 74.02 106.618 171.466 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.88 161.64 12.68 Favored Glycine 0 C--N 1.358 1.754 0 N-CA-C 109.467 -1.453 . . . . 40.02 109.467 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -132.25 88.6 2.56 Favored 'General case' 0 C--N 1.354 0.8 0 CA-C-O 117.937 -1.03 . . . . 72.42 111.733 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -124.84 140.16 53.18 Favored 'General case' 0 C--N 1.361 1.069 0 CA-C-O 116.827 -1.559 . . . . 65.14 108.423 172.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.9 pt -77.5 138.66 20.01 Favored 'Isoleucine or valine' 0 C--N 1.358 0.938 0 N-CA-C 106.661 -1.607 . . . . 62.13 106.661 167.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -149.65 163.67 37.27 Favored 'General case' 0 C--N 1.356 0.85 0 CA-C-N 119.342 0.974 . . . . 75.24 109.227 -176.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 N-CA-C 109.329 -1.508 . . . . 64.11 109.329 178.423 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 117.367 1.707 . . . . 60.32 117.367 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -143.44 -172.79 3.78 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 120.475 2.137 . . . . 64.54 107.222 172.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.21 -25.64 64.42 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.208 -1.377 . . . . 73.02 113.339 -173.056 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.47 151.5 8.09 Favored 'Isoleucine or valine' 0 C--N 1.354 0.782 0 CA-C-N 120.753 1.615 . . . . 74.01 110.695 -175.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.51 -103.8 0.24 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.948 -1.473 . . . . 54.54 111.681 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.04 158.1 28.59 Favored Pre-proline 0 C--N 1.356 0.867 0 CA-C-O 115.413 -2.232 . . . . 73.51 108.097 -173.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.68 134.31 63.27 Favored 'Trans proline' 0 C--N 1.361 1.192 0 CA-C-N 124.759 2.735 . . . . 62.41 112.918 -170.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -72.22 -60.05 2.43 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.181 -1.044 . . . . 71.34 108.181 -178.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.44 -61.35 1.82 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.119 0.872 . . . . 73.23 109.34 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -174.72 -51.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.783 0 CA-C-O 118.673 -0.68 . . . . 64.31 109.75 -177.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.55 145.18 81.85 Favored Pre-proline 0 C--N 1.355 0.809 0 N-CA-C 104.986 -2.227 . . . . 73.53 104.986 172.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.58 72.75 2.37 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.811 2.397 . . . . 64.45 111.973 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.36 -55.13 4.33 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 106.579 -1.637 . . . . 74.1 106.579 171.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.63 160.99 12.91 Favored Glycine 0 C--N 1.357 1.711 0 N-CA-C 109.337 -1.505 . . . . 23.44 109.337 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.64 90.68 2.88 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 117.923 -1.037 . . . . 71.35 111.868 -177.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -127.77 140.08 52.27 Favored 'General case' 0 C--N 1.362 1.112 0 CA-C-O 116.759 -1.591 . . . . 74.25 108.478 172.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.9 pt -77.9 139.17 19.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 N-CA-C 106.662 -1.607 . . . . 54.04 106.662 167.449 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -149.62 163.65 37.3 Favored 'General case' 0 C--N 1.357 0.898 0 CA-C-N 119.303 0.956 . . . . 73.12 109.166 -176.116 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.528 0 N-CA-C 109.298 -1.521 . . . . 72.32 109.298 178.4 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 N-CA-C 117.217 1.647 . . . . 63.41 117.217 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.34 -174.03 4.27 Favored 'General case' 0 C--N 1.355 0.835 0 CA-C-N 120.327 2.064 . . . . 74.11 107.377 173.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -67.68 -25.74 65.84 Favored 'General case' 0 C--N 1.351 0.658 0 CA-C-O 117.164 -1.398 . . . . 72.43 113.426 -173.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.74 152.05 7.4 Favored 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-N 120.83 1.65 . . . . 64.52 110.826 -175.174 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.43 -103.89 0.24 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.962 -1.466 . . . . 72.52 111.522 177.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.21 158.19 28.23 Favored Pre-proline 0 C--N 1.356 0.865 0 CA-C-O 115.31 -2.281 . . . . 61.21 107.981 -174.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -55.27 134.42 63.72 Favored 'Trans proline' 0 C--N 1.359 1.113 0 CA-C-N 124.875 2.777 . . . . 72.4 112.947 -170.449 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -72.45 -59.97 2.46 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.172 -1.048 . . . . 70.44 108.172 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.16 -61.14 1.89 Allowed 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.031 0.832 . . . . 73.55 109.372 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.04 -51.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.724 -0.655 . . . . 44.04 109.711 -177.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.14 144.93 79.75 Favored Pre-proline 0 C--N 1.356 0.866 0 N-CA-C 104.942 -2.244 . . . . 53.51 104.942 172.403 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -71.59 72.96 2.35 Favored 'Trans proline' 0 C--N 1.358 1.032 0 CA-C-N 123.694 2.355 . . . . 62.41 112.09 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.2 mt -84.6 -55.52 4.08 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.592 -1.633 . . . . 73.14 106.592 171.42 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.97 159.05 13.99 Favored Glycine 0 C--N 1.357 1.712 0 N-CA-C 109.225 -1.55 . . . . 73.25 109.225 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -130.29 92.55 3.3 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 117.951 -1.023 . . . . 65.32 111.844 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -128.71 142.76 50.91 Favored 'General case' 0 C--N 1.361 1.072 0 CA-C-O 116.82 -1.562 . . . . 74.33 108.411 172.021 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -80.55 140.62 16.4 Favored 'Isoleucine or valine' 0 C--N 1.357 0.904 0 N-CA-C 106.399 -1.704 . . . . 72.43 106.399 166.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -149.22 164.01 36.01 Favored 'General case' 0 C--N 1.355 0.846 0 CA-C-N 119.33 0.968 . . . . 72.41 109.189 -175.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.08 -1.608 . . . . 62.4 109.08 179.387 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 N-CA-C 116.97 1.548 . . . . 54.44 116.97 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.43 -174.7 4.53 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-N 120.246 2.023 . . . . 72.33 107.528 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -67.0 -26.11 66.64 Favored 'General case' 0 C--N 1.35 0.607 0 CA-C-O 117.12 -1.419 . . . . 63.23 113.393 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.8 152.15 7.28 Favored 'Isoleucine or valine' 0 C--N 1.354 0.796 0 CA-C-N 120.891 1.678 . . . . 74.11 110.888 -174.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.31 -104.27 0.25 Allowed Glycine 0 C--N 1.358 1.759 0 CA-C-O 117.93 -1.483 . . . . 63.43 111.436 178.117 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.06 158.42 28.82 Favored Pre-proline 0 C--N 1.355 0.836 0 CA-C-O 115.342 -2.266 . . . . 73.44 107.909 -174.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.23 134.47 64.0 Favored 'Trans proline' 0 C--N 1.36 1.143 0 CA-C-N 124.878 2.778 . . . . 62.34 112.957 -170.447 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -72.39 -59.53 2.68 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 108.154 -1.054 . . . . 65.44 108.154 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.94 -61.09 1.91 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 119.029 0.831 . . . . 63.24 109.344 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.49 -51.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.819 0 CA-C-O 118.738 -0.648 . . . . 72.01 109.6 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.31 144.93 79.12 Favored Pre-proline 0 C--N 1.356 0.853 0 N-CA-C 104.939 -2.245 . . . . 71.01 104.939 172.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.48 73.52 2.22 Favored 'Trans proline' 0 C--N 1.358 1.048 0 CA-C-N 123.84 2.407 . . . . 71.24 111.987 -179.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 68.8 mt -85.42 -55.63 3.92 Favored 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.516 -1.661 . . . . 61.44 106.516 171.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.04 157.96 14.65 Favored Glycine 0 C--N 1.357 1.704 0 N-CA-C 109.08 -1.608 . . . . 43.04 109.08 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.56 92.56 3.36 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 117.999 -1.001 . . . . 72.44 111.779 -178.127 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -127.13 143.97 51.14 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-O 116.837 -1.554 . . . . 74.42 108.247 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 47.8 pt -79.68 138.98 18.97 Favored 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 106.371 -1.714 . . . . 72.34 106.371 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.3 mt-30 -149.29 164.24 35.42 Favored 'General case' 0 C--N 1.355 0.836 0 CA-C-N 119.455 1.025 . . . . 74.24 109.223 -176.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.522 0 N-CA-C 109.146 -1.582 . . . . 72.1 109.146 179.531 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 117.434 1.734 . . . . 50.34 117.434 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.66 -173.13 3.7 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-N 120.669 2.235 . . . . 54.41 107.185 172.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -69.9 -25.39 63.67 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-O 117.234 -1.365 . . . . 72.12 113.378 -172.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.07 150.97 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 CA-C-N 120.652 1.569 . . . . 73.43 110.558 -175.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.37 -104.57 0.26 Allowed Glycine 0 C--N 1.358 1.781 0 CA-C-O 117.902 -1.499 . . . . 63.44 111.802 178.452 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.14 29.16 Favored Pre-proline 0 C--N 1.356 0.871 0 CA-C-O 115.36 -2.257 . . . . 72.45 108.13 -173.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -55.89 135.95 72.19 Favored 'Trans proline' 0 C--N 1.359 1.088 0 CA-C-N 124.767 2.738 . . . . 54.31 112.94 -170.344 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -73.69 -60.31 2.31 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 108.158 -1.052 . . . . 72.2 108.158 -178.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.43 -61.19 1.86 Allowed 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.081 0.855 . . . . 71.53 109.274 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.65 -51.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.356 0.854 0 CA-C-O 118.672 -0.68 . . . . 64.14 109.75 -177.224 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.12 145.13 82.93 Favored Pre-proline 0 C--N 1.355 0.818 0 N-CA-C 104.997 -2.223 . . . . 73.31 104.997 172.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.64 72.91 2.39 Favored 'Trans proline' 0 C--N 1.358 1.04 0 CA-C-N 123.798 2.392 . . . . 43.22 111.894 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.0 mt -84.55 -55.0 4.36 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.587 -1.635 . . . . 73.52 106.587 171.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.86 161.4 12.76 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 109.43 -1.468 . . . . 74.52 109.43 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.87 88.46 2.56 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.879 -1.058 . . . . 74.23 111.84 -177.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -124.97 139.98 53.33 Favored 'General case' 0 C--N 1.36 1.057 0 CA-C-O 116.777 -1.582 . . . . 73.12 108.498 172.721 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -78.41 139.39 18.57 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 106.647 -1.612 . . . . 75.42 106.647 167.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -149.68 163.21 38.56 Favored 'General case' 0 C--N 1.356 0.863 0 CA-C-N 119.275 0.943 . . . . 73.51 109.2 -176.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.548 0 N-CA-C 109.26 -1.536 . . . . 52.31 109.26 178.425 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 N-CA-C 117.015 1.566 . . . . 60.54 117.015 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.45 -175.17 4.81 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 120.216 2.008 . . . . 73.3 107.847 173.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 51.3 m-85 -65.76 -27.2 68.12 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-O 117.101 -1.428 . . . . 70.05 113.463 -173.341 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.44 152.35 7.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 CA-C-N 120.879 1.672 . . . . 75.54 111.044 -174.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.67 -104.92 0.26 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.957 -1.468 . . . . 70.52 111.147 178.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.03 158.79 29.21 Favored Pre-proline 0 C--N 1.357 0.909 0 CA-C-O 115.525 -2.178 . . . . 73.35 107.791 -174.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -54.76 134.42 62.67 Favored 'Trans proline' 0 C--N 1.36 1.141 0 CA-C-N 124.834 2.762 . . . . 73.0 113.016 -170.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -72.41 -59.26 2.82 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.085 -1.08 . . . . 71.21 108.085 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.72 -60.97 1.95 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 118.968 0.804 . . . . 65.21 109.351 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.72 -51.48 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.805 0 CA-C-O 118.832 -0.604 . . . . 73.4 109.615 -177.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.95 144.97 76.86 Favored Pre-proline 0 C--N 1.355 0.811 0 N-CA-C 104.959 -2.237 . . . . 70.24 104.959 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -71.32 73.83 2.09 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.755 2.377 . . . . 71.35 112.007 -179.418 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.4 mt -86.14 -56.0 3.66 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 106.495 -1.669 . . . . 74.23 106.495 171.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.08 156.33 15.64 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.993 -1.643 . . . . 70.32 108.993 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -128.28 93.48 3.66 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.99 -1.005 . . . . 75.34 111.668 -178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -127.69 146.55 50.53 Favored 'General case' 0 C--N 1.36 1.052 0 CA-C-O 116.908 -1.52 . . . . 54.44 108.198 171.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -82.1 139.65 17.6 Favored 'Isoleucine or valine' 0 C--N 1.357 0.934 0 N-CA-C 106.091 -1.818 . . . . 73.14 106.091 166.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -148.74 164.08 35.45 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.58 1.082 . . . . 72.35 109.392 -175.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.572 0 N-CA-C 109.362 -1.495 . . . . 72.44 109.362 178.667 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.587 -1.119 . . . . 65.42 115.382 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.66 -177.13 6.37 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.366 1.583 . . . . 52.0 108.282 175.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -64.3 -29.32 70.41 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.105 -1.426 . . . . 73.31 113.685 -173.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -156.43 151.6 9.02 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.709 1.595 . . . . 61.22 111.401 -173.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.68 -107.27 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.666 -1.63 . . . . 41.13 111.497 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.78 159.96 31.71 Favored Pre-proline 0 C--N 1.356 0.86 0 CA-C-O 115.45 -2.214 . . . . 63.11 108.248 -176.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -55.35 130.5 40.95 Favored 'Trans proline' 0 C--N 1.362 1.265 0 CA-C-N 124.839 2.764 . . . . 71.34 112.61 -173.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 81.3 mt-10 -68.98 -57.14 5.87 Favored 'General case' 0 C--N 1.354 0.77 0 N-CA-C 108.004 -1.11 . . . . 72.4 108.004 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.15 -61.27 1.85 Allowed 'General case' 0 C--N 1.354 0.782 0 CA-C-O 118.343 -0.837 . . . . 73.2 109.632 179.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.72 -51.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.773 0 CA-C-O 118.64 -0.695 . . . . 63.31 109.786 -176.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.42 145.38 67.87 Favored Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.538 -2.172 . . . . 71.51 105.18 172.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -70.42 75.06 1.52 Allowed 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.752 2.376 . . . . 71.41 112.211 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -88.91 -56.74 3.16 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 106.697 -1.594 . . . . 74.24 106.697 171.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.94 145.16 16.2 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.523 -1.831 . . . . 64.44 108.523 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.22 93.95 4.18 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.937 1.368 . . . . 72.35 111.139 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -120.11 157.19 29.5 Favored 'General case' 0 C--N 1.36 1.047 0 CA-C-O 117.248 -1.358 . . . . 65.33 107.868 170.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -92.3 141.04 15.17 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 105.344 -2.095 . . . . 72.22 105.344 164.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 . . . . . 0 C--N 1.355 0.821 0 CA-C-N 119.84 1.2 . . . . 75.41 109.747 -174.548 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.721 0 CA-C-O 118.708 -1.051 . . . . 73.3 115.306 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.14 -177.33 6.53 Favored 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.273 1.537 . . . . 70.22 108.388 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -63.92 -29.64 70.8 Favored 'General case' 0 C--N 1.351 0.665 0 CA-C-O 117.07 -1.443 . . . . 65.02 113.615 -173.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.9 p -156.37 151.71 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 120.811 1.642 . . . . 74.23 111.374 -173.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.66 -107.12 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.682 -1.621 . . . . 51.12 111.455 177.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.89 159.86 31.77 Favored Pre-proline 0 C--N 1.356 0.859 0 CA-C-O 115.418 -2.23 . . . . 73.52 108.296 -176.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -54.95 129.81 37.31 Favored 'Trans proline' 0 C--N 1.361 1.233 0 CA-C-N 124.818 2.756 . . . . 74.34 112.584 -173.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -68.37 -57.03 6.53 Favored 'General case' 0 C--N 1.355 0.839 0 N-CA-C 108.047 -1.094 . . . . 60.34 108.047 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.11 -61.32 1.84 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-O 118.396 -0.811 . . . . 74.2 109.66 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.73 -50.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-O 118.653 -0.689 . . . . 53.33 109.858 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.68 145.45 66.96 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.566 -2.159 . . . . 73.23 105.194 172.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -70.3 75.14 1.47 Allowed 'Trans proline' 0 C--N 1.358 1.044 0 CA-C-N 123.777 2.384 . . . . 71.02 112.252 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -89.42 -56.85 3.09 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 106.769 -1.567 . . . . 73.14 106.769 171.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.62 144.63 16.06 Favored Glycine 0 C--N 1.357 1.721 0 N-CA-C 108.45 -1.86 . . . . 52.23 108.45 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -120.8 94.16 4.26 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.963 1.381 . . . . 73.41 111.185 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -120.7 156.53 31.56 Favored 'General case' 0 C--N 1.359 1.012 0 CA-C-O 117.186 -1.388 . . . . 75.21 107.843 170.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.6 pt -91.24 141.07 14.98 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.283 -2.117 . . . . 74.31 105.283 164.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 . . . . . 0 C--N 1.355 0.816 0 CA-C-N 119.808 1.185 . . . . 74.33 109.626 -174.41 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 N-CA-C 117.347 1.699 . . . . 62.14 117.347 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.23 -169.52 2.97 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 120.619 2.21 . . . . 72.05 107.081 173.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -72.83 -25.95 61.31 Favored 'General case' 0 C--N 1.351 0.659 0 CA-C-N 120.389 1.45 . . . . 73.13 113.38 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -156.35 149.62 10.83 Favored 'Isoleucine or valine' 0 C--N 1.355 0.816 0 CA-C-N 120.555 1.525 . . . . 70.23 110.569 -175.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.98 -108.37 0.36 Allowed Glycine 0 C--N 1.357 1.74 0 CA-C-O 117.592 -1.671 . . . . 65.43 111.969 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.9 161.12 29.94 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.359 -2.258 . . . . 70.44 108.512 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -57.68 131.83 46.51 Favored 'Trans proline' 0 C--N 1.361 1.195 0 CA-C-N 124.969 2.81 . . . . 75.1 112.119 -172.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -70.26 -58.19 4.04 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.063 -1.088 . . . . 64.11 108.063 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -85.22 -61.78 1.69 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.038 0.835 . . . . 73.44 109.56 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.65 -51.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.767 0 CA-C-O 118.736 -0.65 . . . . 63.53 109.838 -176.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.85 145.51 81.51 Favored Pre-proline 0 C--N 1.355 0.839 0 N-CA-C 105.056 -2.201 . . . . 25.32 105.056 172.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.26 72.87 2.16 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.743 2.373 . . . . 74.43 112.223 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.9 mt -86.24 -55.79 3.75 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.826 -1.546 . . . . 60.42 106.826 171.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.48 155.94 15.94 Favored Glycine 0 C--N 1.357 1.73 0 N-CA-C 109.503 -1.439 . . . . 52.34 109.503 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -129.75 86.56 2.43 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.077 -0.963 . . . . 70.32 111.642 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -120.03 145.21 47.04 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-O 116.67 -1.633 . . . . 62.34 108.243 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.4 pt -84.22 141.35 14.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.924 0 N-CA-C 106.127 -1.805 . . . . 72.52 106.127 166.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 . . . . . 0 C--N 1.355 0.841 0 CA-C-N 119.442 1.019 . . . . 74.12 109.428 -175.894 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.71 0 N-CA-C 116.363 1.305 . . . . 13.41 116.363 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -150.3 -173.47 4.46 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.912 1.856 . . . . 65.23 107.76 174.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -67.86 -27.42 66.67 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.155 -1.402 . . . . 64.32 113.585 -172.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.62 151.03 9.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 120.703 1.592 . . . . 55.32 110.998 -174.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.71 -107.64 0.33 Allowed Glycine 0 C--N 1.358 1.787 0 CA-C-O 117.618 -1.657 . . . . 54.43 111.594 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.09 160.7 30.61 Favored Pre-proline 0 C--N 1.357 0.924 0 CA-C-O 115.314 -2.279 . . . . 70.32 108.428 -175.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -55.96 130.06 38.25 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 125.031 2.832 . . . . 71.52 112.287 -173.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -68.99 -57.27 5.69 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.024 -1.102 . . . . 62.31 108.024 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.69 -61.58 1.75 Allowed 'General case' 0 C--N 1.354 0.775 0 CA-C-O 118.403 -0.808 . . . . 64.12 109.563 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.29 -51.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 118.614 -0.707 . . . . 71.12 109.798 -176.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -77.09 145.42 73.38 Favored Pre-proline 0 C--N 1.354 0.789 0 N-CA-C 105.059 -2.2 . . . . 62.42 105.059 172.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -70.67 74.45 1.69 Allowed 'Trans proline' 0 C--N 1.358 1.053 0 CA-C-N 123.804 2.394 . . . . 73.4 112.168 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 65.5 mt -88.22 -56.52 3.29 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 106.722 -1.584 . . . . 63.11 106.722 171.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.75 150.27 16.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 108.909 -1.677 . . . . 55.31 108.909 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -125.44 91.34 3.39 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 118.452 1.126 . . . . 73.24 111.422 -178.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -120.77 151.82 39.09 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.907 -1.52 . . . . 61.2 107.937 171.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.4 pt -88.01 142.14 13.35 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 105.525 -2.028 . . . . 73.45 105.525 165.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 . . . . . 0 C--N 1.355 0.836 0 CA-C-N 119.718 1.145 . . . . 70.13 109.589 -175.351 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.666 0 N-CA-C 115.658 1.023 . . . . 52.32 115.658 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 -176.9 6.22 Favored 'General case' 0 C--N 1.353 0.747 0 CA-C-N 119.046 1.423 . . . . 63.21 108.438 175.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -64.56 -29.63 70.66 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-O 117.178 -1.391 . . . . 73.11 113.779 -173.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.14 151.56 9.34 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.703 1.592 . . . . 73.01 111.31 -173.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.65 -106.91 0.31 Allowed Glycine 0 C--N 1.358 1.762 0 CA-C-O 117.556 -1.691 . . . . 72.01 111.585 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.7 159.88 31.87 Favored Pre-proline 0 C--N 1.357 0.919 0 CA-C-O 115.247 -2.311 . . . . 75.54 108.333 -176.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -55.32 130.12 38.89 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.865 2.773 . . . . 74.12 112.42 -173.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.6 mt-10 -68.59 -57.17 6.14 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.035 -1.098 . . . . 53.04 108.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.24 1.86 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-O 118.389 -0.815 . . . . 72.01 109.563 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.77 -50.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.538 -0.744 . . . . 51.13 109.755 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.37 145.41 68.14 Favored Pre-proline 0 C--N 1.354 0.803 0 N-CA-C 105.193 -2.151 . . . . 74.11 105.193 172.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.44 75.34 1.51 Allowed 'Trans proline' 0 C--N 1.359 1.13 0 CA-C-N 123.762 2.379 . . . . 61.2 112.161 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 63.3 mt -89.42 -56.87 3.09 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.785 -1.561 . . . . 64.41 106.785 171.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.7 145.12 16.13 Favored Glycine 0 C--N 1.357 1.698 0 N-CA-C 108.517 -1.833 . . . . 71.14 108.517 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.15 93.18 3.94 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.958 1.379 . . . . 74.33 111.104 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -119.13 156.3 30.03 Favored 'General case' 0 C--N 1.359 0.996 0 CA-C-O 117.174 -1.394 . . . . 70.34 107.955 170.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.7 pt -90.58 140.61 15.67 Favored 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 105.245 -2.131 . . . . 71.02 105.245 165.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 . . . . . 0 C--N 1.355 0.83 0 CA-C-N 119.876 1.216 . . . . 74.43 109.642 -174.613 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 N-CA-C 117.019 1.568 . . . . 54.32 117.019 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.79 -171.47 3.7 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-N 120.341 2.07 . . . . 73.11 107.301 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -70.57 -26.42 63.52 Favored 'General case' 0 C--N 1.351 0.663 0 CA-C-O 117.21 -1.376 . . . . 71.31 113.502 -172.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.52 150.09 10.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.823 0 CA-C-N 120.641 1.564 . . . . 73.03 110.795 -174.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.99 -108.11 0.35 Allowed Glycine 0 C--N 1.358 1.796 0 CA-C-O 117.541 -1.699 . . . . 71.25 111.784 178.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.86 161.03 30.22 Favored Pre-proline 0 C--N 1.357 0.892 0 CA-C-O 115.298 -2.287 . . . . 73.12 108.421 -174.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 131.22 44.16 Favored 'Trans proline' 0 C--N 1.361 1.202 0 CA-C-N 125.119 2.864 . . . . 75.01 112.078 -172.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -69.92 -57.73 4.69 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.027 -1.101 . . . . 71.32 108.027 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.97 -61.65 1.72 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.347 -0.835 . . . . 73.03 109.58 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.6 p -174.98 -51.58 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.706 -0.664 . . . . 62.1 109.769 -176.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.74 145.39 78.27 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 105.076 -2.194 . . . . 73.03 105.076 172.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -71.02 73.8 1.92 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.724 2.366 . . . . 73.21 112.137 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.1 mt -87.29 -56.27 3.44 Favored 'General case' 0 C--N 1.355 0.841 0 N-CA-C 106.842 -1.54 . . . . 70.11 106.842 171.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.01 153.14 16.89 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 109.176 -1.569 . . . . 62.22 109.176 -178.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -127.69 88.34 2.76 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.218 1.009 . . . . 72.41 111.509 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -118.97 148.76 42.62 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-O 116.841 -1.552 . . . . 75.22 107.982 171.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 48.4 pt -85.61 141.83 14.0 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.796 -1.927 . . . . 73.05 105.796 165.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 . . . . . 0 C--N 1.355 0.816 0 CA-C-N 119.679 1.127 . . . . 65.31 109.547 -175.704 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.672 0 CA-C-O 118.757 -1.024 . . . . 53.31 114.846 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -159.59 -178.67 7.27 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.107 1.453 . . . . 61.32 108.534 176.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -63.05 -30.56 71.69 Favored 'General case' 0 C--N 1.351 0.671 0 CA-C-O 117.086 -1.435 . . . . 73.31 113.693 -173.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -156.19 151.8 9.03 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 120.741 1.61 . . . . 72.44 111.42 -172.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 151.99 -106.43 0.3 Allowed Glycine 0 C--N 1.358 1.77 0 CA-C-O 117.707 -1.607 . . . . 53.12 111.49 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.72 159.37 32.54 Favored Pre-proline 0 C--N 1.356 0.878 0 CA-C-O 115.395 -2.24 . . . . 72.34 108.347 -176.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -54.95 130.11 38.94 Favored 'Trans proline' 0 C--N 1.362 1.266 0 CA-C-N 124.761 2.736 . . . . 73.33 112.578 -173.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -68.44 -57.2 6.22 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.063 -1.088 . . . . 72.44 108.063 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.83 -61.14 1.9 Allowed 'General case' 0 C--N 1.354 0.788 0 CA-C-O 118.364 -0.827 . . . . 64.55 109.615 179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -175.77 -50.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.572 -0.727 . . . . 72.32 109.86 -176.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -79.04 145.53 65.65 Favored Pre-proline 0 C--N 1.355 0.823 0 CA-C-O 115.56 -2.162 . . . . 74.22 105.249 172.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -70.23 75.42 1.41 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.768 2.381 . . . . 65.43 112.255 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.8 mt -89.83 -56.86 3.07 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 106.725 -1.583 . . . . 73.51 106.725 171.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.64 142.77 15.89 Favored Glycine 0 C--N 1.357 1.719 0 N-CA-C 108.318 -1.913 . . . . 71.14 108.318 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -119.32 94.49 4.44 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-N 119.108 1.454 . . . . 74.15 110.959 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -119.37 155.83 31.21 Favored 'General case' 0 C--N 1.36 1.035 0 CA-C-O 117.165 -1.397 . . . . 64.54 107.903 170.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.5 pt -88.97 140.42 15.82 Favored 'Isoleucine or valine' 0 C--N 1.357 0.922 0 N-CA-C 105.157 -2.164 . . . . 73.05 105.157 164.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 . . . . . 0 C--N 1.355 0.822 0 CA-C-N 119.972 1.26 . . . . 74.42 109.794 -174.691 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.699 0 N-CA-C 117.434 1.734 . . . . 73.44 117.434 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -140.25 -162.39 1.34 Allowed 'General case' 0 C--N 1.356 0.871 0 CA-C-N 120.668 2.234 . . . . 63.23 106.716 172.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -79.39 -27.84 41.84 Favored 'General case' 0 C--N 1.352 0.716 0 CA-C-N 121.023 1.738 . . . . 73.13 113.263 -172.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.5 p -154.16 148.69 13.17 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.286 1.403 . . . . 72.41 110.265 -175.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.26 -106.47 0.3 Allowed Glycine 0 C--N 1.357 1.745 0 CA-C-O 117.603 -1.665 . . . . 61.42 112.278 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.93 160.99 30.32 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.447 -2.216 . . . . 73.12 108.915 -172.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -58.48 128.79 29.7 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.797 2.749 . . . . 73.31 112.048 -173.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -67.34 -57.68 6.18 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 108.228 -1.027 . . . . 73.44 108.228 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -86.16 -62.43 1.52 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.057 0.844 . . . . 52.14 109.646 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.09 -51.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.784 -0.627 . . . . 63.15 109.855 -176.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.23 146.17 84.03 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 104.946 -2.242 . . . . 60.25 104.946 172.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.24 72.01 2.25 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 123.855 2.412 . . . . 73.02 112.188 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.6 mt -86.36 -55.29 3.97 Favored 'General case' 0 C--N 1.354 0.78 0 N-CA-C 106.898 -1.519 . . . . 51.53 106.898 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.3 157.57 15.45 Favored Glycine 0 C--N 1.356 1.67 0 N-CA-C 110.022 -1.231 . . . . 74.22 110.022 -176.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.58 84.24 2.16 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-O 118.13 -0.938 . . . . 72.23 111.758 -177.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -122.81 134.64 54.41 Favored 'General case' 0 C--N 1.36 1.042 0 CA-C-O 116.665 -1.636 . . . . 60.41 108.817 173.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -74.83 140.35 17.64 Favored 'Isoleucine or valine' 0 C--N 1.357 0.926 0 N-CA-C 106.813 -1.551 . . . . 63.32 106.813 167.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.4 mt-30 . . . . . 0 C--N 1.355 0.846 0 CA-C-N 119.405 1.002 . . . . 73.21 109.398 -176.841 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.679 0 N-CA-C 117.288 1.675 . . . . 75.32 117.288 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.02 -174.04 4.16 Favored 'General case' 0 C--N 1.356 0.872 0 CA-C-N 120.384 2.092 . . . . 73.05 107.284 173.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -68.45 -25.76 65.17 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-O 117.147 -1.406 . . . . 74.15 113.343 -172.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.49 151.42 8.14 Favored 'Isoleucine or valine' 0 C--N 1.354 0.787 0 CA-C-N 120.85 1.659 . . . . 60.11 110.75 -175.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.47 -104.72 0.26 Allowed Glycine 0 C--N 1.358 1.758 0 CA-C-O 117.848 -1.529 . . . . 73.32 111.459 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.67 158.55 29.44 Favored Pre-proline 0 C--N 1.355 0.847 0 CA-C-O 115.364 -2.255 . . . . 73.32 107.903 -174.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -55.58 135.7 70.58 Favored 'Trans proline' 0 C--N 1.36 1.156 0 CA-C-N 124.842 2.765 . . . . 65.33 112.901 -170.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -73.39 -59.79 2.54 Favored 'General case' 0 C--N 1.355 0.818 0 N-CA-C 108.116 -1.068 . . . . 64.31 108.116 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.23 -61.17 1.87 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.012 0.824 . . . . 65.54 109.322 178.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.07 -51.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-O 118.727 -0.654 . . . . 73.02 109.697 -177.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.7 145.02 81.23 Favored Pre-proline 0 C--N 1.355 0.832 0 N-CA-C 105.031 -2.211 . . . . 75.25 105.031 172.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -71.51 73.04 2.29 Favored 'Trans proline' 0 C--N 1.357 1.024 0 CA-C-N 123.706 2.359 . . . . 52.11 112.045 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.8 mt -84.82 -55.38 4.12 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 106.585 -1.635 . . . . 74.14 106.585 171.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.47 159.39 13.78 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 109.273 -1.531 . . . . 61.12 109.273 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -130.59 90.15 2.88 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 117.998 -1.001 . . . . 70.11 111.773 -177.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -124.86 143.14 50.99 Favored 'General case' 0 C--N 1.36 1.065 0 CA-C-O 116.868 -1.539 . . . . 72.23 108.259 172.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 46.6 pt -79.09 139.01 19.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.898 0 N-CA-C 106.355 -1.72 . . . . 73.53 106.355 167.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 . . . . . 0 C--N 1.355 0.839 0 CA-C-N 119.507 1.049 . . . . 74.41 109.297 -176.289 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.684 0 N-CA-C 117.447 1.739 . . . . 73.13 117.447 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.53 -173.18 3.7 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-N 120.539 2.17 . . . . 62.1 107.127 172.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -69.95 -25.18 63.52 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-O 117.286 -1.34 . . . . 73.33 113.329 -172.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.34 151.02 8.62 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.733 1.606 . . . . 72.14 110.632 -175.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.39 -104.66 0.26 Allowed Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.865 -1.519 . . . . 63.23 111.703 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.16 29.18 Favored Pre-proline 0 C--N 1.356 0.869 0 CA-C-O 115.433 -2.222 . . . . 75.52 107.975 -173.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -55.88 136.18 73.34 Favored 'Trans proline' 0 C--N 1.361 1.187 0 CA-C-N 124.659 2.7 . . . . 74.4 113.0 -170.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -73.74 -60.12 2.4 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.177 -1.046 . . . . 73.42 108.177 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.58 -61.28 1.83 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-N 119.096 0.862 . . . . 62.01 109.271 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.7 -51.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.822 0 CA-C-O 118.735 -0.65 . . . . 72.11 109.693 -177.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.0 145.16 83.3 Favored Pre-proline 0 C--N 1.355 0.845 0 N-CA-C 104.954 -2.239 . . . . 74.22 104.954 172.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.66 72.73 2.43 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 123.833 2.405 . . . . 63.11 111.911 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.7 mt -84.45 -55.04 4.36 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 106.618 -1.623 . . . . 74.02 106.618 171.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.88 161.64 12.68 Favored Glycine 0 C--N 1.358 1.754 0 N-CA-C 109.467 -1.453 . . . . 40.02 109.467 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -132.25 88.6 2.56 Favored 'General case' 0 C--N 1.354 0.8 0 CA-C-O 117.937 -1.03 . . . . 72.42 111.733 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -124.84 140.16 53.18 Favored 'General case' 0 C--N 1.361 1.069 0 CA-C-O 116.827 -1.559 . . . . 65.14 108.423 172.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.9 pt -77.5 138.66 20.01 Favored 'Isoleucine or valine' 0 C--N 1.358 0.938 0 N-CA-C 106.661 -1.607 . . . . 62.13 106.661 167.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 . . . . . 0 C--N 1.356 0.85 0 CA-C-N 119.342 0.974 . . . . 75.24 109.227 -176.412 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 117.367 1.707 . . . . 60.32 117.367 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -143.44 -172.79 3.78 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 120.475 2.137 . . . . 64.54 107.222 172.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.21 -25.64 64.42 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.208 -1.377 . . . . 73.02 113.339 -173.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.47 151.5 8.09 Favored 'Isoleucine or valine' 0 C--N 1.354 0.782 0 CA-C-N 120.753 1.615 . . . . 74.01 110.695 -175.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.51 -103.8 0.24 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.948 -1.473 . . . . 54.54 111.681 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.04 158.1 28.59 Favored Pre-proline 0 C--N 1.356 0.867 0 CA-C-O 115.413 -2.232 . . . . 73.51 108.097 -173.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.68 134.31 63.27 Favored 'Trans proline' 0 C--N 1.361 1.192 0 CA-C-N 124.759 2.735 . . . . 62.41 112.918 -170.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -72.22 -60.05 2.43 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.181 -1.044 . . . . 71.34 108.181 -178.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.44 -61.35 1.82 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.119 0.872 . . . . 73.23 109.34 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -174.72 -51.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.783 0 CA-C-O 118.673 -0.68 . . . . 64.31 109.75 -177.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.55 145.18 81.85 Favored Pre-proline 0 C--N 1.355 0.809 0 N-CA-C 104.986 -2.227 . . . . 73.53 104.986 172.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.58 72.75 2.37 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.811 2.397 . . . . 64.45 111.973 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.36 -55.13 4.33 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 106.579 -1.637 . . . . 74.1 106.579 171.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.63 160.99 12.91 Favored Glycine 0 C--N 1.357 1.711 0 N-CA-C 109.337 -1.505 . . . . 23.44 109.337 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.64 90.68 2.88 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 117.923 -1.037 . . . . 71.35 111.868 -177.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -127.77 140.08 52.27 Favored 'General case' 0 C--N 1.362 1.112 0 CA-C-O 116.759 -1.591 . . . . 74.25 108.478 172.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.9 pt -77.9 139.17 19.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 N-CA-C 106.662 -1.607 . . . . 54.04 106.662 167.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 . . . . . 0 C--N 1.357 0.898 0 CA-C-N 119.303 0.956 . . . . 73.12 109.166 -176.116 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 N-CA-C 117.217 1.647 . . . . 63.41 117.217 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.34 -174.03 4.27 Favored 'General case' 0 C--N 1.355 0.835 0 CA-C-N 120.327 2.064 . . . . 74.11 107.377 173.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -67.68 -25.74 65.84 Favored 'General case' 0 C--N 1.351 0.658 0 CA-C-O 117.164 -1.398 . . . . 72.43 113.426 -173.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.74 152.05 7.4 Favored 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-N 120.83 1.65 . . . . 64.52 110.826 -175.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.43 -103.89 0.24 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.962 -1.466 . . . . 72.52 111.522 177.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.21 158.19 28.23 Favored Pre-proline 0 C--N 1.356 0.865 0 CA-C-O 115.31 -2.281 . . . . 61.21 107.981 -174.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -55.27 134.42 63.72 Favored 'Trans proline' 0 C--N 1.359 1.113 0 CA-C-N 124.875 2.777 . . . . 72.4 112.947 -170.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -72.45 -59.97 2.46 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.172 -1.048 . . . . 70.44 108.172 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.16 -61.14 1.89 Allowed 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.031 0.832 . . . . 73.55 109.372 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.04 -51.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.724 -0.655 . . . . 44.04 109.711 -177.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.14 144.93 79.75 Favored Pre-proline 0 C--N 1.356 0.866 0 N-CA-C 104.942 -2.244 . . . . 53.51 104.942 172.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -71.59 72.96 2.35 Favored 'Trans proline' 0 C--N 1.358 1.032 0 CA-C-N 123.694 2.355 . . . . 62.41 112.09 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.2 mt -84.6 -55.52 4.08 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.592 -1.633 . . . . 73.14 106.592 171.42 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.97 159.05 13.99 Favored Glycine 0 C--N 1.357 1.712 0 N-CA-C 109.225 -1.55 . . . . 73.25 109.225 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -130.29 92.55 3.3 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 117.951 -1.023 . . . . 65.32 111.844 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -128.71 142.76 50.91 Favored 'General case' 0 C--N 1.361 1.072 0 CA-C-O 116.82 -1.562 . . . . 74.33 108.411 172.021 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -80.55 140.62 16.4 Favored 'Isoleucine or valine' 0 C--N 1.357 0.904 0 N-CA-C 106.399 -1.704 . . . . 72.43 106.399 166.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 . . . . . 0 C--N 1.355 0.846 0 CA-C-N 119.33 0.968 . . . . 72.41 109.189 -175.552 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 N-CA-C 116.97 1.548 . . . . 54.44 116.97 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.43 -174.7 4.53 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-N 120.246 2.023 . . . . 72.33 107.528 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -67.0 -26.11 66.64 Favored 'General case' 0 C--N 1.35 0.607 0 CA-C-O 117.12 -1.419 . . . . 63.23 113.393 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.8 152.15 7.28 Favored 'Isoleucine or valine' 0 C--N 1.354 0.796 0 CA-C-N 120.891 1.678 . . . . 74.11 110.888 -174.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.31 -104.27 0.25 Allowed Glycine 0 C--N 1.358 1.759 0 CA-C-O 117.93 -1.483 . . . . 63.43 111.436 178.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.06 158.42 28.82 Favored Pre-proline 0 C--N 1.355 0.836 0 CA-C-O 115.342 -2.266 . . . . 73.44 107.909 -174.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.23 134.47 64.0 Favored 'Trans proline' 0 C--N 1.36 1.143 0 CA-C-N 124.878 2.778 . . . . 62.34 112.957 -170.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -72.39 -59.53 2.68 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 108.154 -1.054 . . . . 65.44 108.154 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.94 -61.09 1.91 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 119.029 0.831 . . . . 63.24 109.344 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.49 -51.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.819 0 CA-C-O 118.738 -0.648 . . . . 72.01 109.6 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.31 144.93 79.12 Favored Pre-proline 0 C--N 1.356 0.853 0 N-CA-C 104.939 -2.245 . . . . 71.01 104.939 172.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.48 73.52 2.22 Favored 'Trans proline' 0 C--N 1.358 1.048 0 CA-C-N 123.84 2.407 . . . . 71.24 111.987 -179.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 68.8 mt -85.42 -55.63 3.92 Favored 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.516 -1.661 . . . . 61.44 106.516 171.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.04 157.96 14.65 Favored Glycine 0 C--N 1.357 1.704 0 N-CA-C 109.08 -1.608 . . . . 43.04 109.08 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.56 92.56 3.36 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 117.999 -1.001 . . . . 72.44 111.779 -178.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -127.13 143.97 51.14 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-O 116.837 -1.554 . . . . 74.42 108.247 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 47.8 pt -79.68 138.98 18.97 Favored 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 106.371 -1.714 . . . . 72.34 106.371 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.3 mt-30 . . . . . 0 C--N 1.355 0.836 0 CA-C-N 119.455 1.025 . . . . 74.24 109.223 -176.08 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 117.434 1.734 . . . . 50.34 117.434 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.66 -173.13 3.7 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-N 120.669 2.235 . . . . 54.41 107.185 172.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -69.9 -25.39 63.67 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-O 117.234 -1.365 . . . . 72.12 113.378 -172.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.07 150.97 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 CA-C-N 120.652 1.569 . . . . 73.43 110.558 -175.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.37 -104.57 0.26 Allowed Glycine 0 C--N 1.358 1.781 0 CA-C-O 117.902 -1.499 . . . . 63.44 111.802 178.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.14 29.16 Favored Pre-proline 0 C--N 1.356 0.871 0 CA-C-O 115.36 -2.257 . . . . 72.45 108.13 -173.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -55.89 135.95 72.19 Favored 'Trans proline' 0 C--N 1.359 1.088 0 CA-C-N 124.767 2.738 . . . . 54.31 112.94 -170.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -73.69 -60.31 2.31 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 108.158 -1.052 . . . . 72.2 108.158 -178.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.43 -61.19 1.86 Allowed 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.081 0.855 . . . . 71.53 109.274 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.65 -51.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.356 0.854 0 CA-C-O 118.672 -0.68 . . . . 64.14 109.75 -177.224 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.12 145.13 82.93 Favored Pre-proline 0 C--N 1.355 0.818 0 N-CA-C 104.997 -2.223 . . . . 73.31 104.997 172.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.64 72.91 2.39 Favored 'Trans proline' 0 C--N 1.358 1.04 0 CA-C-N 123.798 2.392 . . . . 43.22 111.894 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.0 mt -84.55 -55.0 4.36 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.587 -1.635 . . . . 73.52 106.587 171.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.86 161.4 12.76 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 109.43 -1.468 . . . . 74.52 109.43 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.87 88.46 2.56 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.879 -1.058 . . . . 74.23 111.84 -177.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -124.97 139.98 53.33 Favored 'General case' 0 C--N 1.36 1.057 0 CA-C-O 116.777 -1.582 . . . . 73.12 108.498 172.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -78.41 139.39 18.57 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 106.647 -1.612 . . . . 75.42 106.647 167.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 . . . . . 0 C--N 1.356 0.863 0 CA-C-N 119.275 0.943 . . . . 73.51 109.2 -176.262 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 N-CA-C 117.015 1.566 . . . . 60.54 117.015 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.45 -175.17 4.81 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 120.216 2.008 . . . . 73.3 107.847 173.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 51.3 m-85 -65.76 -27.2 68.12 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-O 117.101 -1.428 . . . . 70.05 113.463 -173.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.44 152.35 7.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 CA-C-N 120.879 1.672 . . . . 75.54 111.044 -174.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.67 -104.92 0.26 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.957 -1.468 . . . . 70.52 111.147 178.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.03 158.79 29.21 Favored Pre-proline 0 C--N 1.357 0.909 0 CA-C-O 115.525 -2.178 . . . . 73.35 107.791 -174.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -54.76 134.42 62.67 Favored 'Trans proline' 0 C--N 1.36 1.141 0 CA-C-N 124.834 2.762 . . . . 73.0 113.016 -170.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -72.41 -59.26 2.82 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.085 -1.08 . . . . 71.21 108.085 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.72 -60.97 1.95 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 118.968 0.804 . . . . 65.21 109.351 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.72 -51.48 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.805 0 CA-C-O 118.832 -0.604 . . . . 73.4 109.615 -177.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.95 144.97 76.86 Favored Pre-proline 0 C--N 1.355 0.811 0 N-CA-C 104.959 -2.237 . . . . 70.24 104.959 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -71.32 73.83 2.09 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.755 2.377 . . . . 71.35 112.007 -179.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.4 mt -86.14 -56.0 3.66 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 106.495 -1.669 . . . . 74.23 106.495 171.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.08 156.33 15.64 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.993 -1.643 . . . . 70.32 108.993 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -128.28 93.48 3.66 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.99 -1.005 . . . . 75.34 111.668 -178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -127.69 146.55 50.53 Favored 'General case' 0 C--N 1.36 1.052 0 CA-C-O 116.908 -1.52 . . . . 54.44 108.198 171.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -82.1 139.65 17.6 Favored 'Isoleucine or valine' 0 C--N 1.357 0.934 0 N-CA-C 106.091 -1.818 . . . . 73.14 106.091 166.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 . . . . . 0 C--N 1.356 0.853 0 CA-C-N 119.58 1.082 . . . . 72.35 109.392 -175.598 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.587 -1.119 . . . . 65.42 115.382 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.66 -177.13 6.37 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.366 1.583 . . . . 52.0 108.282 175.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -64.3 -29.32 70.41 Favored 'General case' 0 C--N 1.352 0.699 0 CA-C-O 117.105 -1.426 . . . . 73.31 113.685 -173.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.8 p -156.43 151.6 9.02 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.709 1.595 . . . . 61.22 111.401 -173.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.68 -107.27 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.666 -1.63 . . . . 41.13 111.497 177.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.78 159.96 31.71 Favored Pre-proline 0 C--N 1.356 0.86 0 CA-C-O 115.45 -2.214 . . . . 63.11 108.248 -176.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -55.35 130.5 40.95 Favored 'Trans proline' 0 C--N 1.362 1.265 0 CA-C-N 124.839 2.764 . . . . 71.34 112.61 -173.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 81.3 mt-10 -68.98 -57.14 5.87 Favored 'General case' 0 C--N 1.354 0.77 0 N-CA-C 108.004 -1.11 . . . . 72.4 108.004 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.15 -61.27 1.85 Allowed 'General case' 0 C--N 1.354 0.782 0 CA-C-O 118.343 -0.837 . . . . 73.2 109.632 179.447 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.72 -51.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.773 0 CA-C-O 118.64 -0.695 . . . . 63.31 109.786 -176.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.42 145.38 67.87 Favored Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.538 -2.172 . . . . 71.51 105.18 172.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -70.42 75.06 1.52 Allowed 'Trans proline' 0 C--N 1.358 1.047 0 CA-C-N 123.752 2.376 . . . . 71.41 112.211 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -88.91 -56.74 3.16 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 106.697 -1.594 . . . . 74.24 106.697 171.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.94 145.16 16.2 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.523 -1.831 . . . . 64.44 108.523 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.22 93.95 4.18 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 118.937 1.368 . . . . 72.35 111.139 -179.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -120.11 157.19 29.5 Favored 'General case' 0 C--N 1.36 1.047 0 CA-C-O 117.248 -1.358 . . . . 65.33 107.868 170.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -92.3 141.04 15.17 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 105.344 -2.095 . . . . 72.22 105.344 164.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -147.73 164.11 34.6 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.84 1.2 . . . . 75.41 109.747 -174.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.545 0 N-CA-C 109.458 -1.457 . . . . 73.31 109.458 179.359 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.721 0 CA-C-O 118.708 -1.051 . . . . 73.3 115.306 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.14 -177.33 6.53 Favored 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.273 1.537 . . . . 70.22 108.388 175.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -63.92 -29.64 70.8 Favored 'General case' 0 C--N 1.351 0.665 0 CA-C-O 117.07 -1.443 . . . . 65.02 113.615 -173.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.9 p -156.37 151.71 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 120.811 1.642 . . . . 74.23 111.374 -173.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.66 -107.12 0.32 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.682 -1.621 . . . . 51.12 111.455 177.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.89 159.86 31.77 Favored Pre-proline 0 C--N 1.356 0.859 0 CA-C-O 115.418 -2.23 . . . . 73.52 108.296 -176.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -54.95 129.81 37.31 Favored 'Trans proline' 0 C--N 1.361 1.233 0 CA-C-N 124.818 2.756 . . . . 74.34 112.584 -173.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.5 mt-10 -68.37 -57.03 6.53 Favored 'General case' 0 C--N 1.355 0.839 0 N-CA-C 108.047 -1.094 . . . . 60.34 108.047 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.11 -61.32 1.84 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-O 118.396 -0.811 . . . . 74.2 109.66 179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.73 -50.87 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-O 118.653 -0.689 . . . . 53.33 109.858 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.68 145.45 66.96 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.566 -2.159 . . . . 73.23 105.194 172.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -70.3 75.14 1.47 Allowed 'Trans proline' 0 C--N 1.358 1.044 0 CA-C-N 123.777 2.384 . . . . 71.02 112.252 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.9 mt -89.42 -56.85 3.09 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 106.769 -1.567 . . . . 73.14 106.769 171.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.62 144.63 16.06 Favored Glycine 0 C--N 1.357 1.721 0 N-CA-C 108.45 -1.86 . . . . 52.23 108.45 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -120.8 94.16 4.26 Favored 'General case' 0 C--N 1.355 0.843 0 CA-C-N 118.963 1.381 . . . . 73.41 111.185 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -120.7 156.53 31.56 Favored 'General case' 0 C--N 1.359 1.012 0 CA-C-O 117.186 -1.388 . . . . 75.21 107.843 170.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.6 pt -91.24 141.07 14.98 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.283 -2.117 . . . . 74.31 105.283 164.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -147.43 164.59 32.87 Favored 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.808 1.185 . . . . 74.33 109.626 -174.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.563 0 N-CA-C 109.169 -1.572 . . . . 74.33 109.169 179.826 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.667 0 N-CA-C 117.347 1.699 . . . . 62.14 117.347 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.23 -169.52 2.97 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-N 120.619 2.21 . . . . 72.05 107.081 173.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -72.83 -25.95 61.31 Favored 'General case' 0 C--N 1.351 0.659 0 CA-C-N 120.389 1.45 . . . . 73.13 113.38 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -156.35 149.62 10.83 Favored 'Isoleucine or valine' 0 C--N 1.355 0.816 0 CA-C-N 120.555 1.525 . . . . 70.23 110.569 -175.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.98 -108.37 0.36 Allowed Glycine 0 C--N 1.357 1.74 0 CA-C-O 117.592 -1.671 . . . . 65.43 111.969 179.122 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.9 161.12 29.94 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.359 -2.258 . . . . 70.44 108.512 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -57.68 131.83 46.51 Favored 'Trans proline' 0 C--N 1.361 1.195 0 CA-C-N 124.969 2.81 . . . . 75.1 112.119 -172.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -70.26 -58.19 4.04 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.063 -1.088 . . . . 64.11 108.063 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -85.22 -61.78 1.69 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.038 0.835 . . . . 73.44 109.56 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.65 -51.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.767 0 CA-C-O 118.736 -0.65 . . . . 63.53 109.838 -176.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.85 145.51 81.51 Favored Pre-proline 0 C--N 1.355 0.839 0 N-CA-C 105.056 -2.201 . . . . 25.32 105.056 172.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.26 72.87 2.16 Favored 'Trans proline' 0 C--N 1.357 1.007 0 CA-C-N 123.743 2.373 . . . . 74.43 112.223 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.9 mt -86.24 -55.79 3.75 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.826 -1.546 . . . . 60.42 106.826 171.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.48 155.94 15.94 Favored Glycine 0 C--N 1.357 1.73 0 N-CA-C 109.503 -1.439 . . . . 52.34 109.503 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -129.75 86.56 2.43 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.077 -0.963 . . . . 70.32 111.642 -177.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -120.03 145.21 47.04 Favored 'General case' 0 C--N 1.36 1.038 0 CA-C-O 116.67 -1.633 . . . . 62.34 108.243 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.4 pt -84.22 141.35 14.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.924 0 N-CA-C 106.127 -1.805 . . . . 72.52 106.127 166.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -149.69 164.39 35.34 Favored 'General case' 0 C--N 1.355 0.841 0 CA-C-N 119.442 1.019 . . . . 74.12 109.428 -175.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.536 0 N-CA-C 109.512 -1.435 . . . . 62.54 109.512 178.973 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.71 0 N-CA-C 116.363 1.305 . . . . 13.41 116.363 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -150.3 -173.47 4.46 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.912 1.856 . . . . 65.23 107.76 174.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -67.86 -27.42 66.67 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.155 -1.402 . . . . 64.32 113.585 -172.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -156.62 151.03 9.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 120.703 1.592 . . . . 55.32 110.998 -174.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.71 -107.64 0.33 Allowed Glycine 0 C--N 1.358 1.787 0 CA-C-O 117.618 -1.657 . . . . 54.43 111.594 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.09 160.7 30.61 Favored Pre-proline 0 C--N 1.357 0.924 0 CA-C-O 115.314 -2.279 . . . . 70.32 108.428 -175.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -55.96 130.06 38.25 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 125.031 2.832 . . . . 71.52 112.287 -173.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -68.99 -57.27 5.69 Favored 'General case' 0 C--N 1.354 0.796 0 N-CA-C 108.024 -1.102 . . . . 62.31 108.024 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.69 -61.58 1.75 Allowed 'General case' 0 C--N 1.354 0.775 0 CA-C-O 118.403 -0.808 . . . . 64.12 109.563 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.29 -51.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 118.614 -0.707 . . . . 71.12 109.798 -176.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -77.09 145.42 73.38 Favored Pre-proline 0 C--N 1.354 0.789 0 N-CA-C 105.059 -2.2 . . . . 62.42 105.059 172.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -70.67 74.45 1.69 Allowed 'Trans proline' 0 C--N 1.358 1.053 0 CA-C-N 123.804 2.394 . . . . 73.4 112.168 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 65.5 mt -88.22 -56.52 3.29 Favored 'General case' 0 C--N 1.355 0.823 0 N-CA-C 106.722 -1.584 . . . . 63.11 106.722 171.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.75 150.27 16.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 108.909 -1.677 . . . . 55.31 108.909 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -125.44 91.34 3.39 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 118.452 1.126 . . . . 73.24 111.422 -178.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 -120.77 151.82 39.09 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.907 -1.52 . . . . 61.2 107.937 171.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.4 pt -88.01 142.14 13.35 Favored 'Isoleucine or valine' 0 C--N 1.357 0.907 0 N-CA-C 105.525 -2.028 . . . . 73.45 105.525 165.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 -148.52 163.88 35.87 Favored 'General case' 0 C--N 1.355 0.836 0 CA-C-N 119.718 1.145 . . . . 70.13 109.589 -175.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.563 0 N-CA-C 109.538 -1.425 . . . . 70.04 109.538 179.252 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.666 0 N-CA-C 115.658 1.023 . . . . 52.32 115.658 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.46 -176.9 6.22 Favored 'General case' 0 C--N 1.353 0.747 0 CA-C-N 119.046 1.423 . . . . 63.21 108.438 175.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -64.56 -29.63 70.66 Favored 'General case' 0 C--N 1.351 0.67 0 CA-C-O 117.178 -1.391 . . . . 73.11 113.779 -173.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.14 151.56 9.34 Favored 'Isoleucine or valine' 0 C--N 1.355 0.835 0 CA-C-N 120.703 1.592 . . . . 73.01 111.31 -173.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.65 -106.91 0.31 Allowed Glycine 0 C--N 1.358 1.762 0 CA-C-O 117.556 -1.691 . . . . 72.01 111.585 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.7 159.88 31.87 Favored Pre-proline 0 C--N 1.357 0.919 0 CA-C-O 115.247 -2.311 . . . . 75.54 108.333 -176.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -55.32 130.12 38.89 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.865 2.773 . . . . 74.12 112.42 -173.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 80.6 mt-10 -68.59 -57.17 6.14 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.035 -1.098 . . . . 53.04 108.035 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.24 1.86 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-O 118.389 -0.815 . . . . 72.01 109.563 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.7 p -175.77 -50.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.538 -0.744 . . . . 51.13 109.755 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.37 145.41 68.14 Favored Pre-proline 0 C--N 1.354 0.803 0 N-CA-C 105.193 -2.151 . . . . 74.11 105.193 172.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.44 75.34 1.51 Allowed 'Trans proline' 0 C--N 1.359 1.13 0 CA-C-N 123.762 2.379 . . . . 61.2 112.161 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 63.3 mt -89.42 -56.87 3.09 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.785 -1.561 . . . . 64.41 106.785 171.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.7 145.12 16.13 Favored Glycine 0 C--N 1.357 1.698 0 N-CA-C 108.517 -1.833 . . . . 71.14 108.517 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -121.15 93.18 3.94 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.958 1.379 . . . . 74.33 111.104 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -119.13 156.3 30.03 Favored 'General case' 0 C--N 1.359 0.996 0 CA-C-O 117.174 -1.394 . . . . 70.34 107.955 170.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.7 pt -90.58 140.61 15.67 Favored 'Isoleucine or valine' 0 C--N 1.357 0.896 0 N-CA-C 105.245 -2.131 . . . . 71.02 105.245 165.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -147.62 164.45 33.45 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 119.876 1.216 . . . . 74.43 109.642 -174.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.579 0 N-CA-C 109.172 -1.571 . . . . 74.31 109.172 179.68 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 N-CA-C 117.019 1.568 . . . . 54.32 117.019 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.79 -171.47 3.7 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-N 120.341 2.07 . . . . 73.11 107.301 173.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -70.57 -26.42 63.52 Favored 'General case' 0 C--N 1.351 0.663 0 CA-C-O 117.21 -1.376 . . . . 71.31 113.502 -172.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -156.52 150.09 10.28 Favored 'Isoleucine or valine' 0 C--N 1.355 0.823 0 CA-C-N 120.641 1.564 . . . . 73.03 110.795 -174.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.99 -108.11 0.35 Allowed Glycine 0 C--N 1.358 1.796 0 CA-C-O 117.541 -1.699 . . . . 71.25 111.784 178.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.86 161.03 30.22 Favored Pre-proline 0 C--N 1.357 0.892 0 CA-C-O 115.298 -2.287 . . . . 73.12 108.421 -174.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.95 131.22 44.16 Favored 'Trans proline' 0 C--N 1.361 1.202 0 CA-C-N 125.119 2.864 . . . . 75.01 112.078 -172.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -69.92 -57.73 4.69 Favored 'General case' 0 C--N 1.354 0.788 0 N-CA-C 108.027 -1.101 . . . . 71.32 108.027 -179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.97 -61.65 1.72 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.347 -0.835 . . . . 73.03 109.58 178.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.6 p -174.98 -51.58 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.808 0 CA-C-O 118.706 -0.664 . . . . 62.1 109.769 -176.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.74 145.39 78.27 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 105.076 -2.194 . . . . 73.03 105.076 172.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -71.02 73.8 1.92 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.724 2.366 . . . . 73.21 112.137 -179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.1 mt -87.29 -56.27 3.44 Favored 'General case' 0 C--N 1.355 0.841 0 N-CA-C 106.842 -1.54 . . . . 70.11 106.842 171.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -108.01 153.14 16.89 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 109.176 -1.569 . . . . 62.22 109.176 -178.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -127.69 88.34 2.76 Favored 'General case' 0 C--N 1.355 0.832 0 CA-C-N 118.218 1.009 . . . . 72.41 111.509 -178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -118.97 148.76 42.62 Favored 'General case' 0 C--N 1.359 1.016 0 CA-C-O 116.841 -1.552 . . . . 75.22 107.982 171.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 48.4 pt -85.61 141.83 14.0 Favored 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 105.796 -1.927 . . . . 73.05 105.796 165.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -149.26 163.77 36.71 Favored 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.679 1.127 . . . . 65.31 109.547 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.593 0 N-CA-C 109.443 -1.463 . . . . 74.35 109.443 178.532 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.672 0 CA-C-O 118.757 -1.024 . . . . 53.31 114.846 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -159.59 -178.67 7.27 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 119.107 1.453 . . . . 61.32 108.534 176.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -63.05 -30.56 71.69 Favored 'General case' 0 C--N 1.351 0.671 0 CA-C-O 117.086 -1.435 . . . . 73.31 113.693 -173.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -156.19 151.8 9.03 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 120.741 1.61 . . . . 72.44 111.42 -172.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 151.99 -106.43 0.3 Allowed Glycine 0 C--N 1.358 1.77 0 CA-C-O 117.707 -1.607 . . . . 53.12 111.49 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -152.72 159.37 32.54 Favored Pre-proline 0 C--N 1.356 0.878 0 CA-C-O 115.395 -2.24 . . . . 72.34 108.347 -176.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -54.95 130.11 38.94 Favored 'Trans proline' 0 C--N 1.362 1.266 0 CA-C-N 124.761 2.736 . . . . 73.33 112.578 -173.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -68.44 -57.2 6.22 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.063 -1.088 . . . . 72.44 108.063 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.83 -61.14 1.9 Allowed 'General case' 0 C--N 1.354 0.788 0 CA-C-O 118.364 -0.827 . . . . 64.55 109.615 179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -175.77 -50.79 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.572 -0.727 . . . . 72.32 109.86 -176.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -79.04 145.53 65.65 Favored Pre-proline 0 C--N 1.355 0.823 0 CA-C-O 115.56 -2.162 . . . . 74.22 105.249 172.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -70.23 75.42 1.41 Allowed 'Trans proline' 0 C--N 1.358 1.074 0 CA-C-N 123.768 2.381 . . . . 65.43 112.255 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 62.8 mt -89.83 -56.86 3.07 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 106.725 -1.583 . . . . 73.51 106.725 171.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.64 142.77 15.89 Favored Glycine 0 C--N 1.357 1.719 0 N-CA-C 108.318 -1.913 . . . . 71.14 108.318 178.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -119.32 94.49 4.44 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-N 119.108 1.454 . . . . 74.15 110.959 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -119.37 155.83 31.21 Favored 'General case' 0 C--N 1.36 1.035 0 CA-C-O 117.165 -1.397 . . . . 64.54 107.903 170.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.5 pt -88.97 140.42 15.82 Favored 'Isoleucine or valine' 0 C--N 1.357 0.922 0 N-CA-C 105.157 -2.164 . . . . 73.05 105.157 164.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -147.46 164.42 33.42 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 119.972 1.26 . . . . 74.42 109.794 -174.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.559 0 N-CA-C 109.551 -1.42 . . . . 70.11 109.551 179.417 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.699 0 N-CA-C 117.434 1.734 . . . . 73.44 117.434 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -140.25 -162.39 1.34 Allowed 'General case' 0 C--N 1.356 0.871 0 CA-C-N 120.668 2.234 . . . . 63.23 106.716 172.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -79.39 -27.84 41.84 Favored 'General case' 0 C--N 1.352 0.716 0 CA-C-N 121.023 1.738 . . . . 73.13 113.263 -172.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.5 p -154.16 148.69 13.17 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.286 1.403 . . . . 72.41 110.265 -175.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.26 -106.47 0.3 Allowed Glycine 0 C--N 1.357 1.745 0 CA-C-O 117.603 -1.665 . . . . 61.42 112.278 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.93 160.99 30.32 Favored Pre-proline 0 C--N 1.357 0.917 0 CA-C-O 115.447 -2.216 . . . . 73.12 108.915 -172.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -58.48 128.79 29.7 Favored 'Trans proline' 0 C--N 1.361 1.198 0 CA-C-N 124.797 2.749 . . . . 73.31 112.048 -173.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -67.34 -57.68 6.18 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 108.228 -1.027 . . . . 73.44 108.228 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -86.16 -62.43 1.52 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.057 0.844 . . . . 52.14 109.646 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.5 p -174.09 -51.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.784 -0.627 . . . . 63.15 109.855 -176.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.23 146.17 84.03 Favored Pre-proline 0 C--N 1.355 0.837 0 N-CA-C 104.946 -2.242 . . . . 60.25 104.946 172.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -71.24 72.01 2.25 Favored 'Trans proline' 0 C--N 1.359 1.104 0 CA-C-N 123.855 2.412 . . . . 73.02 112.188 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.6 mt -86.36 -55.29 3.97 Favored 'General case' 0 C--N 1.354 0.78 0 N-CA-C 106.898 -1.519 . . . . 51.53 106.898 171.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -107.3 157.57 15.45 Favored Glycine 0 C--N 1.356 1.67 0 N-CA-C 110.022 -1.231 . . . . 74.22 110.022 -176.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.58 84.24 2.16 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-O 118.13 -0.938 . . . . 72.23 111.758 -177.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -122.81 134.64 54.41 Favored 'General case' 0 C--N 1.36 1.042 0 CA-C-O 116.665 -1.636 . . . . 60.41 108.817 173.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 pt -74.83 140.35 17.64 Favored 'Isoleucine or valine' 0 C--N 1.357 0.926 0 N-CA-C 106.813 -1.551 . . . . 63.32 106.813 167.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.4 mt-30 -150.06 163.44 38.15 Favored 'General case' 0 C--N 1.355 0.846 0 CA-C-N 119.405 1.002 . . . . 73.21 109.398 -176.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.575 0 N-CA-C 109.305 -1.518 . . . . 41.13 109.305 177.93 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.679 0 N-CA-C 117.288 1.675 . . . . 75.32 117.288 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.02 -174.04 4.16 Favored 'General case' 0 C--N 1.356 0.872 0 CA-C-N 120.384 2.092 . . . . 73.05 107.284 173.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -68.45 -25.76 65.17 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-O 117.147 -1.406 . . . . 74.15 113.343 -172.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.49 151.42 8.14 Favored 'Isoleucine or valine' 0 C--N 1.354 0.787 0 CA-C-N 120.85 1.659 . . . . 60.11 110.75 -175.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.47 -104.72 0.26 Allowed Glycine 0 C--N 1.358 1.758 0 CA-C-O 117.848 -1.529 . . . . 73.32 111.459 178.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.67 158.55 29.44 Favored Pre-proline 0 C--N 1.355 0.847 0 CA-C-O 115.364 -2.255 . . . . 73.32 107.903 -174.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -55.58 135.7 70.58 Favored 'Trans proline' 0 C--N 1.36 1.156 0 CA-C-N 124.842 2.765 . . . . 65.33 112.901 -170.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -73.39 -59.79 2.54 Favored 'General case' 0 C--N 1.355 0.818 0 N-CA-C 108.116 -1.068 . . . . 64.31 108.116 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.23 -61.17 1.87 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-N 119.012 0.824 . . . . 65.54 109.322 178.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.07 -51.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-O 118.727 -0.654 . . . . 73.02 109.697 -177.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.7 145.02 81.23 Favored Pre-proline 0 C--N 1.355 0.832 0 N-CA-C 105.031 -2.211 . . . . 75.25 105.031 172.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -71.51 73.04 2.29 Favored 'Trans proline' 0 C--N 1.357 1.024 0 CA-C-N 123.706 2.359 . . . . 52.11 112.045 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.8 mt -84.82 -55.38 4.12 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 106.585 -1.635 . . . . 74.14 106.585 171.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.47 159.39 13.78 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 109.273 -1.531 . . . . 61.12 109.273 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -130.59 90.15 2.88 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 117.998 -1.001 . . . . 70.11 111.773 -177.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -124.86 143.14 50.99 Favored 'General case' 0 C--N 1.36 1.065 0 CA-C-O 116.868 -1.539 . . . . 72.23 108.259 172.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 46.6 pt -79.09 139.01 19.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.898 0 N-CA-C 106.355 -1.72 . . . . 73.53 106.355 167.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -149.5 163.6 37.36 Favored 'General case' 0 C--N 1.355 0.839 0 CA-C-N 119.507 1.049 . . . . 74.41 109.297 -176.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.577 0 N-CA-C 109.326 -1.51 . . . . 53.42 109.326 178.545 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.684 0 N-CA-C 117.447 1.739 . . . . 73.13 117.447 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.53 -173.18 3.7 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-N 120.539 2.17 . . . . 62.1 107.127 172.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -69.95 -25.18 63.52 Favored 'General case' 0 C--N 1.351 0.666 0 CA-C-O 117.286 -1.34 . . . . 73.33 113.329 -172.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.34 151.02 8.62 Favored 'Isoleucine or valine' 0 C--N 1.355 0.809 0 CA-C-N 120.733 1.606 . . . . 72.14 110.632 -175.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.39 -104.66 0.26 Allowed Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.865 -1.519 . . . . 63.23 111.703 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.16 29.18 Favored Pre-proline 0 C--N 1.356 0.869 0 CA-C-O 115.433 -2.222 . . . . 75.52 107.975 -173.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -55.88 136.18 73.34 Favored 'Trans proline' 0 C--N 1.361 1.187 0 CA-C-N 124.659 2.7 . . . . 74.4 113.0 -170.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -73.74 -60.12 2.4 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.177 -1.046 . . . . 73.42 108.177 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.58 -61.28 1.83 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-N 119.096 0.862 . . . . 62.01 109.271 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.7 -51.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.822 0 CA-C-O 118.735 -0.65 . . . . 72.11 109.693 -177.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.0 145.16 83.3 Favored Pre-proline 0 C--N 1.355 0.845 0 N-CA-C 104.954 -2.239 . . . . 74.22 104.954 172.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.66 72.73 2.43 Favored 'Trans proline' 0 C--N 1.357 1.025 0 CA-C-N 123.833 2.405 . . . . 63.11 111.911 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.7 mt -84.45 -55.04 4.36 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 106.618 -1.623 . . . . 74.02 106.618 171.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.88 161.64 12.68 Favored Glycine 0 C--N 1.358 1.754 0 N-CA-C 109.467 -1.453 . . . . 40.02 109.467 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -132.25 88.6 2.56 Favored 'General case' 0 C--N 1.354 0.8 0 CA-C-O 117.937 -1.03 . . . . 72.42 111.733 -177.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -124.84 140.16 53.18 Favored 'General case' 0 C--N 1.361 1.069 0 CA-C-O 116.827 -1.559 . . . . 65.14 108.423 172.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 38.9 pt -77.5 138.66 20.01 Favored 'Isoleucine or valine' 0 C--N 1.358 0.938 0 N-CA-C 106.661 -1.607 . . . . 62.13 106.661 167.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -149.65 163.67 37.27 Favored 'General case' 0 C--N 1.356 0.85 0 CA-C-N 119.342 0.974 . . . . 75.24 109.227 -176.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 N-CA-C 109.329 -1.508 . . . . 64.11 109.329 178.423 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.669 0 N-CA-C 117.367 1.707 . . . . 60.32 117.367 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -143.44 -172.79 3.78 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 120.475 2.137 . . . . 64.54 107.222 172.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.21 -25.64 64.42 Favored 'General case' 0 C--N 1.351 0.65 0 CA-C-O 117.208 -1.377 . . . . 73.02 113.339 -173.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.47 151.5 8.09 Favored 'Isoleucine or valine' 0 C--N 1.354 0.782 0 CA-C-N 120.753 1.615 . . . . 74.01 110.695 -175.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.51 -103.8 0.24 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.948 -1.473 . . . . 54.54 111.681 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.04 158.1 28.59 Favored Pre-proline 0 C--N 1.356 0.867 0 CA-C-O 115.413 -2.232 . . . . 73.51 108.097 -173.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.68 134.31 63.27 Favored 'Trans proline' 0 C--N 1.361 1.192 0 CA-C-N 124.759 2.735 . . . . 62.41 112.918 -170.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -72.22 -60.05 2.43 Favored 'General case' 0 C--N 1.355 0.806 0 N-CA-C 108.181 -1.044 . . . . 71.34 108.181 -178.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.44 -61.35 1.82 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.119 0.872 . . . . 73.23 109.34 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -174.72 -51.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.783 0 CA-C-O 118.673 -0.68 . . . . 64.31 109.75 -177.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.55 145.18 81.85 Favored Pre-proline 0 C--N 1.355 0.809 0 N-CA-C 104.986 -2.227 . . . . 73.53 104.986 172.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.58 72.75 2.37 Favored 'Trans proline' 0 C--N 1.357 0.996 0 CA-C-N 123.811 2.397 . . . . 64.45 111.973 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 70.4 mt -84.36 -55.13 4.33 Favored 'General case' 0 C--N 1.355 0.819 0 N-CA-C 106.579 -1.637 . . . . 74.1 106.579 171.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.63 160.99 12.91 Favored Glycine 0 C--N 1.357 1.711 0 N-CA-C 109.337 -1.505 . . . . 23.44 109.337 -178.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.64 90.68 2.88 Favored 'General case' 0 C--N 1.355 0.829 0 CA-C-O 117.923 -1.037 . . . . 71.35 111.868 -177.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -127.77 140.08 52.27 Favored 'General case' 0 C--N 1.362 1.112 0 CA-C-O 116.759 -1.591 . . . . 74.25 108.478 172.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.9 pt -77.9 139.17 19.02 Favored 'Isoleucine or valine' 0 C--N 1.357 0.929 0 N-CA-C 106.662 -1.607 . . . . 54.04 106.662 167.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -149.62 163.65 37.3 Favored 'General case' 0 C--N 1.357 0.898 0 CA-C-N 119.303 0.956 . . . . 73.12 109.166 -176.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.528 0 N-CA-C 109.298 -1.521 . . . . 72.32 109.298 178.4 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 N-CA-C 117.217 1.647 . . . . 63.41 117.217 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.34 -174.03 4.27 Favored 'General case' 0 C--N 1.355 0.835 0 CA-C-N 120.327 2.064 . . . . 74.11 107.377 173.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -67.68 -25.74 65.84 Favored 'General case' 0 C--N 1.351 0.658 0 CA-C-O 117.164 -1.398 . . . . 72.43 113.426 -173.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.2 p -157.74 152.05 7.4 Favored 'Isoleucine or valine' 0 C--N 1.354 0.795 0 CA-C-N 120.83 1.65 . . . . 64.52 110.826 -175.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.43 -103.89 0.24 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.962 -1.466 . . . . 72.52 111.522 177.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.21 158.19 28.23 Favored Pre-proline 0 C--N 1.356 0.865 0 CA-C-O 115.31 -2.281 . . . . 61.21 107.981 -174.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -55.27 134.42 63.72 Favored 'Trans proline' 0 C--N 1.359 1.113 0 CA-C-N 124.875 2.777 . . . . 72.4 112.947 -170.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -72.45 -59.97 2.46 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.172 -1.048 . . . . 70.44 108.172 -178.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.16 -61.14 1.89 Allowed 'General case' 0 C--N 1.354 0.794 0 CA-C-N 119.031 0.832 . . . . 73.55 109.372 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -175.04 -51.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.354 0.786 0 CA-C-O 118.724 -0.655 . . . . 44.04 109.711 -177.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.14 144.93 79.75 Favored Pre-proline 0 C--N 1.356 0.866 0 N-CA-C 104.942 -2.244 . . . . 53.51 104.942 172.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -71.59 72.96 2.35 Favored 'Trans proline' 0 C--N 1.358 1.032 0 CA-C-N 123.694 2.355 . . . . 62.41 112.09 -179.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 69.2 mt -84.6 -55.52 4.08 Favored 'General case' 0 C--N 1.355 0.827 0 N-CA-C 106.592 -1.633 . . . . 73.14 106.592 171.42 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.97 159.05 13.99 Favored Glycine 0 C--N 1.357 1.712 0 N-CA-C 109.225 -1.55 . . . . 73.25 109.225 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -130.29 92.55 3.3 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 117.951 -1.023 . . . . 65.32 111.844 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -128.71 142.76 50.91 Favored 'General case' 0 C--N 1.361 1.072 0 CA-C-O 116.82 -1.562 . . . . 74.33 108.411 172.021 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 44.0 pt -80.55 140.62 16.4 Favored 'Isoleucine or valine' 0 C--N 1.357 0.904 0 N-CA-C 106.399 -1.704 . . . . 72.43 106.399 166.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.6 mt-30 -149.22 164.01 36.01 Favored 'General case' 0 C--N 1.355 0.846 0 CA-C-N 119.33 0.968 . . . . 72.41 109.189 -175.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.505 0 N-CA-C 109.08 -1.608 . . . . 62.4 109.08 179.387 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 N-CA-C 116.97 1.548 . . . . 54.44 116.97 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -146.43 -174.7 4.53 Favored 'General case' 0 C--N 1.355 0.815 0 CA-C-N 120.246 2.023 . . . . 72.33 107.528 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -67.0 -26.11 66.64 Favored 'General case' 0 C--N 1.35 0.607 0 CA-C-O 117.12 -1.419 . . . . 63.23 113.393 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.8 152.15 7.28 Favored 'Isoleucine or valine' 0 C--N 1.354 0.796 0 CA-C-N 120.891 1.678 . . . . 74.11 110.888 -174.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.31 -104.27 0.25 Allowed Glycine 0 C--N 1.358 1.759 0 CA-C-O 117.93 -1.483 . . . . 63.43 111.436 178.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.06 158.42 28.82 Favored Pre-proline 0 C--N 1.355 0.836 0 CA-C-O 115.342 -2.266 . . . . 73.44 107.909 -174.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -55.23 134.47 64.0 Favored 'Trans proline' 0 C--N 1.36 1.143 0 CA-C-N 124.878 2.778 . . . . 62.34 112.957 -170.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -72.39 -59.53 2.68 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 108.154 -1.054 . . . . 65.44 108.154 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.94 -61.09 1.91 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 119.029 0.831 . . . . 63.24 109.344 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.49 -51.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.819 0 CA-C-O 118.738 -0.648 . . . . 72.01 109.6 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.31 144.93 79.12 Favored Pre-proline 0 C--N 1.356 0.853 0 N-CA-C 104.939 -2.245 . . . . 71.01 104.939 172.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -71.48 73.52 2.22 Favored 'Trans proline' 0 C--N 1.358 1.048 0 CA-C-N 123.84 2.407 . . . . 71.24 111.987 -179.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 68.8 mt -85.42 -55.63 3.92 Favored 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.516 -1.661 . . . . 61.44 106.516 171.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.04 157.96 14.65 Favored Glycine 0 C--N 1.357 1.704 0 N-CA-C 109.08 -1.608 . . . . 43.04 109.08 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -129.56 92.56 3.36 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 117.999 -1.001 . . . . 72.44 111.779 -178.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -127.13 143.97 51.14 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-O 116.837 -1.554 . . . . 74.42 108.247 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 47.8 pt -79.68 138.98 18.97 Favored 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 106.371 -1.714 . . . . 72.34 106.371 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 39.3 mt-30 -149.29 164.24 35.42 Favored 'General case' 0 C--N 1.355 0.836 0 CA-C-N 119.455 1.025 . . . . 74.24 109.223 -176.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.522 0 N-CA-C 109.146 -1.582 . . . . 72.1 109.146 179.531 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.675 0 N-CA-C 117.434 1.734 . . . . 50.34 117.434 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -141.66 -173.13 3.7 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-N 120.669 2.235 . . . . 54.41 107.185 172.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -69.9 -25.39 63.67 Favored 'General case' 0 C--N 1.352 0.684 0 CA-C-O 117.234 -1.365 . . . . 72.12 113.378 -172.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.07 150.97 8.96 Favored 'Isoleucine or valine' 0 C--N 1.355 0.806 0 CA-C-N 120.652 1.569 . . . . 73.43 110.558 -175.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.37 -104.57 0.26 Allowed Glycine 0 C--N 1.358 1.781 0 CA-C-O 117.902 -1.499 . . . . 63.44 111.802 178.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -158.63 158.14 29.16 Favored Pre-proline 0 C--N 1.356 0.871 0 CA-C-O 115.36 -2.257 . . . . 72.45 108.13 -173.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -55.89 135.95 72.19 Favored 'Trans proline' 0 C--N 1.359 1.088 0 CA-C-N 124.767 2.738 . . . . 54.31 112.94 -170.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -73.69 -60.31 2.31 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 108.158 -1.052 . . . . 72.2 108.158 -178.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -84.43 -61.19 1.86 Allowed 'General case' 0 C--N 1.355 0.811 0 CA-C-N 119.081 0.855 . . . . 71.53 109.274 178.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.3 p -174.65 -51.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.356 0.854 0 CA-C-O 118.672 -0.68 . . . . 64.14 109.75 -177.224 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -74.12 145.13 82.93 Favored Pre-proline 0 C--N 1.355 0.818 0 N-CA-C 104.997 -2.223 . . . . 73.31 104.997 172.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -71.64 72.91 2.39 Favored 'Trans proline' 0 C--N 1.358 1.04 0 CA-C-N 123.798 2.392 . . . . 43.22 111.894 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.0 mt -84.55 -55.0 4.36 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 106.587 -1.635 . . . . 73.52 106.587 171.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -111.86 161.4 12.76 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 109.43 -1.468 . . . . 74.52 109.43 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -131.87 88.46 2.56 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-O 117.879 -1.058 . . . . 74.23 111.84 -177.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -124.97 139.98 53.33 Favored 'General case' 0 C--N 1.36 1.057 0 CA-C-O 116.777 -1.582 . . . . 73.12 108.498 172.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 34.8 pt -78.41 139.39 18.57 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 106.647 -1.612 . . . . 75.42 106.647 167.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 41.5 mt-30 -149.68 163.21 38.56 Favored 'General case' 0 C--N 1.356 0.863 0 CA-C-N 119.275 0.943 . . . . 73.51 109.2 -176.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.548 0 N-CA-C 109.26 -1.536 . . . . 52.31 109.26 178.425 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.748 0 N-CA-C 117.015 1.566 . . . . 60.54 117.015 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.45 -175.17 4.81 Favored 'General case' 0 C--N 1.355 0.822 0 CA-C-N 120.216 2.008 . . . . 73.3 107.847 173.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 51.3 m-85 -65.76 -27.2 68.12 Favored 'General case' 0 C--N 1.351 0.668 0 CA-C-O 117.101 -1.428 . . . . 70.05 113.463 -173.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.4 p -157.44 152.35 7.42 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 CA-C-N 120.879 1.672 . . . . 75.54 111.044 -174.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.67 -104.92 0.26 Allowed Glycine 0 C--N 1.357 1.732 0 CA-C-O 117.957 -1.468 . . . . 70.52 111.147 178.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -159.03 158.79 29.21 Favored Pre-proline 0 C--N 1.357 0.909 0 CA-C-O 115.525 -2.178 . . . . 73.35 107.791 -174.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -54.76 134.42 62.67 Favored 'Trans proline' 0 C--N 1.36 1.141 0 CA-C-N 124.834 2.762 . . . . 73.0 113.016 -170.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -72.41 -59.26 2.82 Favored 'General case' 0 C--N 1.355 0.829 0 N-CA-C 108.085 -1.08 . . . . 71.21 108.085 -179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ALA . . . . . . . . . . . . . . . -83.72 -60.97 1.95 Allowed 'General case' 0 C--N 1.354 0.78 0 CA-C-N 118.968 0.804 . . . . 65.21 109.351 178.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.4 p -175.72 -51.48 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.355 0.805 0 CA-C-O 118.832 -0.604 . . . . 73.4 109.615 -177.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -75.95 144.97 76.86 Favored Pre-proline 0 C--N 1.355 0.811 0 N-CA-C 104.959 -2.237 . . . . 70.24 104.959 172.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -71.32 73.83 2.09 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.755 2.377 . . . . 71.35 112.007 -179.418 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 67.4 mt -86.14 -56.0 3.66 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 106.495 -1.669 . . . . 74.23 106.495 171.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -110.08 156.33 15.64 Favored Glycine 0 C--N 1.357 1.714 0 N-CA-C 108.993 -1.643 . . . . 70.32 108.993 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 1.4 mpp_? -128.28 93.48 3.66 Favored 'General case' 0 C--N 1.355 0.823 0 CA-C-O 117.99 -1.005 . . . . 75.34 111.668 -178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -127.69 146.55 50.53 Favored 'General case' 0 C--N 1.36 1.052 0 CA-C-O 116.908 -1.52 . . . . 54.44 108.198 171.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.0 pt -82.1 139.65 17.6 Favored 'Isoleucine or valine' 0 C--N 1.357 0.934 0 N-CA-C 106.091 -1.818 . . . . 73.14 106.091 166.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -148.74 164.08 35.45 Favored 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.58 1.082 . . . . 72.35 109.392 -175.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.572 0 N-CA-C 109.362 -1.495 . . . . 72.44 109.362 178.667 . . . . . . . . 0 0 . 1 stop_ save_